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Endogenous short peptide modulators of ion channels provide a new level of 
regulation of nervous function. Lynx1 was identified as an endogenous mammalian 
homologue of snake venom peptide neurotoxins capable of binding to and functionally 
modulating nicotinic acetylcholine receptors (nAChR). Lynx1 is a member of the Ly6-
α−neurotoxin superfamily (Ly6SF) of genes.  
Through extensive database searches, I identified 85 members of this superfamily 
including previously unidentified vertebrate and invertebrate family members. I show 
that these proteins are very divergent in their sequences, and identify two conserved 
subfamilies, snake toxins and immune system expressed Ly6 genes through phylogenetic 
inference. I also discovered conserved sequences among Ly6SF proteins additional to the 
cysteines that characterize the three-dimensional topology of Ly6 domain.  From these 
Ly6SF molecules, I characterize three lynx1 homologues: lynx2, lynx3 and Ly6H. These 
have different and specific expression patterns in the central and peripheral nervous 
systems. Importantly, like lynx1, lynx2 and lynx3 are able to bind specific nAChR 
combinations and modulate their desensitization properties, while Ly6H does not bind 
nor modulate the function of nAChRs.  
I have also analyzed the in vivo function of lynx2, through the targeted deletion of 
lynx2 in mice. Lynx2 null mutant (lynx2-/-) mice exhibited increased anxiety, better 
associative learning and better motor coordination and learning than wild type (WT) 
mice. 
Nicotine and nicotinic receptor antagonist, mecamylamine, show distinct effects 
on motor learning in lynx2-/- mice and WT mice. The properties of this new family of 
lynx1-like molecules, taken together with those of lynx1 and the secreted Ly6SF member 
SLURP1 (secreted Ly6/UPAR related protein), suggest a general role for Ly6SF proteins 
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         CHAPTER 1: 
          Introduction 
 1
 Summary 
 Tobacco use is the leading preventable cause of death in the world. Nicotine, 
which is the addictive ingredient of tobacco, exerts its effect through nAChRs in the 
central nervous system (CNS). Besides mediating nicotine addiction, nAChRs have been 
implicated in Alzheimer’s disease, Parkinson’s disease, learning and memory, autism, 
anxiety disorders and depression.  
 Lynx1 has recently been identified as a modulator of nAChRs and it functions in 
nicotinic receptor mediated learning and neurodegeneration. Lynx1 is a member of 
Ly6SF, which is a large protein family that consists of proteins with a characteristic 
three-finger topology.  
 In this chapter, I will briefly review the structure, expression patterns and 
functions of Ly6SF proteins and nicotinic receptors. I will then go over expression and 
function of Lynx1 in vitro and in vivo.    
 2
 Ly6 Superfamily of genes 
Structure, Evolution and Diversity  
Ly6 proteins were first identified in the cells of the immune system in the 1970s 
[1]. The immune system is a complex of organs and specialized cells that is responsible 
for defense of the body against foreign objects. Blood cells are a major part of the 
immune system. All blood cells are made by stem cells, which live mainly in the bone 
marrow, through a process called hematopoiesis. The stem cells produce hemocytoblasts, 
which mature into three types of blood cells: erythrocytes (red blood cells), leukocytes 
(white blood cells), and thrombocytes (platelets). 
The leukocytes consist of granulocytes, which contain large granules in their 
cytoplasm, and agranulocytes, which don’t have granules. The granulocytes are 
subdivided into neutrophils, eosinophils, and basophils and the agranulocytes are 
subdivided into lymphocytes, or lymphoid cells (B cells and T cells), and monocytes. 
Monocytes, granulocytes and erythrocytes are also called myeloid cells. Monocytes 
mature into macrophages, which attract, engulf and digest foreign bodies. 
 Ly6 proteins are named after their founder member that was identified as a 
Lymphocyte antigen in mouse T-cells [1]. Antibodies generated against these proteins 
showed that they are expressed in subpopulations of myeloid and lymphoid cells [2-4]. 
Thus they have been used as differentiation markers for hematopoietic stem cells and T-
cells [5-7]. Most Ly6 genes that are expressed in hematopoietic cells are localized to 
murine chromosome 15 and human syntenic chromosome 8q24 [8-12]. Ly6 proteins are 
also expressed in non-hematopoietic cells. CD59, Ly6D, SLURP1 and Lynx1 are  
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Figure 1: Basic Scheme of Ly6 Domain Sequence. Ly6 domain is a three 
finger structure that is made up by 8-10 cysteine residues dispersed with 
conserved spacings. 
Figure 2: Domain structures of GPI anchored and secreted Ly6 proteins. 
A. GPI anchored Ly6 proteins are comprised of an N-terminal signal 
sequence, a Ly6 domain and a C-terminal GPI-anchorage signal sequence. 
B. Secreted Ly6 proteins consist of an N-terminal signal sequence and a 





Figure 3: Three-dimensional structures of several Ly6 superfamily 
members.  Ly6 domain is characterized by its three-looped structure that 
looks like three fingers. (Tsetlin V., Snake Venom a-neurotoxins and other 
three-finger proteins, Eur. J. Biochem, 1999) 
 examples of such Ly6 genes and they are localized to human chromosome 8q24 as well 
as other chromosomal regions including human chromosome 19q13.3 and 6p21.3 [11, 
13-16].  
Ly6 proteins have a three-finger structure 
Ly6SF is composed of relatively short (~100 amino acid (aa) long) proteins that 
have characteristic three-finger Ly6/UPAR (urokinase-type plasminogen activator 
receptor) domain. This domain is characterized by 8-10 cysteine residues, between which 
there are disulfide bonds that make up the backbone of the three dimensional structure of 
this domain [14, 17] (Figure 1 and 3).  
α-neurotoxins and other snake toxins, which are secreted Ly6SF proteins, have 
the same three-finger structure (60-80 aa long), but they are relatively shorter than 
mammalian Ly6 proteins that have been described so far. These toxins are divided into 
two groups in terms of the number of cysteines: the first group of toxins have 8 cysteine 
residues, which form 4 disulphide bridges, in their backbone, and the second group have 
10 cysteines [17]. The second group is further divided into two subgroups depending on 
the location of the extra disulphide bridge. The first subgroup, so-called weak toxins, 
have the extra disulphide bridge in their first loop, whereas members of the second 
subgroup have the extra bridge in the second, central loop (Figure 3). The integrity of the 
additional disulfide bridge in the second finger of neurotoxins has been shown to be 
necessary for high-affinity binding to α7 nAChRs [18]. The removal of the additional 
disulfide bond in the second finger of κ-bungarotoxin also decreases the affinity of this 
toxin to α3β2 nAChRs [19].  
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 Although most three-finger toxins exert their effect by binding to a target channel 
and receptor, cardiotoxins (or cytotoxins) do not bind to a receptor or a channel, but form 
channels in the membrane [20]. Toxins have various oligomerization properties. 
Cardiotoxins are found in trimers [20] whereas α-neurotoxins are found as monomers 
and κ-bungarotoxins always form dimers [21, 22].  
Almost all mammalian Ly6 proteins identified so far also have all 10 cysteines 
and an additional disulphide bridge in their first finger, like toxins with weaker affinity, 
[23] and N-terminal signal sequences. Except for SLURP1, SLURP2 and SVS-VII 
(seminal vesicle secretion protein VII), which are secreted like three-finger snake toxins, 
all the known mammalian Ly6SF members have GPI (glycosyl-phosphotidylinositol) 
anchorage site and signal at their C-terminal [15, 24, 25] (Figure 2).  
Evolution of Ly6 Proteins 
When Ly6 proteins were first described, they were put into the same protein 
family with the UPAR like proteins. UPAR, which is a 335 aa long protein, is one of the 
founding members of a superfamily of membrane-bound glycoproteins. It has an N-
terminal signal and a GPI anchorage site, like Ly6SF of proteins; however, this protein 
has 3 three-finger domains. Since Ly6SF members have only one three-finger domain, 
investigators have started to classify Ly6 proteins in a superfamily distinct from the 
UPAR protein family, which also includes phospholipase inhibitors [26-28].   
The first invertebrate Ly6SF member described was Sgp-2 (squid glycoprotein-2), 
which was isolated in squid in 1988 [29]. However, no functional data was published on 
this protein. The other invertebrate Ly6SF member, which was identified more recently, 
is odr-2 and its homologues (HOT proteins) described in C. elegans. ODR-2 also 
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 contains an N-terminal signal sequence followed by a Ly6 domain and a GPI-anchorage 
site and signal. The difference between the Ly6 domains in ODR-2 and mammalian Ly6 
proteins is the spacings between the cysteines that make up the backbone of the Ly6 
domain. Although the number of amino acids between the cysteines is well conserved 
among the C. elegans Ly6 proteins, their numbers are relatively higher than those of 
mammalian Ly6 genes. There are three isoforms of ODR-2, which differ in their N-
terminal sequences. They are produced through alternative splicing, and one isoform, 
ODR-2b was shown to be important for olfactory behaviors and might be regulating 
signaling within a specific group of olfactory neurons. ODR-2b is highly expressed in 
sensory and motor neurons as well as interneurons. Odr-2 mutant worms are deficient in 
chemotaxis [30].  
Expression Patterns 
Immune System Expression 
Mammalian Ly6SF members are expressed in various tissues; however, a 
subgroup within the superfamily is expressed mainly in cells of hematopoietic origin. 
Since hematopoietic cells are highly differentiated, ly6 proteins have been very useful 
markers for different stages of differentiation. One of these genes is Ly6A/E, whose two 
alleles Ly6A.2 and Ly6E are mainly expressed in the bone marrow stem cells and the 
developing T-cells in the thymus [31]. The expression patterns and stages of these two 
alleles are different from each other in different T-cells [32]. Another Ly6 protein RIG-E, 
which is also known as TSA-1/Sca-2 and Ly6e, is expressed in various tissues as well as 
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Ly6 Protein Also known as Expression Sites 
Ly6A/E Ly6A.2, Ly6E 
  Bone marrow stem cells, developing T-cells, 




  Widespread expression, thymocytes and myeloid
  cell lines 
Ly6C    CD8+ T-cells, splenic macrophage progenitors, 
Ly6G    Mature granulocytes 
Ly6I  
  Bone marrow cells, granulocytes, macrophages, 
  immature B-cells 
CD59    Erythrocytes, lymphocytes, retina 
PSCA  
Prostate epithelium, prostate cancer, pancreas 
cancer, retina 
Ly6D E48, ThB Keratinocytes, lymphocytes 
SLURP-1  Epithelium, keratinocytes, cornea, endothelium 
SVS-VII  Seminal vesicle secretion 
Ly6H  Brain, acute leukemia cell lines 
Lynx1  Brain, lung 
 
Table 1: Summary of expression patterns of Ly6SF proteins.  
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thymocytes and myeloid cell lines [33, 34]. Ly6C is a useful marker for memory CD8 T 
cells [34], and splenic macrophage progenitors [12]. Its expression pattern allows 
differention between macrophage progenitors from mouse bone marrow and spleen [12]. 
Ly6G is used as Gr-1 marker for granulocytes and is only expressed in mature 
granulocytes during their differentiation [35]. Ly6I has a distinct pattern of expression 
like the other members of Ly6SF. Its expression in vivo is most abundant on bone 
marrow cells and it is co-expressed with Ly6C on granulocytes and macrophages. 
However, Ly6I is also expressed on immature B cell populations that do not express 
Ly6C, to which it is 80% similar in sequence. Expression on mature B cells in 
spleen is uniformly low [6]. Ly6I was isolated by homology to Ly6C and it is 70% 
similar at the protein level to a subset of the Ly6SF that also includes Ly6A/E, Ly6C, 
Ly6F and Ly6G [6].  
CD59, another member of the Ly6SF that is expressed in cells of hematopoietic 
origin, is not located on the same chromosomal location as the other members of this 
subfamily [13]. CD59 is located on chromosome 2 in mice, and on 11p13 in humans.It is 
expressed in erythrocytes and lymphocytes in mice and humans (Table 1).  
Expression in Epithelial Cells 
While many Ly6SF members are expressed primarily in the cells of the immune 
system, others are strongly expressed in other tissues. Ly6D, which is also known as 
thymocyte antigen-B (ThB) in mice and E48 in humans, is expressed in keratinocytes in 
humans, but not in lymphocytes [9, 36, 37]. In mice, Ly6D has two alleles, one of which 
is expressed in both keratinocytes and lymphocytes. The second allele is only expressed 
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 in keratinocytes. The expression of the first allele in keratinocytes is much higher than its 
expression in lymphocytes. There is 67% sequence homology between mouse and human 
Ly6D proteins [2, 11, 38]. Both Ly6D and Ly6K are over-expressed in head-and-neck 
squamous carcinoma [39].  
SLURP-1 expression is very strong in epithelium, keratinocytes, cornea and 
endothelium.  Together with prostate stem cell antigen (PSCA) and CD59, they constitute 
0.5% of total mRNA in retina [40]. PSCA was first identified as a candidate antigen for 
identifying people with prostate cancer. It is expressed in basal cell epithelium in normal 
prostate and its expression is highly elevated in patients with prostate and pancreas 
cancer [41, 42]. SVS VII, another secreted Ly6SF member, is one of the seven major 
proteins in mouse seminal vesicle secretion [25].  
Expression in Nervous System 
Among the mammalian Ly6SF genes that are expressed in nervous system,  
Ly6A/E expression was also shown in astrocytes surrounding blood vessels in the brain 
[43]. Expression of lynx1 is primarily in neurons in the brain, and its expression pattern 
will be explained in detail later this chapter. 
Ly6H is another Ly6SF member that is expressed mainly in non-hematopoietic 
cells. hLy6H was shown to be expressed predominantly in the brain in Northern blot 
analysis. Its expression is high in several regions in the brain including cerebral cortex, 
amygdala, hippocampus and subthalamic nucleus, whereas it’s low in thalamus, corpus 
callosum and cerebellum in humans. Ly6H is also expressed in acute leukemia cell lines 
[44]. The mouse Ly6H was also isolated and shown to be highly expressed in brain, 
whereas its expression was undetectable in various tissues including thymus, spleen, 
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 liver, lung, kidney, heart, skeletal and smooth muscle and prostate [45]. In embryos at 
age E10.5, Ly6 is expressed in ventral neural tube, and at age E12.5, scattered cells in 
spinal cord and rhombocephalon were positive for Ly6H expression [46].  
Activity and Function 
 Ly6 proteins were first identified as markers for cellular differentiation, and they 
have also been implicated in cell-to-cell adhesion, signaling and receptor modulation. 
Some Ly6 proteins are over-expressed in certain types of cancers, and have been used as 
markers for cancer cell differentiation. Some of these functions are summarized below.  
Cell Adhesion 
Several Ly6SF members have been shown to be important for cell-to-cell 
interactions in vivo and in vitro. Transfection of mammalian cultured cells with Ly6D 
increases desmosomal cell-cell adhesion of keratinocytes [9], whereas anti-Ly6C 
monoclonal antibodies prevent cell adhesion of endothelial cells [47]. One of the secreted 
members of this family, SVS-VII, has binding sites that cover the entire surface of the 
sperm. Upon ejaculation, binding of SVS-VII to sperm surface enhances the sperm 
motility [25]. In vivo support for the role of Ly6 in cell adhesion came from Ly6A/E 
transgenic mice. Overexpression of Ly6A/E on lymphocytes in transgenic mice results in 
increased cell adhesion [32, 48]. Ly6A/E was also shown to have a role in cell adhesion 
in lymphocytes and bone marrow stroma in vitro [31, 48].    
 12
 Signaling 
Ly6SF members that are expressed in hematopoietic cells have been shown to be 
involved in various signaling processes in cell differentiation, activation and apoptosis 
[49-51].  Expressed in lymphocytes, Ly6e inhibits T-cell receptor (TCR) mediated T-cell 
activation and apoptosis.  Ly6e was shown to be physically associated with CD3ζ chains 
in T-cell cells with IP and confocal microscopy. When stimulated by anti-Ly6e 
antibodies, CD3ζ chains were tyrosine phosphorylated [52]. In vivo, anti-TCR/ CD3-
mediated apoptosis of thymocytes is blocked by injection of anti-Ly6e antibodies [53, 
54].  
Another example of Ly6 role in signaling is the role of Ly6A/E in lymphocytes. 
Overexpression of Ly6A/E on lymphocytes in transgenic mice causes aberrant 
lymphocyte maturation [55]. Studies in Ly6A/E null-mutant mice suggest that it may 
have an inhibitory role in regulating T-cell activation and T-cell Ag-specific immune 
responses [51].  
CD59 is one of the best-described members of the mammalian Ly6SF of proteins 
[14]. CD59 inhibits formation of membrane attack complex, thus protects cells from 
complement mediated lysis [13]. CD59 is also implicated as a signal transducing 
molecule for human T-cell activation [56].  
Some Ly6SF genes have been associated with cell death and malignancy of tumor 
cells. In cells that have gone through malignant transformation, levels of some Ly6 
proteins are upregulated. PSCA expression is highly elevated in prostate cancer [42] and 
increased expression of Ly6A/E has been associated with malignancy of tumor cells [57].  
Expression of another Ly6SF member, GPI-anchored-molecule-like protein (GML), 
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 whose expression is regulated by p53, suppresses the growth of esophageal cancer cells 
[58]. Ly6e expression in promyelotic leukemia is strongly regulated by retinoic acid, 
which is a differentiation inducer that causes clinical remission in about 90% of the 
patients with acute promyelotic leukemia [10]. 
Ligands 
Although several ligands have been identified for various Ly6SF members, 
physiological importance and results of Ly6-ligand binding have not been clearly 
established yet. Ly6A/E was shown to bind to a 66 kDa protein that is expressed in 
spleen, thymus, macrophages and B-cells [48]. Ly6D binds to an unknown polypeptide 
that is 9 kDa and has a widespread expression. This ligand was described in more detail 
than the first ligand and was shown to share homology with notch proteins [59]. Ly6A/E, 
Ly6I and Ly6C all bind to CD22 in B-cells [3]. On the other hand, SVS VII, which is a 
secreted Ly6SF member, is thought to bind to lipids, specifically 
phosphatidylethanolamine and phosphatidylserine, on the surface of sperm cells [25]. 
Ion Channel Modulation 
In addition to α-neurotoxins that inhibit nAChRs, three-finger-toxins include 
several toxins that bind to muscarinic receptors [60], cardiotoxins that form channels in 
cell membranes [20], calciseptins and other toxins that block the L-type calcium channels 
[61, 62], and fasciculins that inhibit acetylcholinesterase (Cervenansky et al, In Snake 
Toxins (Harvey, A.L., ed), pp. 131-164. Pergamon Press, New York.).  
The ARS-B gene encodes SLURP-1, which is one of the three known secreted 
mammalian Ly6SF members. ARS-B is mutated in patients with a rare autosomal 
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 recessive skin disorder called Mal de Meleda [63]. This disease is characterized by 
progressive keratotic lesions, which can result in reduced mobility of hands and feet and 
possibly spontaneous amputation of digits.  SLURP-1 was shown to increase 
acetylcholine elicited macroscopic currents in α7 nicotinic receptor expressing oocytes 
[64]. The modulatory effect of SLURP-1 on α7 receptors might explain the clinical 
phenotype of Mal de Meleda. SLURP-1 increases activities of caspases 3 and 8, and 
expressions of p21, caspase 3, cytokeratin 10 and transglutaminase type I. Carbachol, an 
agonist for nicotinic receptors, increases the effect of SLURP-1 on gene expression 
which shows this effect might be through modulation of nicotinic receptor activity [65]. 
SLURP-2 was first identified as a protein that is over expressed in patients with 
psoriasis vulgaris. Psoriasis vulgaris is a fairly common (effects ~2% of the population) 
genetic disorder that is characterized by hyperproliferation of epidermal keratinocytes 
and inflammation in the affected regions through T-cells, neutrophils, mast cells and 
macrophages. It has been suggested that SLURP-2 might be involved in pathophysiology 
of psoriasis vulgaris [24]. When cultured keratinocytes were treated with SLURP-2, their 
numbers increased significantly and this effect was blocked by mecamylamine treatment. 
Mecamylamine is a potent antagonist of nicotinic receptors. SLURP-2 also delays 
differentiation of keratinocytes and demonstrates anti-apoptotic effects [66].    
Binding of α-neurotoxins and lynx1 to nAChRs, and modulatory effects of snake 
toxins, lynx1, SLURP-1 and SLURP-2 makes nicotinic receptors interesting targets for 
other members of the Ly6SF family as well [64-67].  
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 Nicotinic Acetylcholine Receptors 
Diversity and Structure 
nAChRs are ion gated receptors and belong to a gene superfamily that also 
includes GABA, glycine and 5-HT3 receptors [68]. There are ten different alpha subunits 
(α1-10), four different beta subunits (β1-4), and gamma (γ), delta (δ) and epsilon (ε) 
subunits that combine to form functional receptors. The muscle nAChR are composed of 
α1, β1, γ and ε subunits in adults and α1, β1, γ and δ subunits in embryo. The 
stochiometry of the muscle subunit is 2 alpha subunits, 1 β, 1 γ and 1 ε or δ subunit 
(reviewed in [69-71]. The other subunits in nAChR family were considered neuronal 
nAChR until recently. However, these subunits are expressed in epithelial tissue as well 
(reviewed in [72, 73]).  
According to the phylogenetic analysis done by Tsuyonoma and Le Novere, 
α9, α7 and α8 are the closest subunits to the ancestral subunit (Figure 4). These subunits 
can form functional receptors without oligomerizing with beta subunits [74, 75]. Insect 
and nematode receptor subunits form the second group in the phylogenetic tree. The 
second group is divided into two major subfamilies. The first major subfamily is 
composed of non-alpha-muscle receptor subfamily (γ, ε, δ, β1) and β2−β4 subfamily. 
The second major subfamily is divided into two main branches: α1 subfamily and 







Figure 4: nAChR Phylogenetic Tree. nAChR subunits form 4 distinct groups. 
First group consists of homomer forming subunits α7, α8 and α9. Second group 
is composed of invertebrate nicotinic receptors. Muscle subunits β1, γ, δ, ε and 
β2 and β4 subunits comprise the third group. Fourth group consists of α1-
muscle, α5, β3, α2, α4, α3 and α6 subunits. (Tsunoyoma et. al, Evolution of 
Nicotinic Acetylcholine Receptor Subunits, Mol. Biol. Evol, 1998) 
 regions of all the subunits are the most conserved parts of the receptor amino acid 
sequences [74, 75]. 
The pharmacological properties of different homopentamers and heteropentamers 
of nicotinic subunits are variable in vitro [76, 77]. However, in nicotinic-receptor knock-
out (KO) animals, it has been observed that function of one subunit can be replaced by 
another in several cases [78-80]. Although it is generally assumed that different 
pharmacological properties in vitro may account for the physiological diversity in vivo, 
this doesn’t look like the reason for the diversity of the nicotinic receptors. Instead, the 
conservation of the diversity of the subunits might be due to the variety of their cellular 
and subcellular distrubution patterns in vivo (reviewed in [69-71]). 
Nicotinic receptors are pentameric in structure. Each subunit contains an 
extracellular ~200 aa long N-terminal domain, four transmembrane domains (M1-M4), 
and an intracellular connection between M3 and M4 that forms a large cytoplasmic 
domain [81, 82]. The structure of acetylcholine binding protein (AChBP) was used as a 
template for computational modeling of the nicotinic receptors [83-85]. These models 
were used to improve the electron microscopy data for the nicotinic receptor structure 
[86-88]. M2 transmembrane domain lines the channel pore [89]. The subunit interfaces 
between the N-terminal extracellular domains of the alpha subunit and the adjoining 
subunit forms the agonist binding site [90, 91].  
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 Expression patterns 
Neuronal 
Expression patterns of nicotinic receptor subunits vary among different species 
and among different strains of mice [92, 93]. The most widely expressed nicotinic 
receptor subunits in the CNS are α7, α4 and β2 subunits. α7 expression has been 
observed in CA2/3, subiculum, amygdala, cortex, cochlear nucleus, Purkinje cells of the 
cerebellum, thalamus, hypothalamus and several brainstem nuclei in rat brain [94-97]. α7 
nicotinic receptors are also expressed in CA1 region of rat and mouse hippocampus [98-
100]. α4β2 is the most prevalent heteromeric receptor combination found in rat brain. α4 
subunit expression is detected in olfactory bulb, purkinje and granular cells of 
cerebellum, cerebral cortex, amygdala, thalamus, hippocampus, midbrain, and medulla in 
rat brain [100-103].  
In the peripheral nervous system, the most widely expressed heteromeric nicotinic 
receptors are α3β2 and α3β4 receptors. α3 subunit is expressed at high levels in 
peripheral nervous system and in low amounts in the cerebral cortex, hippocampus and 
cerebellum in rat [100, 104, 105]. α3β2 expression was detected in the optic chiasm, 
habenula, and colliculus, and α3β4 expression was observed in the habenula-peduncular 
system, cerebellum, developing brain and brainstem motor nuclei, including motor 
trigeminal nucleus, nucleus ambiguous, and dorsal motor nucleus of vagus [103, 106]. β4 
subunit also has a widespread expression throughout the rodent brain. In mice, β4 subunit 
expression has been observed in the midbrain, dispersed cells in the hippocampus, 
olfactory regions, subthalamic nucleus, trigeminal system and granule cells of the 
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 cerebellum [107]. In rat brain, β4 expression was detected mainly in medial habenula, but 
also in the hippocampal formation, entorhinal cortex, trigeminal motor nucleus, 
interpeduncular nucleus and olfactory regions [108]. In rat cerebellum, expression of 
α3α4β4 and α3α4β2 receptors have also been detected [109].  
Other nAChR subunits less widely expressed. For example, α2 is expressed in 
olfactory bulb, interpeduncular nucleus, ventral and dorsal tegmental nucleus, median 
raphe nucleus, and reticular nucleus, hippocampus, and amygdala in both mice and rats. 
α2 subunit is also expressed in gigantocellular reticular nucleus and raphe magnus of 
mice but not in rat brains [110]. α5, which is usually expressed together with another 
α subunit, is highly expressed in subiculum, parasubiculum and presubiculum of 
hippocampus, substantia nigra, interpeduncular nucleus, dorsal motor nucleus of vagus 
and ventral tegmental area [111]. α6 subunit has a very specific expression pattern, and it 
is expressed in substantia nigra, ventral tegmental area and locus coeruleus [112]. α9 and 
α10 subunits are expressed together in adult mechanosensory hair cells [113].  
α2, α3, α4, α5, β2 and β4 are also expressed in rat spinal cord [110, 114]. 
Expression of almost all subunits are developmentally regulated, and some of them have 
transient expression in certain regions of CNS [115].  
Non-neuronal 
 Acetylcholine is found not only in neurons, but also in bacteria, protozoa and 
algae, which shows that it has emerged very early during evolution. Acetylcholine 
synthesizing enzymes, as well as acetylcholine receptors are expressed in various non-
neuronal tissues. α3, α5, α7, β2 and β4  AChR subunits are expressed in bronchial 
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 epithelial cells, and α3, α4, α5, α6 and α7 are expressed in alveolar epithelial cells in 
rodent, monkey and human airways [116-119].  
 In human keratinocytes, expression of α3, α4, α5, α7, α9, α10, β2 and β4 
subunits have been detected with RT-PCR (reverse transcription-polymerase chain 
reaction) and immunohistochemistry [120-122]. In rat urinary bladder epithelial cells, α3, 
α5, α7, β3 and β4 receptor subunit expression were detected with RT-PCR and western 
blots [123]. In mammalian sperm, expression of α7 subunit was observed in acrosome 
[124, 125].  Presence of α3, α5, α7 and β2 nicotinic receptor subunits were also revealed 
in esophageal epithelia [126].  
 In lymphocytes, α4, β4, a3, α7 and β2 nicotinic receptor expression has been 
detected in mice, rats and humans [127-129]. Expression of α2, α5 and α7 has also been 
detected in human mononuclear leukocytes [128].  
Function 
Pharmacology and Physiology of nAChRs 
 nAChRs are allosteric ligand-gated channels. Physiological and pharmacological 
properties of different heteromeric and homomeric combinations of various subunits 
differ from each other. Mecamylamine blocks all nicotinic receptors, but the blocking 
mechanism differs among various subunit combinations [130]. For some combinations, it 
is a competitive antagonist, for others, it is non-competitive antagonist for open channels 
[130-133]. Mecamylamine can pass through the blood brain barrier, however, another 
potent antagonist for almost all nicotinic receptors, hexamethonium, cannot. Since 
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 hexamethonium does not block muscle nAChRs, hexamethonium is used to block 
neuronal nicotinic receptors outside the CNS [131, 134]. 
The most widely expressed nicotinic receptors in the CNS, α7 and α4β2 also 
show distinct pharmacological properties. α7 nAChRs are desensitized faster than α4β2 
nAChRs and are more permeable to Ca2+ than α4β2 nAChRs [135-137] . In addition, α7 
nAChRs can be activated by choline and are blocked by α-bungarotoxin and 
methylcaconitine (MLA), whereas α4β2 nAChRs are not activated by choline, and are 
not affected by α-bungarotoxin or MLA [138, 139]. Instead, another toxin, dihydro-beta-
erythroidine (DHβE) is a potent antagonist for α4β2 receptors [140]. Pharmacological 
differences like these allow researchers to determine what types of receptors are present 
in a cell by comparing responses to such drugs.  
  α3β2 and α3β4 are the two most widely expressed nicotinic receptor 
combinations outside the CNS. α4β2, α3β2 and α3β4 have similar channel 
conductances; however, their desensitization kinetics are different [82]. α3β4 receptors 
desensitize faster than α4β2 receptors, however, slower than α3β2 or α7 nAChRs [76, 
135, 141]. α3 containing nicotinic receptors are blocked by α-conotoxin-MII and κ-
bungaratoxin but not by α-bungaratoxin or DHβE [142, 143]. 
Physiological Function 
Neuronal 
Nicotine was shown to enhance spatial and associative learning performances, as 
well as attention and memory [144]. On the other hand, nicotinic receptor antagonist, 
mecamylamine, deteriorates memory [145]. Nicotinic receptors also play vital roles in the 
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 control of synaptic transmission in the peripheral nervous system as well as the CNS 
[146, 147]. Unlike most of the other subunits, α3 subunit is essential for survival of mice. 
α3 KO mice show major autonomic defects which results in 50% lethality at birth. The 
remaining animals die in the first three months. The phenotype of α3 KO mice has been 
proposed as a model for megacystis microcolon intestinal hypoperistalsis [148].  
Although β2-β4 double KO animals show a similar phenotype to α3 KO mice, 
neither β2 KO nor β4 KO mice show any early lethality [78]. β2 KO animals exhibit 
reduced antinociception, impaired spatial learning, increased neurodegenaration with 
aging and loss of nicotine self-aministration [149-151]. β4 KO mice on the other hand 
have altered anxiety related phenotype and the excitatory postsynaptic potentials (EPSP) 
in these mice were strongly decreased, with a peak current of only 2% of the wild-type 
(WT) mice [152]. β3 cannot form functional receptors without another β subunit, and β3 
KO mice exhibit increased locomotion [153].  
Deficiency of α4 subunit results in reduced antinociception as well as anxiety 
related phenotypes [154-156].  Although α7 KO mice do not show any behavioral or 
physiological abnormalities, α7-L250T mice, which have slowly desensitizing α7 
currents, were not viable 24 hours after birth [138]. Mice that are heterozygous for this 
mutation are viable, but they are more vulnerable to nicotine induced seizures [157, 158]. 
α6 KO mice show normal behavior and no major physiological problems [159]. α9 null 
mutant mice have suppressed cochlear response and abnormal efferent connections 
between olivary complex and cochlea, however, they exhibited no major abnormalities in 
audition, motor coordination or balance [160] (Table 2).   
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 Implication in Disease 
Alterations in nicotinic receptor activity have been shown to be involved in the 
pathophysiology of various diseases including Alzheimer’s disease, Parkinson’s disease, 
autism, anxiety disorders and autoimmune diseases. Alzheimer’s disease, which affects 
2-6% of the population over the age of 65, is characterized by a deficit in the cholinergic 
activity in the brain. The activity of the two enzymes that are involved in the synthesis 
and degradation of acetylcholine are decreased by 90% in patients with Alzheimer’s 
disease. Although cholinergic transmission is important in Alzheimer’s pathopyhsiology, 
abnormalities in other transmission systems including glutamatergic and serotonergic 
transmission are also involved (reviewed in [161]). Studies have shown that expression of 
several nicotinic receptor subunits are down regulated in Alzheimer’s patients including 
α7, α4, α3 and β2 subunits [162-164]. It has also been demonstrated that β-amyloid 
activates nicotinic receptors under certain conditions, and neurons that express α7 
nicotinic receptors are preferentially killed by beta amyloid [165, 166]. Therefore it has 
been hypothesized that the apoptosis induced by beta-amyloid might be through 
disruption of intracellular calcium levels by nicotinic receptor activation [167]. Currently, 
acetylcholinesterase inhibitors are used for treating symptoms of Alzheimer’s disease, 
and cholinergic system continues to be a drug target for future therapies [168].   
Parkinson’s disease is a neurodegenerative disease that affects 1% of the 
population over the age of 65 [169], There’s a significant loss of nicotinic receptors in 
Parkinson’s disease patients [170]; therefore, nicotinic receptors have been suggested to 
be used as drug targets for Parkinson’s disease. Nicotine has been shown to have a 
neuroprotective effect in Parkinson’s disease patients [171, 172]. Effect of nicotine on 
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 cognition in PD patients has also been studied, but there have been some contradictory 
results. Some studies have shown that nicotine improves cognition in Parkinson’s disease 
patients while others have demonstrated nicotine has no positive effect [173-176] 
Autism is a relatively common developmental disorder that affects 1 child in 166 
and is considered to be primarily genetic [177-179]. Several neurotransmitter systems, 
including cholinergic transmission, have been implicated in the neuropathology of this 
disease [180-183]. A significant loss of cholinergic binding sites was observed in the 
cerebral cortex and cerebellum of autistic patients [182, 183]. Specifically α4 and β2 
subunits are down-regulated in the cortex of autistic brains whereas α7 subunit 
expression was the same as healthy subjects [184].  
Although smokers generally accept nicotine as an anxiolytic [185, 186], it has 
been shown to have an anxiogenic effect in anxiety disorders in several studies. One 
study showed that young adults who smoke are more likely to have anxiety disorders than 
non-smoking ones [187]. Increased daily nicotine consumption was shown to be 
associated with a higher risk of the first time occurrence of panic attacks [188]. In animal 
models, the effect of nicotine depends on the administration of nicotine, the emotional 
and physical state of the subject and the type of test that is used to measure the levels of 
anxiety  (reviewed in [189]). This might be due to the fact that nicotinic receptor 
activation regulates not only stimulatory, but also inhibitory and modulatory transmission 
in various brain regions. So, depending on which nicotinic receptors on which region of 






 Tobacco smoking causes cancers in lung, oral cavity, esophagus, pancreas, 
stomach and bladder. In non-neuronal tissues, nicotinic receptor activation has been 
implicated in many functions including regulation of gene expression, adjusting 
intracellular Ca2+, cell-adhesion, cell-differentiation. In bronchial epithelial cells, 
smoking increases nicotinic receptor expression, and exposure to nicotine elevates 
intracellular Ca2+ levels. Exposure to mecamylamine altered cell adhesion and motility, 
and these effects were reversed by nicotine. However, long-term exposure to nicotine 
caused a similar effect to mecamylamine, suggesting that the induction of desensitization 
through nicotine has a similar effect to receptor blocking [116]. α3β2α5 nAChRs were 
found to modulate wound repair process in human bronchial epithelial cells. The cells 
that were exposed to nicotine were faster in wound healing, and the speed of cell 
migration to the wound site was inhibited by mecamylamine, κ-bungaratoxin and α-
conotoxin-MII [190].    
In cultured keratinocytes, cholinergic drugs can change cell proliferation, 
adhesion, migration and differentiation through adjusting levels of intracellular calcium. 
Changes in calcium levels then modify the expression and function of nicotinic receptors 
[122, 191-193]. Keratinocytes exposed to nicotinic receptor antagonists kappa-
bungaratoxin and mecamylamine had cell detachment and stopped migrating [120]. 
Exposure to nicotine elevates expression levels of α7, β2 and β4 subunits as well as cell 
cycle and cell differentiation markers in oral keratinocytes. This elevation is blocked by 
mecamylamine, which suggests that some pathophysiological results of nicotine in oral 
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 tissue is due to nicotinic receptor activation [194]. More specifically, blockers of α3β2 
receptor, α3-antisense mRNA and α-conotoxin-MII were able to reverse the effects of 
nicotine on oral keratinocytes, suggesting that α3β2 receptor combination is the main 
culprit in nicotine pathophysiology in the oral cavity [195].  
In rat urinary bladder, exposure to nicotine, choline and a nicotinic receptor 
antagonist, hexamethonium, increased the interval between contractions, and an α7 
subunit antagonist prevented this effect. These results demonstrate the importance of 
nicotinic receptor activation in urinary bladder control through the receptors expressed in 
the epithelial cells [123]. Activation of α7 containing nicotinic receptors was also shown 
to effect acrosome reaction in mammalian sperm which is crucial for fertilization [196]. 
Nicotinic receptors found in esophageal epithelia were demonstrated to be important for 
regulation of cell adhesion and motility and nicotine was shown to stimulate proliferation 
of gastric cancer cells [126, 197, 198]. The effect of nicotinic receptor activation on the 
gastric system was further demonstrated in α5-subunit-KO mice. α5 KO mice have 
significantly more colitis in their colonic epithelium than WT mice [199].   
 In lymphocytes, nicotinic receptors regulate Ca2+ signaling [128, 129]. Nicotinic 
receptor expression is downregulated by nicotine in lymphocytes, suggesting that 
pathobiology of smoking in the immune system might be through this mechanism [129, 
200]. α7 nicotinic receptors were established to be crucial for inhibition of cytokine 
synthesis in human macrophages [201]. α1, α3 and α9 subunits were also implicated in 
various autoimmune diseases including myasthenia gravis and pemphigus [202].  
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 Lynx1 
Sequence and Structure 
Lynx1 was initially identified as a developmentally regulated gene expressed in 
mouse cerebellum. Lynx1 encodes a 116 aa long protein that has an N-terminal signal 
sequence, a Ly6 domain and a C-terminal GPI anchorage site and signal sequence (Figure 
2). The sequence alignment shows that the Ly6 domain of lynx1 has all the mammalian-
conserved cysteine residues as well as the N-terminal leucine/isoleucine and the C-
terminal asparagines [203].   
Expression 
Lynx1 has very strong expression in specific regions in adult mouse brain and 
lungs. In brain, lynx1 is highly expressed in the CA2 and CA3 regions of hippocampus, 
layer 5 in cortex, Purkinje cells in the cerebellum and large pyramidal cells in deep nuclei 
[203]. It is also expressed in high levels in basolateral amygdala, medial habenula and 
mitral cells in olfactory bulb (unpublished data). In lungs, lynx1 was shown to be 
expressed in bronchial epithelial cells, where they colocalize with α4, β2 and β4 
containing nicotinic receptors [204, 205].  
Lynx1 colocalizes with α4 containing nicotinic receptors in neurons in several 
regions in adult mouse brain, including cortex, amygdala, habenula and substantia nigra. 
α7 containing nicotinic receptors colocalize with lynx1 on the membranes of neurons in 
cortex, hippocampus, amygdala and thalamic reticular nucleus [67].  
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 Function 
 Since the expression pattern of lynx1 was similar to those of the nAChRs and it 
has the same three-finger structure as α-neurotoxins that block nicotinic receptors, Miwa 
et. al. and Ibanez-Tallon et. al. have analyzed the functional interaction between the 
nicotinic receptors and lynx1. lynx1 co-immunoprecipitated with α4β2 nicotinic 
receptors and α7 nicotinic receptors when expressed in HEK293 cells and pulled down 
with nicotinic receptor subunit specific antibodies. This demonstrated that lynx1 forms 
stable complexes with nicotinic receptors [67]. In order to analyze the effect of lynx1 on 
nicotinic receptors, electrophysiology and lynx1 KO animal model was used.  
Electrophysiology 
 Lynx1 was shown to modulate desensitization kinetics of α4β2 nAChRs in vitro. 
It also alters the sensitivity of the nicotinic receptors to their agonists in vitro and in vivo 
[67, 203, 206] (Miwa et. al., Neuron, 2006, manuscript accepted). Detailed analysis of 
these modulations is described below.  
Oocyte experiments 
 In the first paper published by Miwa, et al., secreted lynx1 was shown to increase 
the acetylcholine (ACh) elicited macroscopic currents when measured by voltage clamp 
recordings. When exposed to secreted Lynx1, Xenopus oocytes expressing α4β2 
nicotinic receptors did not elicit any currents, which showed that secreted lynx1 is not 
acting as an agonist. However, in the presence of secreted lynx1, amplitude of the ACh 
elicited currents increased by 30-40% [203].  
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 When expressed together with α4β2 nicotinic receptor subunits, GPI-anchored 
lynx1 was shown to significantly increase their desensitization rate in Xenopus oocytes. 
The fast time-constant for the desensitization of α4β2 receptor without the presence of 
lynx1 was measured to be 2.73s, whereas the fast-time-constant was measured to be 1.09s 
for oocytes expressing α4β2 receptors and lynx1 [67]. 
Lynx1 also decreases the sensitivity of α4β2 receptors to their agonist, ACh. 
Voltage-clamp recordings on Xenopus oocytes expressing α4β2 receptors which were 
exposed to different concentrations of ACh revealed that lynx1 shifts EC50 of α4β2 
receptors from 1.8uM to 35uM ACh [67]. 
According to the three-dimensional model of Lynx1 which was generated by using 
structures of CD59, α-bungaratoxin and cardiotoxins as independent templates, cysteines 
1-5, 2-3, 4-6, 7-8 and 9-10 form disulphide bridges that determine their tertiary structure 
[203]. When single cysteines were mutated to alanine to test the importance of each 
disulfide bond, bridges between cysteines 2-3 and 4-6 were found to be the critical 
determinants of the effect of lynx1 on desensitization kinetics of nicotinic receptors 
through mutational analysis of the cysteine residues. These cysteines are located on 
finger 1 of the three-finger structure [67].  
Cultured Mammalian Cells 
 Patch clamp recordings on α4β2 transfected and α4β2-lynx1 transfected cultured 
mammalian cells revealed modulatory effect of lynx1 on single channel recordings. 
When perfused with ACh, α4β2 transfected cells fired for several tens of seconds, 
however, when transfected with α4β2 and lynx1, the channel events only lasted less than 
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 10 seconds. This result provided further evidence that lynx1 enhances the rate and extent 
of desensitization of α4β2 nicotinic receptors.  
Slice Physiology  
 Patch clamp recordings in medial habenula region of WT and lynx1 KO mouse 
brain sections revealed that lynx1 decreases the agonist sensitivity of nAChRs. The 
amplitudes of currents elicited in WT brain sections were larger than the currents in KO 
animals. To measure the difference in the EC50 of nicotinic receptors due to lynx1, the 
WT and KO brain sections were exposed to different concentrations of acetylcholine, and 
EC50 was observed to be ~89μM in WT sections whereas it was ~9μM in lynx1 KO 
animals (Miwa et. al., Neuron, 2006, in press). 
Anatomical Phenotype 
 Until ~9 months of age, there were no major anatomical differences between the 
KO and WT mice. After 9 months, increased vacuolation was observed in cerebellum and 
striatum of lynx1 KO mice with respect to WT littermates. Although the mechanism 
through which the vacuoles are caused is not clear, it was observed that the nicotinic 
receptor and lynx1 double KO mice have less vacuoles in their brains than the lynx1 KO 
animals (Miwa et. al., Neuron, 2006, in press).   
Behavior 
 Lynx1 KO mice exhibited increased performance in associative learning, but no 
difference from WT mice in contextual learning, or anxiety tests. In fear conditioning 
experiments, lynx1 mice were trained to associate a tone to a mild electric shock, and 
next day their response to the training environment was measured. This response, which 
 31
 is a measure of contextual associative learning, was the same as the WT mice. When the 
mice were placed in a novel environment and exposed to the training tone, the KO mice 
froze to tone more than WT mice, which demonstrates that lynx1 KO mice perform better 
in auditory-cue-associative learning tasks. Lynx1 KO mice performed similar to WT 
mice in two other contextual learning tests, passive avoidance conditioning test and 
Morris water maze learning. In anxiety related tests, elevated plus maze and light-dark 
box, lynx1 KO mice showed no difference from WT mice (Miwa et. al., Neuron, 2006, in 
press).  
 In rotarod test, which measures motor learning, lynx1 KO mice that drank 
saccharin water for 6 weeks performed similar to WT mice that were fed with saccharin 
water. However, lynx1 KO mice that drank nicotine for six weeks and had elevated 
nicotinic receptor activation due to it demonstrated better motor learning than WT mice 
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 Introduction  
Lynx1 is the founder member of a subfamily of Ly6SF proteins that modulates 
nicotinic receptors. Identification of SLURP-1 and SLURP-2 as modulators of nAChRs 
in keratinocytes further strengthened our theory that other Ly6SF members might be 
performing a similar function in CNS or other tissues. Nicotinic receptors have been 
implicated in many disease phenotypes and they have been drug targets for treating these 
diseases, however, the extensive diversity of its subunits and their overlapping 
widespread expression patterns has made it hard to find drugs that target the correct 
subunit or the expression area. Since one subunit might be regulating multiple functions 
in various regions of the brain, targeting one subunit also brings complications associated 
with side effects. Lynx1 has a very specific expression pattern and lynx1 KO animals 
have a specific phenotype related to associative learning. I have hypothesized that other 
members of lynx1 subfamily might target different functions related to nicotinic 
receptors, and therefore, will be valuable tools for understanding the mechanism of 
nicotinic receptor function and will be important drug targets.   
Identification of Ly6SF proteins and Alignment of Sequences 
In order to find other members of lynx1 subfamily, I have decided to identify and 
analyze phylogenetic relationships between novel and known Ly6SF members. I 
searched the vertebrate and invertebrate genomic DNA, cDNA and protein collections of 
both Celera and NCBI databases through homology searches for lynx1 and several ly6 
genes. Among the genes that I have found, I selected the ones that shared gross exon-
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 intron structure similarity to lynx1 and the ones that had necessary cysteine residues to 
make up the Ly6 domain. I found 85 genes that have the same genomic structure as other 
characterized Ly6SF members and encode proteins containing only one Ly6 domain.   
Sequence comparison of these putative proteins indicated that these Ly6 
molecules are very divergent (Figure 5). It appears that except for the cysteines that form 
the backbone for the three-finger structure, primary sequences are not well conserved in 
Ly6SF genes. However, there were multiple amino acids that were more conserved than 
others. Some of these most conserved residues might be to provide structural integrity of 
the domain. Moreover, the aa’s that are conserved exclusively in the Ly6SF proteins that 
modulate nicotinic receptors may be important for receptor selectivity. For example, the 
first residues of the Ly6 domains of most Ly6SF proteins were aliphatic amino acids, 
either leucine or isoleucine. The amino acids that were next to the first cysteine residue in 
most Ly6SF proteins were aromatic followed by a polar amino acid. Another amino acid 
that was conserved in most Ly6 domains was a positively charged amino acid at the end 
of the second loop, close to the disulphide bridge forming 6th cysteine, either a lysine or 
an arginine. In addition, the 5-6 amino acids at the end of the Ly6 domains of the 
majority of the Ly6SF proteins shared a strong sequence similarity. All the Ly6 domains 
ended with a cysteine-asparagine peptide, preceded by an amino acid that has a big side 
group. There were polar amino acids followed by amino acids with small side groups in 






CD59-RABBIT    LMCYHCL--L--P--S---P------N------C-ST--V--TN----------C----T--PN-HDA-------CLTAVSG-PRVYR-------Q----CWRY 
CD59-PIG       LQCYNCI--N--P--A---G------S------C-TT--A--MN----------C----S--HN-QDA-------CIFVEAVPPKTYY-------Q----CWRF 
CD59-MARMOSET  LQCYSCP--Y--S--T---A------R------C-TT--T--TN----------C----T--SN-LDS-------CLIAKAG-LRVYY-------R----CWKF 
CD59-MONKEY    LQCYSCP--L--P--TMESM------E------C-TA--S--TN----------C----T--SN-LDS-------CLIAKAG-SGVYY-------R----CWKF 
CD59-OWLMONKEY LQCYSCP--Y--P--T---T------Q------C-TM--T--TN----------C----T--SN-LDS-------CLIAKAG-SRVYY-------R----CWKF 
CD59-GREENMONK LQCYNCP--N--P--T---T------D------C-KT--A--IN----------C----S--SG-FDT-------CLIARAG-LQVYN-------Q----CWKF 
CD59-BABOON    LQCYNCP--N--P--T---T------N------C-KT--A--IN----------C----S--SG-FDT-------CLIARAG-LQVYN-------Q----CWKF 
hCD59          LQCYNCP--N--P--T---A------D------C-KT--A--VN----------C----S--SD-FDA-------CLITKAG-LQVYN-------K----CWKF 
mCD59          LTCYHCF--Q--PV-V---S------S------C-NM--N--ST----------C----S--PD-QDS-------CLYAVAG-MQVYQR-----------CWKQ 
rLY6A          LNCYNCT--M--IPFG---N------T------C-SST-A--T-----------CPY-------PDGV-------CAIQVAEVVMSSVRQKVKDHI----C--- 
mLY6A          LECYQCY--G--VPFE---T------S------C-PS--I--T-----------CPY-------PDGV-------CVTQEAAVIVDSQTRKVKNNL----C--- 
PUT-LY6B       LNCYNCT--M--IPFG---N------T------C-SST-A--T-----------CPY-------PDGV-------CTIQVAEVVVSSVRLKVKSNL----C--- 
rLY6C          LKCYSCI--E--VPLN---A------N------C-ST--A--T-----------CPY-------SDGV-------CVSQVLEAVEGSVRRTAKSNL----C--- 
mLY6F          LECYNCL--G--VSLG---I------A------C-KS--I--T-----------CPY-------PDAV-------CISQQVELIVDSQKNK----L----C--- 
BC010764       LQCYECY--G--VPIE---T------S------C-PA--V--T-----------C----R--AS-DGF-------CIAQNIELIEDSQRRKLKTRQ----C--- 
hCP1610069     LHCHVCC--G----HE----------H------C-ES--L--VE----------CAP-------TDKY-------CVITRATSPGGILV----MKS----C--- 
hCP49117       IWCHQCT--G--FGG------------------C-SH--G--SR----------C----L--RD-STH-------CVTTATRVLSNTEDLPLVTKM----C--- 
mLY6I          LECYQCY--G--VPFE---T------S------C-PS--F--T-----------CPY-------PDGF-------CVAQEEEFIANSQRKKVKSRS----C--- 
mLy6G          LECYNCI--G--VPPE---T------S------C-NT--T--T-----------CPF-------SDGF-------CVALEIEVIVDSHRSKVKSNL----C--- 
mCP17885       LECYNCL--G--VSLG---I------A------C-KS--I--T-----------CPY-------PDAV-------CISQQVELIVDSQRRKVKNKL----C--- 
AK009303       LRCYTCS-----FAKP-----------------C-DPV-P--RE----------C-------RE-DEV-------CGVSVGTSEQKEEEVIER-KQ----C--- 
mLY6C          LQCYECY--G--VPIE---T------S------C-PA--V--T-----------CRA-------SDGF-------CIAQNIELIEDSQRRKLKTRQ----C--- 
hLY6E          LMCFSCL--N--QKSN---L------Y------C-LK--P--TI----------C----S--DQ-DNY-------CVTVSASAGIGNLVTFGHSLSKT--C--- 
mLY6E          LMCFSCT--D--QKNN---I------N------C-LW--P--VS----------C----Q--EK-DHY-------CITLSAAAGFGNVNLGYTLNKG---C--- 
SCA-2-CHICKEN  LICFSCS--D--ASSN---W------A------C-LT--P--VK----------C----A--EN-EEH-------CVTTYVGVGIGGKSGQSISKG----C--- 
hPSCA          LLCYSCK--A--QVSN---E------D------C-LQ--V--EN----------C----T--QL-GEQ-------CWTARIRAVGLLTV---ISKG----C--- 
mPSCA          LQCYSCT--A--QMNN---R------D------C-LN--V--QN----------C----S--LD-QHS-------CFTSRIRAIGLVTV---ISKG----C--- 
mHEMT-1        LTCHKCYISN-TFS-------------------C-PKLSE--------------CS--SNL-----RR-------CMTVSFRVNIRLLYV---LKD----C--- 
mHEMT-3        MRCHSCQEHN-TFY-------------------C-PHIHY--------------CDMDI-------RR-------CLTVAIRVNIRLLYV---LKD----C--- 
mSlurp1        FRCYTCE--Q--PTAI---N------S------C-KN--I--AQ----------C----K--ME-DTA-------CKTVLETVEAAFPFNHSPMVTRS--C-- 
hSlurp1        LKCYTCK--E--PMTS---A------S------C-RT--I--TR----------C----K--PE-DTA-------CMTTLVTVEAEYPFNQSPVVTRS--C--- 
hGML           LRCHDCAVIN-DFN-------------------CPNIRV---------------CPYHI-------RR-------CMTISIRINSRELLVY---KN----C--- 
hNG24          IRCHSCY--K--VP-V---L------G------C-VD--R--QS----------C----R--LEPGQQ-------CLTTHAYLGKMWVFSN---LR----C--- 
hLy6D          LRCHVCT--S-SSN-------------------CKHSVV---------------CPASS-------RF-------CKTTNTVEPLRGNLVK---KD----C--- 
mLy6D          LRCHVCT--N-SAN-------------------CKNPQV---------------CPSNF-------YF-------CKTVTSVEPLNGNLVR---KE----C--- 
AK010485       LTCHVCE--A--QNSY---A-------------CSNPSQ---------------CPGEK-------KF-------CLLAVTRIFERFFYVS---KQ----C--- 
AK009282       FKCFTCE--N--AGDN---Y------N------C-NR--W--AE-DKW------C-------PQDTQY-------CLTVHHFTSHGRSTSIT—KK-----C--- 
AK005760       KDCVFCE--L--T-DS---A------R------CPGTHMR--------------C----G---D-DED-------CFTGHGVAQGVGPIIN---RG----C--- 
hLynx3         LRCYVCP--E--PTGV---S------D------C-VT--I--AT----------C----T--TN-ETM-------CKTILYSREIVYPFQGDSTVTKS--C--- 
mLynx3         LQCYTCA--N--PVSA---S------N------C-VT--T--TH----------C----H--IN-ETM-------CKTTLYSLEIVFPFLGDSTVTKS--C--- 
hLynx1         LDCHVCAY-N---GDN-----------------CFNP-MR--------------CPAMV-------AY-------CMTTRTYYTP-TMKVS---KS----C--- 








hLynx2         IQCYQCE--E--FQLN---N------D------C-SS--P--EFIV-N------C------TVNVQDM-------CQKEVMEQSAGIMYR----KS----C--- 
mLynx2         IQCYQCE--E--FQLN---N------D------C-SS--P--EFIV-N------C------TVNVQDM-------CQKEVTEQSAGIMYR----KS----C--- 
hLy6H          LWCQDCT--L--TTNS---S------H------C-TP--K--Q-----------CQP-------SDTV-------CASVRITDPSSSRKDHSVNKM----C--- 
mLy6H          LWCQDCT--L--A-NS---S------H------C-AP--K--Q-----------CQP-------TDTV-------CASVRITDPSSSRKDHSVNKM----C--- 
MCP9191        LKCHECS--G--IED------------------CYKPK----T-----------CSS-------QSLY-------CLTNWYTPPGQQTTVT---KT----C--- 
MCP9209        LQCHLC------KGF----G------G------C-SR--P--SS----------CPW--S--S---TH-------CVIIATRSPISFTDLPLVTKM----CY-- 
MCP3824        LICNSCE--K--SRDS----------R------CTMS--Q—SR-----------C-V-----AKPGES-------C-STVSHVGTKVY----SKQM----C--- 
α-bungarotx    IVCHT-T--A--T--I---P------S--------SA--V--T-----------CP------PG-ENL-------CYRKMWCDAFCSSRGKVVELG----C--- 
α-cobratx      LECHN-Q--Q--S--S---Q------T--------PT--T--TG----------C----S--GG-ETN-------CYKKRWRDHRGYR----TERG----C--- 
m3tx           LTCVT-S--K--S--I---F------G--------IT--T--EN----------CP------AG-QNL-------CFKRRHYVIPRYT---EITRG----C--- 
Erb            RICFN-H--Q--S--S---Q------P--------QT--T--KT----------C----S--PG-ESS-------CYHKQWSD-FRGI---IIERG----C--- 
κ-bungarotx    RTCLI-S--P--S--S---T------P--------QT-----------------CP------NG-QDI-------CFLKAQCDKFCSIRGPVIEQG----C--- 
CT             LKCKK-L--V--P--L---F------S---------------KT----------CP------AG-KNL-------CYKMFMVAAPH-----PVKRG----C--- 
FAS            TICYS-H--T--T--T---S------R--------AI--L--KD----------C--------G-ENS-------CYRKSRRHPPKM----VLGRG----C--- 
HagFishLeukme  LQCYRQE--K--DKVQ---TPK----N------C-SSG-E--Q-----------CASVKDKAGKVTKD-------C---------------------------- 
DCP34786       IKCWDCR--S--DNDP---K-------------CGDP-FDNSTLAITD------CQQAPELEHLKGVRPTM----CRKIRQKVHGEWRY----FRS----C--- 
DCP5238        IKCYQCE--S--LTMP---K-------------CGLK-FEADETLLLD------CSRIGPPRYLQNFFPLRNATGCMKKTLESVAGHP-QI—VRS-----C--- 
DCP5240        IKCYQCD--S--LTNS---E-------------CGKD-IKSDSSLVLD------CTKMAPPRFLQNFFPVRNATGCMKQTIDIPGNPQI----VRS----C--- 
DCP19784       LMCYDCN--S--EFDP---R-------------CGDP-FEPYSIGEVN------CSKQEPLEHLKDKYKPTL---CRKTVQKIYGKTRI----VRG----C--- 
DCP20347       IKCYQCK--S--LTDP---N-------------CAKDKIDSASNIRAVD-----CDSVPKPNTMEQLQPVTR---CNKVVTSDRAGTIV----SRD----C--- 
DCP3405        ITCYECD--S--VNNP---G-------------CGER-FVGDDISTTD------CDVVANMRSLGAEAT------CLTKYHEGMPGDTRFV—RRS-----C--- 
DCP23672       IKCFVCN--S--HKDA---N-------------CALD-I-PPDNLLKD------CDEQYSSRGKGIPTY------CRKITQIIEFSVNSLPPDSRVIRT-C--- 
DCP20494       IRCYQCS--S--DQDR---KGHDS---------CGAYKRFNRTEHISIE-----CNSDESHMPGSF---------CMKVVQQGPRGFIWDGRWRQVIRR-C--- 
DCP34289       IDCFKCV--S--YNGA---N-----KA------CDDPFHNNYSTAILESP----CMGGRKGRDGLFPATA-----CIKIAGYYDGTGET-IT-VRG----C--- 
DCP5234        LQCWHCS--S--D--TIGAE------DFCDVTFQEDNIPTDLIKERNINLLRS-CNGTINSDHERA-V-------CRKTVEENNGKLIT----KRF----C--- 
DCP18941       IWCYRCT--S--A--T---P------G------CAEKFNWRGIGFLGEH-----CPE-------PDDI-------CVKVTERRGARETI----TRD----C--- 
DCP33900       IRCHQCN--S--HDNE---D-------------CGGLVVNTPRAQRDNQVLTD-C----VPPSGEVAF-------CRKTVINFEQNDER-RI-ERS----C--- 
DCP34091       IECYVCD--T--SDTE---HPFQ----------CGEWFERYDIPDIQPQN----C-----SSVHGAQF-------CVKHVGRFEGGIGA----KRF----C--- 
DCP3238        RRCYQCR--S--RGEL---G-----------SCKDPFTFNATDVEQEPGVAAIPC--------ASGW--------CGKVIEGGGTYAIDDYDLAIQRM--C -- 
C15H9.9        ISCYQCT--S--NENP---T-------------CDAN-DDGALEAFKT------CTPLTEGTFKGNAAVG-----CRKITQSVEGVL-SV---VRE----C--- 
K11H12.6       LNCYICN--S--LNQP---E-------------CVHNY--EKFNKI--------CPVKSFGGMKSVKPLG-----CRVSRQYVKEET-SI---VRE----C--- 
K11H12.7       LNCYICN--S--KKQP---D-------------CIDN--Y--QAFNTI------CPVRSLGGVKLHEPVG-----CRVTRQYSKEKM-WI---IRE----C--- 
TO7D1.3        LKCRLYHRIWEDGHLLRINPDI-----------CHTSSQY--------------CVRATYSDPDERKKNGYSMG-CDK-------VD-------------CQG- 
PRED.PROT.     LQCHVVP--AG--NLSVPDT--SQRQE------CG--IG-SLT-----------CVKVVDFTRGTYTKQ------CQT---------------MN-----CTL 
CO9B9          -RCYSCM--S--KYYG---A------LW-RF-A---G-YTR-IYQEPGLFT----D------------------------------------------S-C-- 
HOT-1          ARCYSCM--SKLYEAVWPSLSHIYKRPRNFTDDCDDERIAEGRVPIVH------C----------------PTI-CVSLFEQPNIAGV—RIKGYIRG---C-- 
HOT-2          VECYSCM--SLSYQTSWKYLQTTYIYPKVFTDRCRDPKSERGMPTV-M------C----------------GSV-CVSLMEPDVEAGVFIGFKHI-RG--C-- 
HOT-3          -RCFSCM-SQMYEGFMSNGLDRYFNRPRNFSSQCDGEMDVTNMHTV-P------C----------------RTI-CLTIQQNLVVMGQPTGHRLYMRG--C-- 
HOT-4          -----CA--SFVYLPLWSQLMHHYYPPKNFTDRCWQPDS-GIGL-V-P------C----------------SSA-CFTLVERIDDVSEQHG-VIRG----C-- 
HOT-5          LKCFSCASFEYRVLFDKDTSLSRKVRVPKFDRLCDLEEMVRGYAPVEA------C----------------HST-CVTIFEPQYFGGLQSLQRPFLYIRGC-- 
ODR-2-2B       LPCYSCM--SPYLEDHYPYISHLYRKPLSFDTHCDKHSLETSYLYSKN------C----------------SDM-CVTLRINDVVGGRRRHGYMRG----C-- 
ODR-2-16       LPCYSCM--SPYLEDHYPYISHLYRKPLSFDTHCDKHSLETSYLYSKN------C----------------SDM-CVTLRINDVVGGRRRHGYMRG----C-- 






CD59-RABBIT     ----------------------EDC----------------------------NFEFIS--------NRL------E------ENSLKYNC---CRKDL-CN 
CD59-PIG        ----------------------DEC----------------------------NFDFIS--------RNL------A------EKKLKYNC---CRKDL-CN 
CD59-MARMOSET   ----------------------EDC----------------------------TFRQLS--------NQL------S------ENELKYHC---CRENL-CN 
CD59-MONKEY     ----------------------DDC----------------------------SFKRIS--------NQL------S------ETQLKYHC---CKKNL-CN 
CD59-OWLMONKEY  ----------------------EDC----------------------------TFSRVS--------NQL------S------ENELKYYC---CKKNL-CN 
CD59-GREENMONK  ----------------------ANC----------------------------NFNDIS--------TLL------K------ESELQYFC---CKKDL-CN 
CD59-BABOON     ----------------------ANC----------------------------NFNDIS--------TLL------K------ESELQYFC---CKEDL-CN 
hCD59           ----------------------EHC----------------------------NFNDVT--------TRL------R------ENELTYYC---CKKDL-CN 
mCD59           ----------------------SDC----------------------------HGEIIM--------DQL------E------ETKLKFRC---CQFNL-CN 
rLY6A           --------LPV-------------C--------------PTSP----------QT----------TEILG------T------VVDMKISC---CNTDL-CN 
mLY6A           --------LPI-------------C--------------PPNI----------ES----------MEILG------T------KVNVKTSC---CQEDL-CN 
PUT-LY6B        --------LPG-------------C--------------PKSP----------QT----------PEVLG------T------VVHVNTDC---CNTDL-CN 
rLY6C           --------LPI-------------C--------------PKFP----------QR----------TEILG------T------VVYTKVSC---CNTDL-CN 
mLY6F           --------FPF-------------C--------------PANL----------EN----------MEILG------T------TVNVNTSC---CKEDL-CN 
BC010764        --------LSF-------------C-----------------P----------AG----------VPIRD------P------NIRERTSC---CSEDL-CN 
hCP1610069      --------SPT-------------C-----------------P----------NSTVSS------------------------SRALSVSC---CQGSQ-CN 
hCP49117        --------HIG-------------C-----------------P------------DIPS--------LGL-------------GPYVSIAC---CQTSL-CN 
mLY6I           --------HPF-------------C--------------PDEI----------EK----------KFILD------P------NTKMNISC---CQEDL-CN 
mLy6G           --------LPI-------------C--------------PTTL----------DN----------TEITG------N------AVNVKTYC---CKEDL-CN 
mCP17885        --------FPF-------------C--------------PANL----------EN----------MEILG------T------TVNVNTSC---CKEDL-CN 
AK009303        --------LPR-----------AQC-----------------P------LLGH-ATYWS-----------------R------SYSLRHQC---CEQDL-CN 
mLY6C           --------LSF-------------C--------------PAGV-----------------------PIKD------P------NIRERTSC---CSEDL-CN 
hLY6E           --------------------SPA-C-----------------P--------------------IPEGVNV------G------VASMGISC---CQSFL-CN 
mLY6E           ----VNLG-YT--L------NKG-C--------------SPIC----------PSENVN--------LNL------G------VASVNSYC---CQSSF-CN 
SCA-2-CHICKEN   --------------------SPV-C----------------------------PS----------AGINL------G------IAAASVYC---CDSFL-CN 
hPSCA           --------------------SLN-C----------------------------VD----------DSQDY------Y------VGKKNITC---CDTDL-CN 
mPSCA           --------------------SSQ-C----------------------------ED----------DSENY------Y------LGKKNITC---CYSDL-CN 
mHEMT-1         --------TKD-------------CTF------------IYR---------------EHVPPELPRVLKD------V------KNFYFVMC---CSSIT-CN 
mHEMT-3         --------TKD-------------CTF------------IYR---------------EHVPPELPRVLKD------V------KNFYFVMC---CSSIT-CN 
mSlurp1         --------------------SSS-C----------------------------LA----------TDPDG------I------GVAHPVFC---CFRDL-CN 
hSlurp1         --------------------SSS-C----------------------------VA----------TDPDS------I------GAAHLIFC---CFRDL-CN 
hGML            --------TNN-------------CTF------------VYA---------------AEQPPEAPGKIFK------T------NSFYWVCC---CNSMV-CN 
hNG24           ----GTP--------E-EP-----CQE------------AFN---------------QT--------NRK------L------GLTYNTTC---CNKDN-CN 
hLy6D           --------AES-------------CTP------------SYT---------------LQ--------GQV------S------SGTSSTQC---CQEDL-CN 
mLy6D           --------ANS-------------CTS------------DYS---------------QQ--------GHV------S------SGSEVTQC---CQTDL-CN 
AK010485        --------TRR-------------CPTPVVSPPSTNP--PS--------------------EPKEFLIEK------P------MPFLFYKC---CQWDS-CN 
AK009282        --------ASK-NE----------CHF------------VGC---------------RH--------SRD------S------EHTECRSC---CEGMI-CN 
AK005760        ---------------VHST----SC------------------GRE-------EP----------ISYMG------L------TYSLTTTC---CSGHL-CN 
hLynx3          --------ASK-------------C-----------------------------------------DVDG------I------GQTLPVSC---CNTEL-CN 
mLynx3          --------ASK-------------C----------------------------EP----------SDVDG------I------GQTRPVSC---CNSDL-CN 
hLynx1          --------VPR-------------C-----------------------------FETVY--------DGY------S------KHASTTSC---CQYDL-CN 
mLynx1          --------VPS-------------C-----------------------------FETVY--------DGY------S------KHASATSC---CQYYL-CN 






mLynx2          --------ASS-----------AAC--------------LIA---------------SA--------GYQ------SFCSPGKLNSVCISC---CNTPL-CN 
hLy6H           --------ASS-------------CDF------------VKR---------------HFFSDYLMGFINS------G------ILKVDVDC---CEKDL-CN 
mLy6H           --------ASS-------------CDF------------VKR---------------HFFSDYLMGFINS------G------ILKVDVDC---CEKDL-CN 
MCP9191         --------A-------------YTC----------------------------------PD------INH------V------TANSKSSC---CNTDL-CN 
MCP9209         ----------------------SGC----------------------------------PDV----SSLG------L------GPHVSIAC---CQSNL-CN 
MCP3824         ----------S-----------PQC--------------KEK-----------Q-------------LNT------G------KKLIYIMC---CEKNL-CN 
a-bungarotx     --------AAT-------------C-----------------P----------SK----------------------------KPYEEVTC---CSTDK-CN 
a-cobratx       -----------------------GC-----------------P----------SV----------------------------KNGIEINC---CTTDR-CN 
m3tx            --------AAT-------------C-----------------P----------IP----------------------------ENYDSIHC---CKTDK-CN 
Erb             -----------------------GC-----------------P----------TV----------------------------KPGIKLSC---CESEV-CN 
k-bungarotx     --------VAT-------------C-----------------P----------QF---------------------R------SNYRSLLC---CTTDN-CN 
CT              --------IDV-------------C-----------------P----------KS----------------------------SLLVKYVC---CNTDK-CN 
FAS             -----------------------GC-----------------P----------PG----------------------------DDYLEVKC---CTSPDKCN 
HagFishLeukme   --------ATT-----------EMC--------------KKE---------------KNVT------ILD--------------VTGTIKC---CKKDL-CN 
DCP34786        ----AYMGE------PGIEGDERFC----------------------------LM----------RTGSY------N------IFMEF--CT--CNSKDGCN 
DCP5238         ----YFGDI---------NNIQAGC----------------------------QS----------DPSMP------F------VKQLG--CDV-CTKDE-CN 
DCP5240         ----YFGNI---------ADTKVGC----------------------------QT----------DPSLT------I------NKLLS--CEV-CTEDE-CN 
DCP19784        ----GYIPD---------ENTDNKC----------------------------V-----------RRSGT------H------DVAAIY-CS--CTKDL-CN 
DCP20347        ----HFESI---------GQKDNEC----------------------------TV----------THSRQ---------------VES--CYT-CKGDL-CN 
DCP3405         ----YFGDA---------SPIGVSC----------------------------D--------DGPDPVVP------F------MNFLG--CTL-CDTDL-CN 
DCP23672        ----AYQNQ----------TSTNYC--------------------------------YQ--------RAG------F------GGRQVV-CS--CDTDN-CN 
DCP20494        ----ASVSD---------TGVVGVC----------------------------N--------WG---VYE------N------GVYWEE-CY--CSSDS-CN 
DCP34289        ----ALDSGTLTTDTEIIRMSH--C-----------------------------GKFYY--------DDK------Y------VHG----CLQSCSDADACN 
DCP5234         ----YYTNK---------SDPVELC----------------------------NI----------TSPEK------N------VRRIF--CED-CLTDR-CN 
DCP18941        -------LSALSFRKDIPADKYEGC-RPAAHDEKLANYVNHTIKE------------HDVRR------DY------Y-------TDTTF-CF--CFLDHRCN 
DCP33900        ----GFIPE----------KIQNAC--------------------------------FT--------ADN------E------GYKQII-CT--CPDEG-CN 
DCP34091        --------SSK--------DMGNYC--------------------------------DYVR----NKGDR------M------DYRS---CIYTCDTDG-CN 
DCP3238         -----VQRGPD--------DNMDRC--------------------------------AD--------TIY------N------YKKVYM-CF--CQGDL-CN 
C15H9.9         -----AYSGE-----PVD---------------------G-------------L-----------KKTGN------H-----AIRIHYYQCENE-KAGTPCN 
K11H12.6        -----AYTGE-----DIE---------------------R-------------K-----------SNKGS------L-----GVSRVYSQCSEN----L-CN 
K11H12.7        -----GYLGE-----ERE---------------------R-------------K-----------FNTTTYLNGVKE------PAT---CVFSQCSENL-CN 
TO7D1.3         IDDPTYTGWQQK-------KTGEYC--------------------------------RK--------SRD------Y------GKKGEICC---CADDM-CN 
PRED.PROT.      ----MQ-------------NAAANC--------------------------------QN--------SSA------F------GVNGATCC---CYGDG-CN 
CO9B9           --VSGT-G---AK-GY-IRG ---CWGSVFLFGFNRT---------------------------------------------------V-CS--CRGPL-CN 
HOT-1           MSDVLISGFNQTIVTWYRWMHRDSC----------------RPYRKKELFKL--------------GGESA-----D-------DSTIDVCT--CYADH-CN 
HOT-2           LDRVLRHGFNQSALRTHRFHQNNHC----------------RTLSRSALFNP------------ARQTDPP-----A-------LGDVQLCS--CYGDR-CN 
HOT-3           A----LTIARANNHTLSMFDRYDICRDM-------------S----------------ASDLF---SHEHA-----D-------SQRIRVCS--CLGDR-CN 
HOT-4           MDRLLLFGLDDDVRNILSAYENQRVC---------------R----------------HTDRKLLRLFPLS-----G-------QTDVTFCS--CNGDF-CN 
HOT-5           A-DHIFSSMKDRPIEVEFLHRSPIC----------------VKLQLS----QI-------------YPQVQ-----A-------NEIVQVCS--CDKDG-CN 
ODR-2-2B        L----SDLHGYNHSLIRTLAERQGC----------------LDTTARELFLP------------TAQRQEL-----E-------PSRLSLCA--CHNNL-CN 
ODR-2-16        L----SDLHGYNHSLIRTLAERQGC----------------LDTTARELFLP------------TAQRQEL-----E-------PSRLSLCA--CHNNL-CN 
ODR-2-18        L----SDLHGYNHSLIRTLAERQGC----------------LDTTARELFLP------------TAQRQEL-----E-------PSRLSLCA--CHNNL-CN 
 
 Figure 5: Sequence Alignment of Ly6 domains of Ly6SF proteins. Ly6 domain 
sequences of 85 Ly6SF proteins were aligned with Dialign2 program and adjusted 
manually. Cysteines that are used for disulphide bridges and the final aa’s of the ly6 
domains are highly conserved. Color coding was designed as follows: X. aliphatic 
residues; C. conserved cysteines; X. aromatic residues; X. polar residues; D. small 
residues; L. aa’s with large side-groups; N. conserved asparagines. 
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 Since the conserved aa's above were alike in most Ly6SF proteins, they might be 
conserved for structural purposes. When the sequences of Lynx1, Lynx2, Lynx3 and 
Ly6H were analyzed separately from this group, there are certain residues that are 
conserved in Lynx1, 2 and 3 but not in Ly6H, which suggested that these might be 
involved in target receptor specificity. For instance, the serine residues that precede the 
6th and 8th cysteines are conserved in Lynx1, Lynx2 and Lynx3, while in Ly6H, there is 
either a methionine or an aspartate instead. Serines are not only smaller than methionines, 
and are targets for phosphorylation, but also not charged like aspartate or hydrophobic 
like methionines. Since lynx1, lynx2 and lynx3 can bind to and modulate nicotinic 
receptors and Ly6H cannot (please see chapter 3 for further information), conserved 
amino acids like these serines might be important for receptor specificity (Figure 7).  
In vertebrates, Ly6 proteins are mostly GPI anchored, with the exceptions of 
snake venom toxins, SLURP1, SLURP2 and SVSVII.  Some Ly6SF proteins in C. 
elegans lack the GPI anchor signal sequence, although they still have the N-terminal 
signal sequence, suggesting that they may be secreted. In D. melanogaster, most of the 
Ly6 proteins have a short trans-membrane sequence instead of a GPI anchor. One of the 
C. elegans Ly6SF members has only 7 cysteine residues, but was still included since 
some of the three finger toxins have less cysteine residues than the α-neurotoxins. 
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 Phylogenetic Inference 
I have collaborated with Dr. Marcelo Briones for modeling the phylogenetic tree 
of these proteins. Phylogenetic inference was performed using the Vanilla 1.2 frontEnd to 
PAL 1.2 (Phylogenetic Analysis Library) [207]. An unrooted tree was inferred from 
maximum likelihood distance matrices. In the phylogenetic tree, there are very few 
branches for specific subfamilies, which also correlates with the divergence of the 
sequences. Some of these subfamilies, including CD59 subfamily, snake venom toxin 
subfamily and mammalian Ly6 genes that are expressed mainly in hematopoietic cells are 
highlighted in figure 6. 
There were four large branches that originated from the unrooted tree. The first 
large branch included most of the invertebrate Ly6SF genes and the snake toxins as well 
as a couple of mammalian genes. The snake toxins formed a single small branch 
suggesting that they share a stronger homology. Some of the mammalian genes formed 
very small branches with invertebrate genes, which might suggest they might be 
orthologues. For instance, Lynx5, which was shown as AK009282, shared a small branch 
with one C. elegans and two Drosophila genes. In the second large branch, CD59 
proteins from various vertebrate organisms formed a smaller close branch. The C. 
elegans proteins CO9B9 and the Drosophila protein DCP20347 might be orthologues of 
CD59 in invertebrates. Since complement mediated immune system is present in both 
these organisms, these proteins might have a similar function to their mammalian 
orthologues.  
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 The third large branch in the unrooted tree included the Ly6 proteins expressed in 
cells of the immune system and some Drosophila and C. elegans proteins. Neither 
Drosophila nor C. elegans have cells of adaptive immunity. However, Drosophila 
homologues of several T-cell differentiation proteins have been shown to function in 
innate immunity and development. Therefore, these proteins may function as a part of 
innate immunity or might be involved in development.   
The fourth large branch included a very divergent group of vertebrate Ly6SF 
proteins and C. elegans and Drosophila homologues of lynx2. In this branch, lynx3, 
SLURP-1, PSCA and Ly6E form a smaller branch. Lynx3 and SLURP-1 both modulate 
nAChRs and are expressed in keratinocytes and epithelial cells. PSCA and Ly6E are also 
expressed in epithelial cells, and might be involved in nicotinic receptor modulation as 
well. mLynx2, hLynx2 and C. elegans and Drosophila homologues of Lynx2 form 
another smaller branch, which is due to high level of sequence conservation of lynx2 
among different organisms (Figure 6).  
Among the 85 proteins that were analyzed with phylogenetic inference, 56 are 
expressed in vertebrates and 29 are expressed in invertebrates. There are 23 murine and 
14 human Ly6SF genes. Among the human and mouse Ly6 proteins, only 23 have been 
previously described, 14 are encoded by novel genes (Figure 8).  
Lynx Subfamily of Proteins 
Lynx1 is a Ly6 protein that is expressed in the CNS and modulates nAChRs. 
Since sequence similarities do not point out to a subfamily of lynx1 homologues, in a 







Figure 6: Phylogeny of Ly6SF proteins and sequence alignment of lynx1 homologues. 
 Ly6 domain sequences of 85 members of Ly6SF from invertebrates and vertebrates 
were phylogenetically analyzed and an unrooted phylogeny was inferred. The 
sequences are very divergent except for the Ly6SF members expressed in hemopoietic 
cells (green circle), CD59 homologues in different organisms (pink circle) and toxins 
(blue circle). Lynx homologues are shown in yellow circles. B. Ly6 domain sequences 
of lynx1 homologues were aligned by Dialign2 (Morgenstern, 1999) and Boxshade 
programs.  
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Figure 7: Scheme of ly6 domain structure after our analysis.  The black 
aminoacids are conserved in most ly6 proteins. The red amino acids are 
conserved in lynx1, lynx2, and lynx3 but not in ly6h. 
            +-------+        +-------------------------+                                  +-------+    
             |          |          |                                   |                                   |           |  
AxCRPCxxxxCxxxxCxxxxCxxxxxxxxxKSCxxxxCxxxxxxxxxSCCPxTBCN  
     |                                       |                                   |                      |   
    +----------------------------+                                  +---------------+          
  
‘A’: aliphatic aminoacid (Leucine or Isoleucine)  
‘C’: conserved cysteine involved in a disulfide bond.  
‘R’: Aromatic amino acid (histidine, phenylalanine, tyrosine, tryptophan) 
‘P’: polar aminoacid 
‘K’: Positively charged aminoacid 
‘T’: amino acid with a small side group 


















Figure 8: Species distribution of Ly6SF genes. Out of 85 Ly6SF genes analyzed, 
29 of them were found in invertebrates and 56 of them are vertebrate genes. 
Among the vertebrate Ly6SF genes, 23 of them are expressed in mice and 14 are 
expressed in humans. 23 of the mouse and human genes were previously 
described and 14 of them are novel genes.  
 identified as brain enriched Ly6 proteins. While lynx2 and lynx5 are heavily expressed in 
the brain, lynx3 and lynx4 were later shown to be expressed primarily in other tissues. 
Lynx2 was first identified as a part of Sugano brain cDNA library. 
Many of the Ly6SF genes are clustered in a small region (~ 600CM) on 
chromosome 15 in mice and human chromosome 8. Lynx-2 and Lynx5 have been 
mapped to chromosome 1 in mice and chromosome 2 in humans, which are not Ly6 
cluster regions. However, we already know that CD59, which is another Ly6SF member, 
is also on another chromosome. Lynx-1, Lynx-3, Lynx4 and Ly6H are located on the 
same chromosome, next to other Ly6 genes. Their alignment on mouse chromosome 15 
is shown in figure 9. 
Exon-Intron Structures of Ly6SF genes 
All vertebrate Ly6SF genes share similar exon-intron structures including lynx1, 
lynx2, lynx3, lynx4 and lynx5.  Thorough analysis of genomic structures of lynx1, lynx2, 
lynx3, lynx4 and lynx5 are shown in figure 10. There are three exons that make up the 
coding region. In some Ly6SF genes, there is an extra exon, which encodes the 5’UTR 
sequence. An example for this is the human Ly6D gene. For most Ly6SF genes, the three 
coding exons have the scheme shown in Figure 10. The 5’UTR region and part of the 
signal sequence that is required for secretion or for directing the proteins to the 
membrane are encoded by the first exon. The second exon encodes the rest of the signal 
sequence, which is approximately 30 aas long in total, and the first half of the Ly6 
domain, which is shown as “mature protein” in the figure. The third coding exon has the 
second half of the Ly6  
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        mouse chr15
lynx3                    NG               lynx1                 ly6D                 NG                 lynx4 
1                        10467            15560               29759              38616             66630 
2069                  14397            20657               31315              46029             69625 
Figure 9: The alignment of Lynx1, Lynx3 and Lynx4 on murine chromosome 
15. NG represents novel gene. The numbers under the gene names represent the  
relative distances of the coding sequences of these genes from each other in base 








5’UTR Signal Seq Mature Protein GPI 3’UTR 
Figure 10: Exon-intron structures of Lynx homologues. Organizations of exon-
intron boundries of lynx homologues are similar to each other and other ly6 
superfamily members. Exons are represented in boxes. The green boxes 
symbolize 5’UTR regions, the pink boxes symbolize the signal sequence, the 
blue boxes symbolize the mature protein, the yellow boxes symbolize the GPI  
anchorage sequence, and the purple boxes symbolize the 3’UTR sequence.  
 domain, the GPI anchorage signal in case of the GPI-anchored Ly6 proteins or the short 
hydrophobic – potentially transmembrane- domain in some D. melanogaster Ly6 genes, 
or no such domain in secreted Ly6SF proteins, and a 3’UTR sequence (Figure 10).   
After phylogenetic inference of Ly6SF proteins was completed, the Nishi lab 
initiated collaboration with our lab that aims to identify lynx proteins in avian genome. 
Nicotinic signaling results in programmed cell death in avian ciliary ganglion. After 
lynx1 has been shown to modulate nAChRs, they wanted to analyze effects of lynx 
proteins in nicotinic induced cell death in avian ciliary ganglion. I have identified six 
novel avian ly6SF proteins by searching avian genome for lynx1 and lynx2 homology 
using the same criteria from my previous study. Nishi lab analyzed their expression 
patterns in developing chick ciliary ganglion and found that one of these genes, ChLy6, is 
upregulated during apoptosis. When this molecule was misexpressed, it rescued neurons 
from dying. I have identified that ChLy6 is a homologue of mammalian prostate stem cell 
antigen (PSCA). Sequence alignments of Ly6 domains of avian Ly6SF proteins and 
whole protein sequences of ChLy6 and mPSCA are shown in figure 11 and figure 12 
respectively. 
These results identify novel Ly6SF genes in several organisms, and demonstrate 
the extreme divergence of this gene family in spite of the high conservation of the 























Figure 11: Sequence alignment of Ly6 domains of avian Ly6SF proteins. Six 
avian Ly6SF proteins were identified according to previously described criteria. 





Ch6Ly  MKVFFILLLAAILCTDPGSSLQCYSCKTKLSNSNCQATMNCKENE-MCKT 
mPsca  MKTVFFLLLATYLALHPGAALQCYSCTAQMNNRDCLNVQNCSLDQHSCFT          
   **..*:****: *. .**::******.:::.* :*  . **. ::  * * 
 
Ch6Ly  DVIRVIGFFSIISKGCEASCQEDYQDFKVGNRNVSCCSTNLCNVNAAGSV 
mPsca  SRIRAIGLVTVISKGCSSQCEDDSENYYLGKKNITCCYSDLCNVNGAHTL 
  . **.**:.::*****.:.*::* ::: :*::*::** ::*****.* ::  
 
Ch6Ly  R--SSYGMAAGISASLLWTFLNNRL 
mPsca  KPPTTLGLLTVLCSLLLWGSS--RL 
       :  :: *: : :.: ***     **   
 
Figure 12: Ch6Ly is a homologue of mPsca. The protein sequences of Ch6Ly and 
mPsca were aligned with Dialign2 and alignment was analyzed with Boxshade 







CHAPTER 3:  




 I have identified 24 mouse Ly6SF genes in our phylogenetic analysis, 11 of which 
are novel genes. In order to identify lynx homologues that function in nicotinic receptor 
modulation, I searched expression databases for expression information on mouse and 
human Ly6SF genes. I further analyzed expression patterns of mouse Ly6SF genes that 
have little expression information in the databases with RT-PCR (reverse transcriptase-
polymerase chain reaction) analysis. Among these genes, CNS expression of lynx2, 
lynx3, lynx4 and Ly6H were assessed with EGFP expressing-BAC transgenic mice. 
Lynx2 expression was further investigated with Northern and Western blotting and was 
compared with lynx1. Since lynx3 is expressed mostly in the periphery, distribution of 
lynx3 protein in various tissues including stomach, lungs, thymus and olfactory epithelia 
was analyzed with fluorescent microscopy and immunohistochemistry in lynx3 BAC 
transgenic mice. 
 Lynx1 forms stable complexes with α4β2 and α7 nAChRs in mammalian tissue 
culture cells. I have investigated if lynx2, lynx3 and Ly6H can also form stable 
complexes with nAChRs through co-immunoprecipitation analysis. I also tested if lynx2, 
lynx3 and Ly6H can modulate desensitization of nAChRs through voltage clamp 
recordings in Xenopus oocytes.  
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 Expression Analysis of Lynx1 Homologues 
Database analysis for expression of human and mouse Ly6 genes 
  I have analyzed various databases including the Institute for Genomic Research 
(TIGR), Serial Analysis of Gene Expression (SAGE) and expressed sequence tag (EST) 
databases for expression information for the novel mammalian genes. Summaries of the 
preliminary examinations for some of the human and mouse Ly6SF genes are shown in 









 Table 2: Summary of Expression information of human Ly6SF genes derived from 
TIGR, SAGE and UNIGENE databases. Ly6SF genes are also expressed in many cancer 
cell lines. All the proteins whose names start with hCP or mCP are initially identified as 








Expression in Human tissues according to 
TIGR, UNIGENE and SAGE databases 
hLynx5 2 mLynx5 Lung, colon, ear, esophagus, head-neck, 
ovary, kidney, testis 
hNG24 6p21.33 mNG24 Heart, ovary, placenta, brain, skin 
hG5B 6p21.3 mG5B Placenta, prostate, stomach 
hG5C 6p21.33 mG5C Breast, CNS, eye, heart, ovary, thymus, testis, 
lung, tonsil, pancreas, cerebellum, mammary 
gland, fetal lung  
hCP49117 8 mCP128173 Brain, colon, esophagus, lung, head-neck, 
placenta, kidney, uterus 
hLynx3 8q24 mLynx3 No expression information 
hPSCA 8q24.2 mPSCA Prostate, blood, breast, colon, heart, kidney, 
pancreas, placenta, skin, stomach  
GML 8q24.3  Prostate, cerebellum, pancreas, mammary 
gland 
hLy6E 8q24.3 mLy6E Widespread expression including: breast, 
lung, pancreas, placenta, brain 
hSLURP-1 8q24.3 mSLURP-1 Keratinocytes, heart, cervix, esophagus, 
larynx, lung, pancreas, mammary glands, 
prostate, uterus 
hLy6D 8q24.3 mLy6D Pancreas, fetal heart 
hSP-10 11p12-q13 mSP-10 Sperm, testis, brain 
hCD59 11p13 mCD59 Widespread expression including: mammary 
epithelial cells, skin, brain, placenta, liver, 
spleen, pancreas, heart, lung, testis,, kidney 
hCP49491 19 AK008654 Brain, heart, breast, lung, colon 
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 Table 3: Summary of expression information of mouse Ly6SF genes derived from TIGR, 





Expression in Mouse tissues according to 
TIGR, UNIGENE and SAGE databases 
mSLURP-1 15 hSLURP-1 embryo 
mPSCA 15 hPSCA Widespread expression including: prostate, 
testis 
AK008851 5  Embryo, liver, kidney, stomach, tongue. 
Shares 99% homology with mPSCA. 
mLy6A/E 15 hLy6A/E Widespread expression including: kidney, T-
cells, spleen, embryo, brain, placenta 
mLy6C 15 hLy6C Colon, embryo, heart, kidney, liver, lung, 
mammary gland, muscle, placenta, skin, 
brain, spleen  
mLy6I 15 hLy6I lung 
mLy6F 15 hLy6F Kidney 
mLy6D 15 hLy6D Embryo, lymphocytes, skin, spleen, 
mammary gland, salivary gland 
mLy6E 15 hLy6E Brain, colon, salivary gland, liver, stomach, 
placenta, thymus 
mCD59 2 hCD59 Widespread expression 
mHEMT1 15 hGML Uterus, testis 
mLynx1 15 hLynx1 Brain, embryo, muscle, skin, mammary gland 
mLy6H 15 hLy6H Embryo, brain, mammary gland 
AI747831 15  Kidney, liver 
BB646386 15  Uterus, colon, testis 
AK009303 17  Embryo, lung, skin 
AV082481 15  tongue 
mSVSVII 9  Urinary bladder 
AK008654 7  Embryo, skin, stomach 
mLynx3 15 hLynx3 Embryo, kidney 
mLynx4 15  Thymus, testis, tongue, placenta 
mLynx5 1 hLynx5 Colon, embryo, skin, spleen, kidney, thymus 
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 RT-PCR Analysis of Ly6 Genes and Northern Blots 
  Database searches gave us only preliminary information about the expression 
data of some of the Ly6SF genes. Therefore, I decided to analyze the expression patterns 
of these genes with Reverse Transcriptase Polymerase Chain Reaction (RT-PCR). I have 
used total RNA isolated from multiple tissues as template. The genes analyzed through 
this method and the results of their RT-PCR analysis are described below and shown in 
figure 13.  
AK008654 is located on mouse chromosome 7, and in RT-PCR, I observed that it 
has a strong expression in lungs, and weak expression in brain and liver. I didn’t detect 
any expression in stomach, kidney, heart or muscle. AK009303 is located in chromosome 
17 and its expression was strong in brain, stomach and lung and in weak in liver and 
kidney. I couldn’t detect AK009303 mRNA in heart or muscle.  
AI747831 is located on mouse chromosome 15, within the Ly6 locus. I have 
observed that it has high levels of expression in brain, liver, stomach, kidney and heart 
and expressed in lower amounts in lung. BB646386 is also located within the Ly6 locus 
on chromosome 15, and it is expressed strongly in brain and weakly in lung, liver, kidney 
and heart. 
AV082481 is also located in Ly6 locus on chromosome 15, and strong expression 
of this gene was detected in brain, stomach, kidney, heart and lung. I observed a low level 
of expression in liver. 
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Figure 13: RT-PCR analysis of Ly6 protein in seven different tissues: In all 
pictures, the order of tissues is as following: 1) Brain, 2) Liver, 3) Stomach, 
4) Kidney, 5) Heart, 6) Muscle, 7) Lung. A: B-actin as positive control, is 
expressed in all seven tissues, however, the amplification in muscle RNA is 
low, which suggests that muscle RNA was not as good as the other tissues. B: 
AK008654 is amplified in stomach and lung, and wasn’t amplified in other 
tissues. C: AI747831 is amplified in brain, liver, stomach, kidney and heart. 
D: BB646386 is expressed in brain, kidney and lung in high amounts (highest 
in brain), and is expressed in low amounts in liver and heart. E: AK009303 is 
expressed in high amounts in brain and in stomach and in lower amounts in 
liver, kidney and lungs. F: AV082481 is expressed in high amounts in brain, 
stomach, kidney, heart and lung, and in low amounts in liver. G: Lynx5 is 
expressed in high amounts in brain and heart.  
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            AK009282, which is located close to lynx2 on chromosome 2, is expressed in high 
amounts in brain and heart and has weak expression in lung and stomach. The results of 
this preliminary expression analysis are important for finding future targets of study. 
The expression analysis of Lynx-2 has been performed with a mouse multiple 
tissue Northern blot shown in figure 14. Lynx2 cDNA is ~1500bp in size. A specific high 
level of expression of Lynx-2 was observed in brain whereas I couldn’t detect any Lynx2 
expression in heart, liver, skeletal muscle, testis, spleen, lung and kidney. In a multiple 
tissue dot-blot analysis, I observed that Lynx2 is expressed highly in brain, and it has 
very low levels of expression in submaximillary gland, prostate, epididymis and testis. I 
also observed that Lynx2 is expressed early in development, having expression in 
embryos at age E11, E15 and E17 and no expression at age E7 (Figure 15).  
Lynx2 expression pattern in embryos and parts of adult CNS has been recently 
published by Dessaud et. al. [46]. They have shown that at age E10.5 and E12.5, lynx2 is 
expressed in trigeminal motor nucleus (cranial nerve V), and glossopharyngeal (cranial 
nerve IX) and vagal (X) cranial ganglia. At age E12.5, lynx2 expression is detected in 
brachial motor neurons, caudal thoracic motor neurons and few lumbar motor neurons in 
spinal cord. Lynx2 is also expressed in developing limb buds at age E12.5. Although it is 
clear that the lynx2 expressing cells in developing limb buds are not muscle cells, the 
identity of these cells is not known [46]. 
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A       B      C      D      E       F      G      H
Figure 14: Northern blot analysis of lynx2. lynx2 mRNA expression was 
higher in brain compared to other organs represented on the blot. A. Heart; B. 
Brain; C. Spleen; D. Lung; E. Liver; F. Skeletal muscle; G. Kidney; H. Testis 
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Figure 15: Dot blot analysis of lynx2 expression. Lynx2 is highly 
expressed in brain and expressed in lower amounts in prostate, 
epididymis, submaxillary gland and uterus. In embryo, lynx2 expression 
is observed at age E11, E15 and E17 but is not detectable at E7.  
  
 In situ hybridization analysis 
As described by Miwa et al. [69], Lynx1 is expressed in CA2 and CA3 regions of 
hippocampus, Purkinje cells of cerebellum, and layers V and VI of cortex in the adult 
mouse brain. Through in situ hybridization analysis, I found that mouse Lynx2 and Ly6H 
are also expressed in the adult brain; however, their expression patterns differ from the 
one of Lynx1. Lynx2 is expressed in CA1 region of hippocampus, dentate gyrus, Golgi 
cells of the cerebellum, and in scattered cells in layers IV and V in cortex. Lynx2 is also 
observed in amygdala, and specific nuclei in the brainstem (data not shown). Ly6H has a 
more widespread expression, it is expressed in all three CA regions of hippocampus, 
dentate gyrus, layers I-V in cortex and in the purkinje cell layer of cerebellum. Although 
I didn’t observe any detectable expression of Lynx3 in adult mouse brain, I detected its 
expression in olfactory epithelia on E15.5 mouse head sections through in situ 
hybridization. The in situ hybridization detection sites match with the expression data 
from the GENSAT BAC transgenic database for Lynx3 and Ly6H. The in situ 
hybridization results I had also match Allen Brain Atlas Database results for lynx1 and 
lynx2 (Figure 16).  
On E15.5 head cryostat sections, Lynx1 is expressed in specific nuclei in brain 
stem. Lynx2 is also expressed in the same region in brain stem however its expression is 
stronger and the area it’s expressed in is larger than Lynx1. Lynx2 is also expressed in 
migrating interneurons in cerebellum. Lynx3 is expressed in olfactory tract. Ly6H is 
expressed in cortex, brainstem, olfactory bulb and cerebellum in very low levels so that it 
was barely detectable through in situ hybridization. Lynx1 and Lynx2 do not have any 
expression data on GENSAT server (Figure 17). 
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 Taken together, these results show that Lynx1 homologues have distinct 
expression patterns in mice. 
BAC Transgenic Mice Show Expression Patterns of Lynx Homologues 
 BAC transgenic animals were prepared by the method described in Gong et al 
[208]. Lynx3 BAC transgenic mice expressed Enhanced Green Flourescent Protein 
(EGFP) under the lynx3 promoter; therefore, the cells that normally express lynx3 also 
expressed EGFP. The lynx3 BAC transgenic mice were analyzed at three different ages. 
At age E15.5, immunohistochemistry with anti-EGFP antibodies on frozen embryo head 
sections revealed lynx3 expression in olfactory cells, respiratory epithelium, developing 
colliculi, pituitary gland and retina (Figure 18-GENSAT data). When I perfused the 
whole embryos at age E15.5, and visualized EGFP in the whole embryo, I also detected 
fluorescence in olfactory epithelia and in palate (Figure 19).  
At age P7, lynx3 expression was detected in olfactory bulb, scattered cells in 
dentate gyrus, olfactory cells, superior colliculus, visual afferents, vestibular nucleus and 
forebrain on frozen brain sections (Figure 20-GENSAT data). In adult frozen brain 
sections, lynx3 expression could only be detected in olfactory bulb, probably in the 
olfactory ensheathing cells surrounding the exons coming to the glomeruli, through 




Figure 16: Differential expression of lynx1, lynx2, lynx3 and ly6h in the adult mouse 
cerebral cortex and hippocampus. In situ hybridization analysis using lynx1, lynx2, lynx3 
and ly6h as probes, showed that in hippocampus, lynx1 is expressed in CA2 and CA3 
regions (A), lynx2 is expressed in CA1 and dentate gyrus (B), lynx3 is not expressed (C), 
and ly6h is expressed in CA1, CA2, CA3 and dentate gyrus (D). In cerebral cortex, we 
observed expression of lynx1 in layers V and VI (E), lynx2 in layers IV and V (F) and 
ly6h in layers I through V (H). We didn’t detect any expression of lynx3 in cerebral cortex 
(G)   
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Figure 17: Expression analysis of Lynx1 homologues in brains sections from 
E15.5 mouse embryos with colorimetric in situ hybridization. A. lynx1 
expression was detected in low amounts in brain stem. B. lynx2 is expressed in 
high levels in brain stem, cerebellum, and midbrain. C. High levels of lynx3 
expression was detected in olfactory epithelia and retina (not shown). D. ly6H 
mRNA has a widespread expression in low amounts in many regions of the 
brain including cortex, cerebellum, midbrain and brainstem. 
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Figure 18: Expression analysis of lynx3 in heads of BAC-transgenic animals 
at age E15.5. Expression was detected with immunohostochemistry with anti-
EGFP antibodies. Lynx3 is expressed in olfactory epithelium, respiratory 
epithelium, retina, pituitary gland, midbrain, colliculi and cortex. (GENSAT) 
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Figure 19: Expression of lynx3 in BAC-transgenic embryos at age E15.5. 
Whole mount embryos were visualized under fluorescent microscope. lynx3 
is expressed in olfactory epithelia and tongue.   
            Lynx3 is mainly expressed outside the CNS in BAC transgenic mice. When I 
looked at the perfused BAC transgenic mice under fluorescent microscope at age P10, I 
have observed that lynx3 is expressed in many tissues including anterior nasal cavity, 
lungs, stomach, thymus, reproductive organs and spleen, so I decided to analyze the 
expression pattern of lynx3 in these tissues in more detail. lynx3 is found in mostly 
epithelial cells in these tissues, and I haven’t observed any significant expression in 
kidneys, prostate and heart. 
In anterior nasal cavity, lynx3 is expressed in both stratified squamous epithelium 
that lines the beginning of the anterior nasal cavity and the nostrils and the respiratory 
epithelium, which is composed of ciliated pseudostratified columnar epithelium that lines 
the rest of the trachea (Figure 22).   
In lungs, lynx3 expression was observed through both direct immunoflourescence 
and through immunohistochemistry with anti-EGFP antibodies. Lynx3 is expressed in the 
respiratory ciliated pseudostratified columnar epithelium in trachea. Trachea is bifurcated 
into primary bronchi, which subsequently branches into smaller intrapulmonary bronchi, 
terminal bronchioles and respiratory bronchioles. Lynx3 is expressed throughout the  
bronchial tree in various types of epithelia, so that under fluorescent microscope, the 
bronchial tree lights up like two small green trees. In intrapulmonary bronchi, lynx3 is 
expressed in respiratory ciliated pseudostratified columnar epithelium. Lynx3 is 
expressed in ciliated simple columnar epithelium in smaller bronchi and in cuboidal 




Figure 20: Expression of lynx3 in BAC-transgenic mice at age P7. lynx3 
expression was analyzed through immunohistochemistry with anti-EGFP 
antibodies. At age P7, high levels of lynx3 expression is observed in the olfactory 
bulb, hippocampus, thalamus, superior colliculus and brain stem. (GENSAT) 
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Figure 21: Expression of lynx3 in brain sections from the adult BAC-transgenic 
mice. lynx3 expression was analyzed through immunohistochemistry with anti-





Figure 22: lynx3 is expressed in olfactory epithelia and respiratory epithelia, EGFP 
expression in Lynx3 BAC transgenic mice (A) Lynx3 expression detected in 
anterior nasal cavity, stratified squamous epithelium is labelled. Bar=25μm. (B) 
Lynx3 expression is detected in ciliated pseudostratified columnar respiratory 
epithelium.Bar=25μm. (C) Lynx3 expressed in the transition between the olfactory 
epithelium and the respiratory epithelium. Bar=10μm. 
  
Mouse stomach has two well-defined parts that are separated with a ridge. The 
first part is non-glandular forestomach, which is similar to esophagus, and the second part 
is the glandular stomach. Lynx3 is expressed in stratified squamous epithelium that lines 
up the esophagus and the fore-stomach; however, it is not expressed in the stratified 
squamous epithelium in glandular stomach (Figure 24). In thymus, scattered epithelial 
cells and some lymphocytes had revealed lynx3 expression with immunohistochemistry 
and direct fluorescent microscopy (Figure 25).  In female reproductive organ, lynx3 is 
expressed in the squamous stratified epithelium in vaginal mucosa (Figure 26).  
There were two tissues in which I have observed lynx3 expression in neurons. 
One of them was the brain sections in which I observed a subset of olfactory sensory 
neuron axons coming to glomeruli. The other one was in the spleen, where I observed 
lynx3 expression in nerve axons surrounding the blood vessels (Figure 27).  
 BAC transgenic mice that express EGFP under lynx4 promoter control were also 
made by GENSAT. Transgenic mice were analyzed at three different stages.  At age 
E15.5, Lynx4 is expressed in non-keratinized stratified squamous epithelia in palate, and 
various epithelial cells in vibrissa (Figure 28). At age P7, lynx4 is expressed in scattered 
cells in pons, geniculate and cerebellum (Figure 30), and in adult brain sections lynx4 










Figure 23: lynx3 expression in trachea and lungs in Lynx3 BAC transgenic 
mice visualized with immunohistochemistry with EGFP-antibodies and direct 
immunoflourescence. Lynx3 is expressed in ciliated pseudostratified columnar 
respiratory epithelium in trachea and ciliated simple columnar epithelium in 
bronchi, cuboidal epithelium in bronchioles. A. Lung section of adult Lynx3 
BAC-transgenic mice. Higher magnification pictures of B. bronchi, C. 
cartilage in lung, D, Bar=30μm, E, Bar=80μm, F, Bar=40μm, G,                       
Bar=80μm. bronchi and bronchioli,  
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Figure 24: lynx3 expression esophageal epithelium in Lynx3 BAC transgenic 
mice visualized with direct immunoflourescence. Lynx3 is expressed in 





Figure 25: lynx3 expression in thymus of BAC-transgenic mice.  Expression 
visualized with immunohistochemistry with anti-EGFP antibodies and direct 















Figure 26: Expression of lynx3 in vaginal mucosa of BAC-transgenic mice 
shown by direct flourescence microscopy. Lynx3 is expressed in squamous 
stratified epithelium. A. Bar=40μm B. Bar=10μm 
Figure 27: Expression of 
lynx3 in neurons 
surrounding blood 
vessels in spleen. Direct 
flourescence microscopy 
was used to visualize 
lynx3 expression in 
spleen of BAC-





Figure 28: lynx4 expression analyzed in BAC-transgenic mice at age E15.5. 
EGFP-lynx4 expression was detected through immunohistochemistry with anti-
EGFP antibodies. Lynx 4 is expressed in whiskers at high levels. No significant 
level of expression was detected in brain. (GENSAT)  
Figure 29:  Expression of ly6H at age E15.5 in BAC-transgenic mice. Ly6H 
expression was detected with anti-EGFP antibodies. Ly6H has a widespread 
expression in brain and spinal cord at E15.5. (GENSAT) 
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Figure 30: lynx4 expression analyzed in BAC-transgenic mice brain sections. 
Immunohistochemistry was performed with anti-EGFP antibodies. Lynx4 is 
expressed in thalamus, cerebellum and brain stem. (GENSAT) 
              Ly6H expression pattern was also analyzed in BAC transgenic mice.  BAC 
transgenic mice that express EGFP under Ly6H promoter were perfused, their brains 
were dissected and sectioned and immunohistochemistry was performed on these brain 
sections with anti-EGFP antibodies. The results revealed that Ly6H has a widespread 
expression pattern in neurons in brain and spinal cord at all three stages analyzed, E15.5, 
P7 and adult mice (Figure 29, 31, 32).  The expression pattern observed in Ly6H BAC 
transgenic mice correlates with the expression information I have gathered through in situ 
hybridization studies.  
The last BAC transgenic mouse line that was made by GENSAT was lynx2 BAC 
transgenic line. Although the sites where EGFP expression was observed are also positive 
in lynx2 in situ hybridization studies, not all brain regions that express lynx2 according to 
in situ hybridization studies show EGFP expression in BAC transgenic mice. For 
example, lynx2 expression is detected in CA1 region of the brain, subiculum, and post-
subiculum in both BAC transgenic mice and in situ hybridization analysis, however, 
lynx2 expression is very strong and widespread in amygdala according to in situ 
hybridization results, but BAC transgenic mice show EGFP expression in scattered cells 
in amygdala. Since the expression was not complete, I have not included pictures of the 
lynx2 BAC transgenic mouse brain sections. The pictures can be found at GENSAT 
website at www.gensat.org.  
Western Blot Analysis 
 A peptide that has the sequence of the second loop of the three-finger structure in 
lynx2 was synthesized and injected into two rabbits. The serum taken from those rabbits 
were purified with IgG purification columns. The purified antibodies bound to a single  
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Figure 31: Expression of ly6H in BAC-transgenic mice at age P7. A widespread 
ly6H expression was detected in neurons in brain and spinal cord with anti-
EGFP antibodies. (GENSAT) 
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Figure 32: ly6H expression analyzed in the adult brain and spinal cord sections 
in BAC transgenic mice. Ly6H has a widespread expression in brain except for 
cerebellum. It is also expressed in the dorsal horms of the spinal cord. 
(GENSAT) 
 band with a size of  ~16 kDa on brain extract western blots. ~16 kDa is the expected size 
for lynx2 protein. This purified antibody was used for further western blots at 1:2000 
dilution.  
For multiple tissue western blot, protein extracts were prepared from brain, heart, 
spleen, kidney, lung, liver and muscle tissues from C57Bl6 mice with a solution that 
contained 8M Urea to completely linearize the proteins. Equal amounts of protein 
extracts from each tissue were run on a bis-tris gel and blotted on a membrane. Western 
blotting was performed on this membrane with anti-lynx2 antibody. Among these tissues, 
the highest lynx2 expression was detected in brain. Lynx2 expression was also observed 
in spleen and kidney and a lower level in liver (Figure 33). 
In order to analyze the developmental expression patterns of lynx1 and lynx2, I 
extracted proteins from embryos at age E8.5 and E15.5, heads of embryos at age P1 and 
brains of mice at ages P4, P7. P10, P15, P19 and P30. C57Bl6 mice were used for all 
ages and extraction solution contained 8M Urea to linearize all proteins. Equal amounts 
of protein extracts from each sample were run on a 4-12% bis-tris gel from Invitrogen 
and blotted with a semi-dry gel blotting system from BioRad. The blots were incubated 
with Lynx1 polyclonal antibody 1:100 and with Lynx2 polyclonal antibody 1:2000. HRP-
conjugated anti-rabbit antibodies were used as secondary antibodies. As a result of our 
analysis, I have observed that lynx1 is expressed late in development after age P10 and 
continues to be expressed in adulthood whereas Lynx2 is expressed in all developmental 
stages that I looked at, from E8.5 to adulthood (Figure 34). 
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Brain     Heart   Spleen  Kidney  Lung    Liver    Muscle  
Figure 33: lynx2 expression analyzed in multiple tissue Western blot: Lynx2 is 
very highly expressed in brain, expressed in lower amounts in spleen, kidney 
and liver  
B 
A 
Figure 34:  Analysis of developmental expression of lynx1 and lynx2. A. 
Western blot using lynx1 polyclonal antibody showed that lynx1 is expressed 
very late in development after P10 and is expressed in adult brain. B. Lynx2 is 
expressed throughout the development, expression starting as early as E8.5. 
 Lynx2 is a membrane protein 
 Polyclonal Lynx2 antibody was made against a 15 amino acid long peptide on the 
second finger of Lynx2 protein. The serum was affinity purified and was used for 
immunocytochemistry on Lynx2 transfected HEK 293T cells, non-transfected control 
cells and cells that were transfected with an intracellular protein, pacsin. The cells that 
were transfected with pacsin, were stained with anti-rabbit fluorescence conjugated 
antibodies when there was detergent in the solution. However, they were negative for 
fluorescence when there was no detergent in the staining solution, since the antibodies 
couldn’t pass the cell membrane in the absence of detergents, confirming that pacsin is an 
intracellular protein.  Non-transfected cells were incubated with anti-lynx2 antibodies and 
later with anti-rabbit fluorescence conjugated antibodies in the presence or absence of 
detergent. In both cases, non-transfected cells were not stained, showing that anti-lynx2 
antibodies do not bind to other proteins on HEK293T cells. Lynx2 transfected cells were 
also incubated with anti-lynx2 polyclonal antibodies and later with anti-rabbit 
fluorescence conjugated antibodies with and without detergent. Lynx2 transfected cells 
were positive for fluorescence in the presence and absence of detergent meaning that 
lynx2 antibodies do not need membrane permeabilization with detergents to bind to lynx2 
proteins. These results confirm that lynx2 is a membrane protein (Figure 35).  
Immunohistochemistry 
The same polyclonal antibody that was used for immunocytochemistry was used 
for immunohistochemistry studies. 1:100 ratio of the purified antibody was used on free-
floating brain cryostat-sections. Lynx2 polyclonal antibodies have stained CA1 region of  
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EFigure 35: lynx2 is a 
membrane protein. A, B: lynx2 
transfected cells stained with 
affinity purified anti-lynx2 pAb 
(1:1000) and anti-rabbit Alexa 
Ab in blocking solutions with 
(B) and without (A) triton. 
C, D: pacsin (myc tagged) 
control
transfected cells stained with anti-myc (1:200) and anti-rabbit 
Alexa Ab in blocking solutions with (D) and without (C) triton. E: 
none transfected cells stained with anti-lynx2 pAb (1:1000) and 
anti-rabbit Alexa Ab in blocking solution with triton. 
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 the hippocampus, however, did not bind to CA2 or CA3 regions which correlate with the 
in situ hybridization analysis. In addition, scattered neurons in deep nuclei and cortex 
also showed lynx2 expression (Figure 36). I have tried many different perfusion 
conditions and sectioning conditions as well as staining solutions to improve these 
results, and have a more clear immunohistochemistry result, however, they haven’t 
worked well enough. Optimization of this polyclonal antibody for immunohistochemistry 
still needs more analysis. 
 Since the polyclonal antibody did not work well with immunohistochemistry, I 
have made another polyclonal antibody against a peptide with the sequence of the first 
finger of the three-finger domain of lynx2. The 10 week and 14 week bleeds of this 
polyclonal antibody didn’t work on western blots and worked very poorly in 
immunocytochemistry compared with Lynx2-second-finger-pAb.  
I have made two polyclonal antibodies against lynx3 as well. The first one was 
against a peptide that the sequence of the second loop of lynx3, but it did not work either 
on western blots or with immunocytochemistry on lynx3-transfected cells. The second 
polyclonal antibody against lynx3 was made against the third finger peptide, and I am on 
the process of analyzing its binding affinity to lynx3 on western blots and 
immunocytochemistry.   
In conclusion, I have observed that Lynx1, Lynx2, Lynx3 and Ly6H have distinct 
expression patterns in mice. Dissimilarity in their expression patterns suggests that they 
may have similar or complementary functions in different cell types. Since their 






Figure 36: lynx2 expression in brain 
analyzed with immunohistochemistry. 
A: Lower magnification of hippocampal 
staining with pAb. CA1 region shows 
lynx2 expression whereas CA2 and CA3 
doesn’t, which also correlates with the 
in situ analysis. B: Higher magnification 
of the transition between CA1 and CA2 
regions of hippocampus.C: Higher 
magnification of CA1 region of hippocampus. D: lynx2 also showed expression 
in deep nuclei, which also correlates with the in situ hybridization analysis 
results. E: Although not as clear as in situ hybridization analysis, lynx2 pAb 
showed staining in scattered neurons of cortex.  
 
 and lynx1 was already shown to modulate and form stable complexes with nAChRs, I 
decided to check whether lynx1 homologues behave similarly.   
Functional Analysis of Lynx1 homologues 
Co-immunoprecipitation analysis 
In the recent paper by Ibanez-Tallon et. al. [67], Lynx-1 was shown to co-
immunoprecipitate with nAChR subtypes α4β2 and α7. These experiments were 
performed with avian nAChR subunits. Lynx2 also co-immunoprecipitates with avian 
α4β2 receptors, however Ly6H doesn’t. In order to find out if there is any specificity in 
binding of Lynx1 and Lynx2 to different nAChR subtypes, mouse and rat nAChR 
subunits were cloned into expression vectors and Flag-tags were added at C-terminus. 
Flag-tagged and myc-tagged constructs of Lynx1, Lynx2 and Ly6H were also prepared. 
The following receptor subunits were subcloned with Flag-tags, and the following 
subunit compositions were transfected to HEK293T cells: 
muscle nAChR subunits: α1β1 γδ 
neuronal nAChR subunits:  α2, α3, α4, α5, α6, α7, α9, α10  
     β2, β3, β4 
Receptor combinations: α2β2  α3β2  α4β2  α6β2 
    α2β4 α3β4  α4β4  α9α10 
    α7 α1β1γδ  
The HEK 293T cell extracts were incubated with either subunit specific antibody 
or Flag antibody (in that case myc-tagged Lynx proteins are expressed instead of Flag-
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 tagged constructs) coated protein G beads overnight and the samples were run in PAGE 
gels and western-blot was performed with anti-Flag-HRP antibody or anti-myc-HRP 
antibody. As negative control, I transfected HEK cells with myc-tagged lynx constructs 
and performed immunoprecipitations with anti-Flag antibodies. Unfortunately, I have 
observed that anti-flag antibodies pulled down myc-tagged lynx subunits, which 
suggested that we shouldn’t use anti-flag antibodies for the immunoprecipitations to 
eliminate false positive results. Therefore, we decided to use nicotinic receptor subunit 
specific antibodies for the pull down assays. Since there aren’t any good antibodies 
against some of these subunits, after trying to Co-IP all of these for a while, I decided to 
narrow the combinations to the following widely expressed nicotinic receptors: Flag-
tagged α4β2, chick-α7, Flag-tagged α1β1 γδ and the Flag-tagged α4β4 receptor 
combination (Figure 37).  
Membrane fractions were prepared from cells co-expressing α7-lynx1, α7-lynx2, 
α7-lynx3 and α7-Ly6H. For immunoprecipitation studies, membrane fractions were 
incubated with protein G beads bound to α7 monoclonal antibody. Immunoblot analysis 
with another α7 monoclonal antibody demonstrated that α7 was specifically 
immunoprecipitated. Immunodetection on the same fractions with an antibody against 
flag-tag showed that lynx1 and lynx2 immunoprecipitate with α7 receptor, however, 
lynx3 and Ly6H do not. Same experimental set-up was used for α4β2, α1β1γδ and α4β4 
receptors and lynx1 and its homologues. For immunoprecipitating α4β2 and α4β4 
receptors, we used protein G beads bound to α4 monoclonal antibody, and for 
immunoprecipitating α1β1γδ, we used β1monoclonal antibody bound protein G beads. 
Through immunoblot analysis with an antibody against flag-epitope, we showed that 
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 α4β2, α1β1γδ and α4β4 receptors were specifically immunoprecipitated. We also 
demonstrated that lynx1 and lynx2 immunoprecipitate with all three of these receptor 
subtypes and Ly6H does not immunoprecipitate with any of them. Lynx3 
immunoprecipitates with α4β2 and α4β4 receptors, however, does not 
immunoprecipitate with α1β1γδ receptor. Control experiments with membrane fractions 
from cells that are transfected with only lynx1 or its homologues demonstrated that lynx1 
or its homologues were not precipitated with protein G beads bound to any of the 
β1, α1, or α7 antibodies in the absence of the receptors.  Our results are consistent with 
previous findings for both α7 and α4β2 co-immunoprecipitations with lynx1 [67]. lynx1 
also immunoprecipitates when co-expressed with α4β4 and muscle nAChRs. lynx2 acts 
similar to lynx1 in co-immunoprecipitation experiments with all four nAChR subtypes 
tested. Interestingly, lynx3 forms stable complexes with α4β2 and α4β4 nAChRs, but 
does not co-immunoprecipitate with neither α7 nor muscle nAChRs. Ly6H does not form 
stable complexes with any of the four nAChR subtypes that were tested (Table 4). 
           These results demonstrate that lynx1 homologues form stable complexes with 
specific nAChR subtypes. Although their target nAChR subtypes are the same, lynx1 and 
lynx2 do not function redundantly since their expression sites are distinct and even 
complementary in hippocampus (lynx1 is expressed in CA2 and CA3regions, whereas 
lynx2 is expressed in CA1 region). lynx3, however, co-immunoprecipitates with only 
α4β2 and α4β4 nAChR subtypes and does not form stable complexes with neither α7 nor 
muscle type of nAChRs. This suggests that lynx3’s effect on modulation of nAChRs is  
more specific than its homologues. The expression patterns of lynx3 and α4β2 nAChRs  
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Figure 37: Distinct interactions of lynx1, lynx2, lynx3 and ly6h with nAChRs. 
Membrane extracts from HEK293 cells expressing α4β2-lynx1 (A), α4β2-lynx2 (B), 
α4β2-lynx3 (C), and α4β2-ly6H (D) were analyzed. All of the constructs, α4, β2, lynx1, 
lynx2, lynx3 and ly6h, were flag-tagged. The first lane in each blot show a sample of the 
membrane extract input and indicated with letter I. The second lane in each blot contain 
the immunoprecipitation fractions incubated with protein G beads bound to a4 
monoclonal antibody. The blots were probed with anti-flag-epitope monoclonal 
antibody. The upper panels show that a4 (~69kDa) and b2 (~45kDa) subunits were 
immunoprecipitated with protein G beads bound to a4 monoclonal antibody (upper 
panels, A, B, C and D). lynx1, was also immunodetected with anti-flag antibody in the 
precipitate fraction (~11-13 kDa), demonstrating that lynx1 forms stable complexes with 
α4β2 nAChRs (A, lower panel). lynx2 was immunodetected in the precipitate fraction, 
showing that lynx2 also co-immunoprecipitates with α4β2 nAChRs (B, lower panel). 
Immunoblot analysis showed that lynx3 also immunoprecipitated with α4β2 nAChRs 
(C, lower panel). Although ly6h could be detected in the membrane extract input 
fraction, I, it could not be detected in the precipitate fraction, IP, showing that ly6h does 
not immunoprecipitate with α4β2 nAChRs (D, lower panel).  
  
Table 4: Summary of co-immunoprecipitation analysis with nAChRs and lynx 
homologues.  lynx1 and lynx2 both form stable complexes with α4β2, α4β4, α7 and 
muscle nAChRs. Lynx3 binds to α4β2 and α4β4 nicotinic receptors, but does not bind 
to α7 or muscle receptors. Ly6H does not bind to any of the four nicotinic receptors we 
have assayed. 
– – – – Ly6H 
– – √ √ Lynx3 
√ √ √ √ Lynx2 
√ √ √ √ Lynx1 
α1β1γδ α7 α4β4 α4β2 nAChR 
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 overlap in tissues like bronchial epithelium suggesting that Lynx1 homologues might also 
be modulating nAChR subtypes in non-neuronal tissues.  
Electrophysiology 
Lynx1, Lynx2 and Lynx3 modulate desensitization kinetics of alpha4-beta2 
nAChRs whereas Ly6H does not 
It was previously shown that co-expression of lynx1 modulates the rate and extent 
of desensitization of ACh-evoked responses through α4β2 nAChRs [67]. To assess 
whether lynx1 homologues share similar functional traits with lynx1, we performed two-
electrode voltage clamp recordings in Xenopus oocytes expressing α4β2 nAChRs alone, 
or in combination with lynx1, lynx2, lynx3 and ly6H.  Oocytes were exposed to 
acetylcholine (ACh) for 20 seconds and the evoked currents were analyzed. In oocytes 
expressing the receptor alone, ACh elicited a fast peak current followed by a slow 
biphasic desensitization phase during ACh application. At the end of the ACh exposure, 
the currents quickly returned to baseline. In contrast, in oocytes expressing either lynx1,  
lynx2 or lynx3 with α4β2 nAChRs, the ACh evoked responses after the initial peak 
showed a significantly faster desensitization in the first biphasic component before 
reaching the second biphasic component or plateau (Figure 38A). This effect on 
desensitization is not observed when α4β2 receptors are co-expressed with ly6H. To 
measure these differences in desensitization, two exponential component equations were 
fitted to the desensitizating currents during ACh application, and fast (Figure 38B) and 
slow (Figure 38C) time constants were calculated as described in [67]. Figure 38B and 
38C shows the average values of these time constants for ACh responses. As shown in 
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 Figure 38B, the fast time constant is significantly faster in oocytes co-expressing lynx1, 
lynx2 and lynx3, and is not affected in oocytes co-expressing ly6H.  No differences in the 
slow time constant during the plateau phase were observed (Figure 38C). These results 
indicate that lynx1, lynx2 and lynx3 share similar modulatory properties on nAChRs. 
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α4β2          + lynx1     + lynx2         + lynx3             + ly6h 
















































Figure 38: lynx1, lynx2 and lynx3 enhance desensitization of ACh-evoked currents 
mediated through α4β2 nAChRs in oocytes. A. Representative recordings of voltage 
clamped oocytes expressing α4β2 nAChRs alone, or in combination with lynx1, lynx2, 
lynx3 and ly6H.  The inward currents were evoked by 20 sec periods of superfusion 
(horizontal calibration bar) with external saline containing 1mM ACh. ACh evoked 
responses in oocytes coexpressing α4β2 nAChRs with lynx1, lynx2 or lynx3 showed 
significantly faster desensitization during agonist application immediately after the 
initial peak. ly6h had no effect on desensitization when coexpressed with a4b2 
receptors. B and C. The differences in desensitization are shown with bar graphs. As 
described in (2), two exponentials equations were fitted to the desensitization currents 
during ACh application. Using these equations, fast (B) and slow (C) time constants 
were calculated and the average values of these constants for ACh responses are shown 
in B and C. In oocytes coexpressing α4β2 nAChRs with lynx1, lynx2 or lynx3, the fast 
time constant is significantly faster, while the slow time constant during the plateau 
phase remained the same. Both constants are unaffected in oocytes coexpressing Ly6. 
10 s 






Gene-targeted Deletion Analysis for Lynx2 and Lynx3 
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 Summary 
 Nicotinic receptors are involved in many biological processes in the CNS and in 
the periphery. Some of these processes are learning and memory and modulation of 
anxiety in the CNS and cell-to-cell adhesion and signaling in the periphery. lynx2 and 
lynx3 modulate nicotinic receptor desensitization in vitro and they form stable complexes 
with specific nAChRs in mammalian cell cultures. The expression patterns of both lynx2 
and lynx3 correlate with nAChR expression as well.  
 In order to find out which nicotinic receptor mediated biological process lynx2 
and lynx3 might be effecting, we have generated lynx2 and lynx3 null mutant mice. As a 
result of phenotypical analysis of lynx2-/- mice, we have observed that there are no gross 
anatomical differences between brain sections of lynx2-/- and WT mice till the age of 8 
months. However, lynx2-/- mice exhibited abnormal anxiety related responses, motor 




Straight KO Construct Preparation 
Three different KO constructs were prepared with C57Bl6 genomic DNA. The 
arms for homologous recombination were cloned by subcloning a Bacterial Artificial 
Chromosome (BAC) and Expand long-template PCR reaction from a lynx2 containing 
BAC. The first construct aimed to delete the first exon, which has the start codon and had 
a neomycin (neo) cassette with a poly-A tail sequence in it. Since we could only get less 
than 10 ES clones as a result of the electroporation, and no homologous recombination, 
we chose to prepare another construct with a different neo cassette. The second construct 
had the same properties as the first one, but had another neo cassette in it. The 
electroporation of this construct yielded about 50 colonies and no homologous 
recombination, which is still less than average (~200 colonies is the average). To solve 
this problem, I prepared a third construct which contained a longer homology arm, a neo 
cassette without a poly-A tail and a diphtheria toxin (DTA) sequence at the end of the 
second homology arm for increased selection. This construct aimed to delete first and the 
second exon of lynx2, since the second exon had two in frame ATG sequences, which 
might be targeted for translation. Third construct is shown in figure 39. 
Chimeras and Breeding: 
KO constructs were electroporated into Bruce4 ES cells 5 times total (first and 
second construct once, the third one three times). Out of ~800 colonies picked up 4 were 
positive for homologous recombination. These 4 positive colonies were injected into 
 97
  98
Left Arm Right Arm 
     BamHI  BamHI                                                                                 Probe BamHI 
Neo DTA
   NotI                   SnaBI XhoI                BamHI                SalI  AscI          ApaI           
Unique for linearization 
Exon 1 Exon2                                                           Exon3 
pBluescript SK 
Neo cassette has TK promoter and LoxP sites at both ends 
Linearization enzyme is NotI 
For Southern analysis, RE enzyme is BamHI, KO~8kb, WT~12kb 
 
Figure 39: Lynx2 KO construct. Homologous recombination arms of the KO 
construct were prepared with C57Bl6 genomic DNA, and a modified version of 
the pBluescript SK vector was used as the backbone of the construct.  
Exon 1   Exon2                                                                    Exon3
  AvrII BamHI BamHI                                       AvrII           BamHI


















Figure 40: Lynx2 Conditional KO construct. A. Scheme of the genomic 
structure of Lynx2 gene. B. Lynx2 KO construct scheme. C. Scheme of result of 
homologous recombination of the KO construct with genomic DNA. (Construct 
designed and prepared by Dr. Ivo Lieberam) 
 FVB, Balb/C and AlbinoB6 blastocytes. We had 7 chimeras which were three 5% 
chimeric males, and four females (with 10%, 85%, 80% and 40% chimerism). After 
breeding the chimeras to C57Bl6 males and females for at least 6 generations, we had 
~600 pups but no germline transmission. 
Conditional KO construct properties 
The construct for the conditional KO was prepared by Dr. Ivo Lieberam in Jessell 
Lab at Columbia University. These constructs were also prepared by using C57Bl6 
genomic DNA. Two different constructs were prepared since the first construct failed to 
yield any positive clones for homologous recombination among ~600 colonies after 
electroporation into Bruce4 ES cells. The second construct had two short homology arms 
and one long homology arm and there were three lox-P sites that separates the first and 
the second homology arms, the second homology arm and the neo cassette and at the end 
of the neo cassette. The construct was designed to be able to yield in three different 
deletions after being processed by cre. The construct and the results of possible deletions 
are described in the figure 40. 
Chimeras and Breeding 
 The conditional KO construct was electroporated into Bruce4 ES cells at 
Columbia University, which resulted in two colonies with homologous recombination. 
These two ES cell colonies were injected into C57Bl6 blastocysts in Columbia University 
and into Albino B6 and Balb/C blastocysts at Rockefeller University Gene Targeting 
Facility. As a result of the injections at Rockefeller University, we had 10 chimeras from 
3 different injections of 2 separate ES clones: 6 males (5%, 90%, 5%, 1%, 95%, 60% 
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 chimeric), and 4 females (50%, 45%, 10%, 90% chimeric). We had success in germline 
transmission with these chimeras and have crossed the heterozygotes to EIIa-cre 
transgenic mice on C57Bl6 genetic background. We have had both total deletions and 
partial deletion of neo cassette, which resulted in conditional KO allele. Both 




                               β-Actin                          lynx2 








Figure  41: RT-PCR analysis shows lynx2 mRNA is absent in lynx2-/- mice. mRNA 
was isolated from brains of WT and lynx2-/- mice with Trizol reagent. RT-PCR 
analysis was done with primers for amplifying β-actin mRNA and lynx2 mRNA 
with single-step RT-PCR kit from Invitrogen. β-actin control band was amplified in 
both samples. Lynx2 mRNA was amplified in WT sample but not in the null mutant 
mRNA sample. The primers were chosen from two different exons to exclude 
amplification from genomic DNA contamination.  
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 Anatomical Analysis of lynx2-/- Animals 
As a result of preliminary analysis, we have not observed any major anatomical 
differences between the brain sections from the WT and mutant mice around 6-8 months 
of age. The body weights and sizes of the mutant mice are also similar to the WT 
animals. All the lynx2-/- and WT animals are on pure C57Bl6 background, which 
minimizes the problems that are associated with genetic background. Pictures of 
hippocampus and cortex from the WT and lynx2-/- mice brain sections are in the 
following figure 41. The mice brains were perfused, dissected and embedded in paraffin 
and sectioned and stained with Hemotoxylene-Eosine (H&E) staining (figure 42). 
Behavioral Phenotyping of lynx2-/- Mice 
Using expression pattern of Lynx2 mRNA and protein as a guide, we analyzed 
behavioral phenotypes of lynx2-/-. Some of the major expression sites of Lynx2 in the 
mouse brain are regions associated with emotional behavior including: amygdala, stria 
terminalis, CA1 region of hippocampus, subiculum, cortex, ventromedial hypothalamic 
nucleus and mammilary body; motor functions and learning: interneurons in cerebellum 
and deep nuclei, caudate putamen; sites associated with olfaction: olfactory bulb, 
olfactory tubercle, anterior olfactory cortex, piriform cortex and entorhinal cortex; 
nociception: anterior pretectal nucleus; and several motor nuclei in medulla and pons: 
motor trigeminal nucleus (jaw movement control), parabrachial nucleus (cardiovascular 
regulation, pain conduction and vasopressin release regulation), gigantocellular reticular 
nucleus (part of sensory innervation of the arm-touch, pain), nucleus ambiguous 








of hippocampus and 
retrosplenial cortex in 
lynx2-/- and WT mice. 
There were no gross 
anatomical differences 
between brain sections of 
WT and lynx2-/- mice at 7 
months of age. 
Hematoxylene-eosine 
stained sections. A. 
lynx2-/-  hippocampus, B. 
WT hippocampus, C. 
lynx2-/-  cortex, D. WT 
cortex.  
             In order to check if there were any major motor abnormalities in the lynx2-/- mice, 
we first observed and analyzed their behavior in open-field exploration test. 12 male 
lynx2-/- mice and 12 male WT mice were tested at 22 weeks of age. The WT and lynx2-/- 
mice behaved similarly in terms of the distance moved, percentage of time they spent 
moving, mean velocity and percentage of time spent in the center. Both the WT and 
lynx2-/- mice jumped during the trial, however, the lynx2-/- mice jumped significantly 
more than the WT mice (Student’s-T-Test performed, p-value < 0.01). The results are 
shown in figure 43.  
The mice were then tested for ear-twitch and eye-blink reflexes, and both the WT 
and lynx2-/- mice behaved in the same way. Following the reflex tested, the lynx2-/- and 
WT mice were analyzed for motor strength. The lynx2-/- animals have less motor strength 
than the WT mice assessed by hanging wire test, during which the latency of the animals 
to fall from a wire cage, where they hang with their paws, is measured. The results are 
shown in figure 44.  
Since lynx2 is expressed in various regions that are associated with motor 
coordination and learning, I also tested them with a rotarod task during which the latency 
of the mice to fall from a cylindrical accelerating rod is measured. The lynx2-/- animals 
exhibited a superior motor coordination with respect to the WT mice on the first day of 
experiment (Mixed effects ANOVA, p-value < 0.01). The lynx2-/- mice continued to 
perform better than the WT mice in the following 3 days that the test was performed, 
which shows that the lynx2-/- mice have enhanced motor learning (Repeated measures 




























































Figure 43: Open Field Exploration Test. lynx2-/- mice and WT mice were tested 
to compare their gross motor skills. lynx2-/- mice and WT mice had similar mean 
velocities, moved similar amount of distances and moved for similar durations. 
They spent similar amount of time in the center, too. However, lynx2-/- mice 
jumped significantly more times than WT mice. N=12 male mice per genotype. 




















Figure 44: Hanging wire test. 
Motor strengths of lynx2-/- mice and 
wild type mice were compared with 
hanging wire test. Latency to fall 
from a wire cage was measured 
with a cut off of 60 seconds since 
WT mice should easily be able to 
stay on the wires for that period.  
lynx2-/- mice tended to fall off 
























Figure 45: Rotarod test. Motor coordination and learning of lynx2-/- mice 
and wild type mice were compared with an accelarating rotarod for four 
consecutive days. lynx2-/- mice performed siginificantly better than wild 
type mice on day one and on the following days. (Repeated measures 
ANOVA, p-value < 0.001) 
            Activation of the nicotinic receptors through intraperitoneal nicotine injections has 
been shown to deteriorate motor coordination in the WT animals [209]. In order to assess 
the effects of nicotine on motor coordination of the lynx2-/- animals, they were tested on 
rotarod assay. I observed that motor performance of the lynx2-/- animals is not affected by 
nicotine, however the WT mice perform worse than saline injected control the WT mice 
(Mixed effects ANOVA, p-value=0.06).  
Mecamylamine is an antagonist of nicotinic receptors and it was previously 
shown that nicotinic receptor antagonists impair rotarod performance [209]. In my 
experiments, injection of mecamylamine, an antagonist of nAChRs that affects both 
central and peripheral nicotinic receptors, also causes a decrease in motor coordination 
and motor learning for the WT mice when compared with the control WT mice. 
Intraperitoneal injection of mecamylamine also deteriorates motor coordination and 
motor learning in the lynx2-/- mice with respect to saline injected the control lynx2-/- mice. 
These results confirm my previous data that shows modulatory effect of lynx2 on 
nicotinic receptors in vivo (Mixed effects ANOVA, p-value = 0.06). 
In order to assess whether the effect of lynx2 on motor coordination is due to the 
nicotinic receptors in the peripheral or central nervous system, we injected the lynx2-/- 
and WT mice with saline and hexamethonium, which is a nicotinic receptor antagonist 
that blocks receptors expressed in peripheral nervous system that does not pass blood-
brain barrier. Hexamethonium didn’t affect the motor coordination of either the WT mice 
or the lynx2-/- animals, which suggests that lynx2 effect on rotarod performance is 
through it action on nAChRs in CNS (Mixed effects ANOVA, p-value ~ 0.2)  
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 Another test that I have done using rotarod assay was using mecamylamine 
injection followed by nicotine injection. Animals injected with both of these drugs 
performed like animals injected only with nicotine. The results of the rotarod test are 
shown in figures 46 and 47.  
lynx2 is expressed very highly in brain regions involved in emotional behaviors, 
including amygdala, stria terminalis and hippocampus. Therefore, I used several tests to 
investigate if the lynx2-/- mice perform differently than the WT mice in emotional 
behavior. Basolateral amygdala, in which lynx2 is very highly expressed, has been 
associated with auditory-cue-associative and context-associative learning in the fear 
conditioning test [210]. When the lynx2-/- mice and the WT mice were analyzed with fear 
conditioning test, on the first day, mice were trained to associate a mild electric shock to 
a tone, a conditioned cue (Figure 49).  
On the second day, mice are placed in the training environment without any 
auditory-cue, and they were observed every 10 seconds to count the number of times they 
freeze. The lynx2-/- mice demonstrated similar contextual-associative learning to the WT 
mice as a result of comparison with Student-T-test (p-value=0.55) (Figure 49).  
In the second part of the day 2, the mice were placed in a novel environment and 
the number of freezes were recorded every 10 seconds, with or without the auditory cue. 
The lynx2-/- mice exhibited a significant higher number of freezes to the tone than the WT 
mice, which might suggest that the lynx2-/- mice show better auditory-cued-associative 
learning than the WT mice or have increased fear due to the auditory-stimulus. (results 
analyzed with Student-T-test, p-value<0.01) (Figure 49).  
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 Anatomical regions of the brain that are associated with anxiety are not very well 
characterized; however, amygdala, hippocampus, stria terminalis and cortex have been 
implicated as major sites for regulating anxiety [189, 211, 212]. Since lynx2 is heavily 
expressed in amygdala, stria-terminalis, CA1 region of hippocampus and layer 4 and 5 of 
cortex, and nicotinic receptor activation have been implicated in several forms of anxiety, 
I have tested the lynx2-/- animals on various anxiety-related assays. In light-dark box test, 
where the amount of time spent in light and dark compartments of a test box is measured, 
I observed that the lynx2-/- animals spent less time in light with respect to the WT mice 
(Student’s-T-Test, p-value < 0.05) (Figure 50). 
Intraperitoneal injections of nicotine have been shown to have an anxiolytic effect 
in light dark box test [213]. Since lynx2 modulates nicotinic receptors and lack of lynx2 
increases anxiety related responses in mice, I wanted to test the effect of nicotine on the 
lynx2-/- mice in light-dark box test. The WT and KO mice were injected with saline or 
1mg/kg nicotine and were tested 40 minutes after injection. I have observed that indeed 
nicotine injections have an anxiolytic effect on the WT mice, since it increases the time 
spent in the light compartment of the light dark box, with respect to the mice that were 
injected with saline. However, nicotine injections had no significant effect, on anxiety 
related behaviors of the lynx2-/- mice. The lynx2-/- mice injected with nicotine behaved 
similarly to the lynx2-/- mice injected with saline. This result suggests that lynx2 
modulates nicotine-mediated anxiety (Figure 51) (Two-way ANOVA, p-value < 0.05 for 



























































Figure 46: Effects of nAChR agonists and antagonists on rotarod performance 
of WT and lynx2-/- mice. lynx2-/- mice and WT mice were injected with 1mg/kg 
nicotine, saline, 4 mg/kg mecamylamine, 4 mg/kg mecamylamine followed by 
1mg/kg nicotine, and 4 mg/kg hexamethonium. Tests were performed 5 minutes 
after nicotine or saline injections, and 15 minutes after mecamylamine or 
hexamethonium injections. 4 consecutive tests were done with 5-minute 
intervals on each test day for 4 days. The results are shown as bar graphs and 
line graph as means of four trials per day for each test days. At least 8 age 

























Figure 47: Effects of nicotine and nAChR antagonists on the motor skills 
of lynx2-/- mice and WT mice. Nicotine injections impair motor 
coordination of WT mice, however, it has no significant effect on lynx2-/- 
mice. Mecamylamine injection impairs motor coordination of not only 
WT mice, but also lynx2-/- mice. Hexamethonium injections have no 
effect on either WT or lynx2-/- mice. Mecamylamine injections followed 







































Figure 48: Elevated Plus Maze test. In another anxiety related test, elevated 
plus maze, lynx2-/- mice and wild type mice performed similarly. A. Duration 
of stays of wild type and lynx2-/- mice in open arms were measured. B. 





























































Figure 51: Light-Dark Box Test. As a measure of anxiety related behavior, lynx2-/- 
mice and wild type mice were tested on light-dark box. A. lynx2-/- mice entered 
light compartment significantly less times than wild type mice. B. Percentage of 
time that the lynx2-/- mice spent in light compartment was significantly less than 
wild type mice (Student’s-T-Test, p-value < 0.05 for both measures).  
Figure 50: Fear Conditioning test. lynx2-/- mice and WT mice were for their 
contextual and associative learning abilities. lynx2-/- and WT mice showed 
similar fear responses on training day, before and after being exposed to a tone 
followed by a mild electric shock. On test day, when mice were placed in the 
training environment, lynx2-/- and WT mice exhibited similar freezing responses 
to the context without any tone. On the second part of the test day, mice were 
placed in a novel environment, lynx2-/- and WT mice showed similar fear 
responses before tone. However, lynx2-/- mice froze significantly more times to 
the tone than the WT mice, showing they demonstrated better associative 
learning (for auditory-cued conditioning, Student’s-T-test, p-value < 0.05).  
  
Another test that is related to anxiety-associated behavior is social interaction test. In 
social interaction test, the tendency of spending time with a novel mouse with respect to 
an empty cage is tested. A diagram of the test apparatus and the labeled areas in the 
apparatus are shown in figure 52. In the first part of this test, mice are kept in the middle  
region, with doors closed for 10 minutes. After 10 minutes, the doors are opened and test 
mouse starts to freely explore the apparatus. The time spent in the compartment where 
the caged-mouse is present is named as Sniff1-stranger1. The time spent in the 
compartment, where there is an empty cage, is named Sniff2-empty cage. The close areas 
around the cages, where the test mouse sniffs the cages, are labeled as Sniff1 and Sniff2. 
In this test, we observed that the lynx2-/- spends significantly less time with the novel 
mice than the WT mice. Instead, the lynx2-/- mice prefer to spend time in the 
compartment where there’s an empty cage (Figure 53). Our results from this test and the 
light-dark box test show that the lynx2-/- mice exhibit more anxious behavior than the WT 
mice. Statistical comparison was performed with Student-T-test, p-value<0.05) 
During the second part of social interaction test, another novel mouse was placed 
in the empty cage, and the previous novel mouse, which is familiar to the test mouse 
now, is kept in the same cage. After rehabituation in the middle compartment for two 
minutes, the doors are opened again, and the test mouse roamed freely between the 
compartments. On this part of the test, there were no significant differences between the 
WT and lynx2-/- mice in terms of the time spent with the familiar mouse or novel mouse, 











































Figure 51: Effect of nicotine on anxiety related behavior. lynx2-/- mice and wild 
type mice were tested with light dark box 40 minutes after being injected with 
saline or 1mg/kg nicotine. I did not observe a statistically significant difference 
in the number of entries in to light compartment between saline or nicotine 
injected wild type or lynx2-/- mice. However, wildtype mice injected with 
nicotine spent more time in light than saline injected wild type mice.  
lynx2-/-  mice injected with nicotine or saline spent similar durations in light 
compartment (Two-way ANOVA, p-value < 0.05 for genotypic variance and p-
value = 0.08 for treatment variance).  
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Figure 52: lynx2-/- mice were tested for anxiety related behavior with the Social 
Interaction test. A. A scheme of the test box used for the social interation test. 
There were three compartments divided with removable doors; middle 
compartment was used for habitation, for the first Part of this test, a novel 
mouse was put in a round cage in the Stranger 1 compartment in the blue circle. 
The close area around the cage was counted as interaction area with the novel 
mouse and was named Sniff 1. The cage in the Empty Cage compartment was 
empty, and it was also placed in the blue circle. The time spent around the 
empty cage, in Sniff 2 area, was counted as interaction with the empty cage. B. 
The results of the first part of the social interaction test are shown. 
   
In another test for anxiety, elevated plus maze, where a different aspect of anxiety 
is measured, mice are placed in a cross shaped elevated platform. Two of the arms have 
walls and named closed arms, and two of the arms don’t have walls and are named open-
arms. The time spent in the closed arms, open arms and center are measured. In this test, 
the lynx2-/- mice performed similarly to the WT mice (Student’s-T-test, p-value>0.05 for 
both number of entries into open arms and duration in open arms). Since elevated-plus 
maze and the other two anxiety tests that I have performed are testing different measures 
of anxiety in mice, this result does not contradict with our previous results (Figure 48). 
Since lynx2 is expressed in many regions of the brain that are associated with 
olfaction, I performed a basic olfaction test, called buried-food retrieval test. In this test, 
mice are starved for 18 hours and the next day they are placed in a clean empty mouse 
cage in which a food pellet is buried approximately 1cm under the bedding. The time 
interval between placing the mouse in the cage and the time mouse starts eating the pellet 
or holds it with its two front paws is measured. The mice then are fed for 6 hours and 
starved for another 18 hours for testing in four consecutive days. On the first day of the 
buried-food-retrieval test, the lynx2-/- animals performed similar to the WT animals, 
showing that they don’t have any olfactory deficiencies (Figure 56). However, they 
performed differently when the test was repeated two days later in 3 consecutive days. 
The lynx2-/- mice, found the food pellets which were buried in random places better than 
the WT mice on the first day of the 3 day series (Repeated Measures ANOVA, p-
value<0.05), but didn’t improve their finding abilities in the following trials, whereas the 
 115
 WT mice performed better than before in consecutive days of trials (Figure 57) (Repeated 
measures ANOVA, p-value>0.05). 
Anterior pretectal nucleus have been associated with pain [214]. Nicotinic 
receptors have also been shown to be important for nociception [156].  Since lynx2 is 
very highly expressed in the anterior pretectal nucleus and modulates nicotinic receptors, 
we tested the lynx2-/- mice on hot plate test. In this test, the animal is placed on a 55ºC 
plate and its latency to jump or lick paws is measured. In hot-plate test, KO mice and WT 
mice had similar latencies responding to pain (Student’s-T-test, p-value>0.05) (Figure 
55). 
As a result of our behavioral phenotyping analysis of the lynx2-/- mice, I conclude 
that, like lynx1-/- mice, lynx2-/- mice performed different than the WT mice in audio-cued-
associative learning task. Unlike lynx1-/- mice, lynx2-/- mice exhibit more anxiety behavior 
than WT mice in light-dark box test. lynx2-/- mice also show increased anxiety in social 
interaction test but not in elevated-plus maze test. In motor coordination and learning 
tests, lynx2-/- mice show superior motor coordination and learning than WT mice. 
However, the lynx2-/- mice had less motor strength than the WT mice as assessed by the 
hanging-wire test. I couldn’t detect any significant effect of lynx2 on olfaction, 
contextual learning, pain perception, eye-blink and ear-twitch reflexes or basic motor 






















Figure 53: lynx2-/- mice and wild type mice behave differently in Part 1 of 
Social Interaction Test. Among the various behaviors measured, the time spent 
with the novel mice for the lynx2-/- and WT mice were significantly different 
from each other. lynx2-/- mice spent less time interacting with the novel mouse 
than WT mice. They also spent less time in the compartment where there is a 
























Figure 54: lynx2-/- and WT mice behaved similarly in the Social Interaction test 
Part 2. In Part 2, a novel mouse was placed in the Empty cage, and the novel 
mouse from part 1, which is not novel to the test mouse anymore, was kept in its 
initial cage. WT mice and lynx2-/- mice behaved similar in every measure that I 



























Figure 55: Hot Plate test. 
Antinociception properties of 
lynx2-/- mice and wild type 
mice were compared by 
measuring their latencies to 
respond to heat in hot plate test. 
lynx2-/- mice performed similar 
to wild type mice. 
Figure 56: Finding Buried 
Food Test. The latencies of 
wild type and lynx2-/- mice for 
finding buried food were 
measured. lynx2-/- mice 





























Figure 57: Olfactory learning tested with buried food finding test. One 
day after the first day of finding buried food pellet test, the same test was 
performed for 3 consecutive days. lynx2-/- mice found the pellet faster 
than WT mice on first day of the consecutive days, but their performances 
   
 
 
Table 5: Summary of behavioral phenotyping of lynx2-/- mice. At least 10 age-matched 
male mice per genotype were used for each test. All our results are statistically 
significant. 
 
Behavior Test Are WT and lynx2-/- different ? 
Gross motor skills Open-field exploration No. Only difference is lynx2-/- jump 
more times than WT. 
Basic reflexes Eye-blink and ear-twitch No. 
Motor strength Hanging wire (will repeat 
without a cut-off point) 
Yes. lynx2-/- are weaker than WT. 
Motor coordination Rotarod- Day 1 Yes. lynx2-/- are superior to WT. 
Motor learning Rotarod-4 Days Yes. lynx2-/- learn better than WT.  
Contextual-cued 
Associative learning 
Fear conditioning-Part 1 No. 
Audio-cued 
Associative learning 
Fear conditioning-Part 2 Yes. lynx2-/- freeze more than WT. 
Anxiety Light-dark box Yes. lynx2-/- more anxious than WT. 
Anxiety Social interaction Yes. lynx2-/- more anxious than WT. 
Anxiety Elevated-plus maze No. 
Nociception Hot-plate No. 
Olfaction Finding buried food-Day1 No. 
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 Lynx3 
KO construct preparation 
Lynx3 is expressed in a few neuronal and mostly epithelial tissues and its 
expression is distinct from that of Lynx1 and Lynx2. Lynx3 also binds to and modulates 
α4β2 nicotinic receptors, but it does not bind to α7 nicotinic receptors, which makes it a 
more specific nicotinic receptor modulator. Nicotinic receptors have been implicated in 
various important functions including cell-to-cell adhesion and signaling in epithelial 
tissue. In order to analyze the function of lynx3 in vivo, I made a targeted-deletion for 
Lynx3 gene. The KO construct has been prepared with C57Bl6 genomic DNA and it was 
electroporated to Bruce4 and C2J cells in Rockefeller University’s Gene Targeting 
Facility (Figure 58).  
Chimeras and Breeding 
 Electroporation of the KO construct to Bruce4 cells yielded 2 positive ES clones 
for homologous recombination. These clones were injected into FVB blastocysts and out 
of 3 injections, we had 5 female chimeras with 40%, 30%, 15%, 10% and 5% chimerism 
and 2 male chimeras with 20% and 10% and three males with 5% chimerism. None of 
these chimeras went germline.  
Electroporation to C2J cells, which are derived from albino C57Bl6 mice, resulted 
in 3 ES cell colonies with homologous recombination. These colonies were injected into 
C57Bl6 blastocysts and out of 5 injections, we had two 100% male chimeras, one 90% 
male chimera, one 70% male chimera and ~10 more male chimeras with lower chimerism 
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 rates. I had germline transmission in the first breeding from multiple chimeras, the 
heterozygote mice have been bred together to get homozygous mice. I have multiple male 
and female lynx3-/- mice that are viable and will require further tests to assess any 
phenotypical abnormalities. 
  
AseI       AseI                                                             Probe       AseI                      AseI 
 
 
Neo cassette has pgk promoter and LoxP sites at both ends 
Linearization enzyme is NotI 
Figure 58: Lynx3 KO conctruct. A. Scheme of genomic organization of 
lynx3 coding exons. The probe for analyzing homologous recombination 
is shown as a black bar. The first and second coding exons, which 
encoded the translation-start and most of the ly6 domain were deleted by 
the null mutation. The homologous arms were 3.5kb and 5kb long and 
were sub-cloned from C57Bl6 genomic DNA containing clones. B. 
Scheme of the KO construct with a Neomycin cassette with LoxP sites, 
and DTA cassette outside the homology arms.    
   
Neo
Left Arm ~3.5kb Right Arm ~5kb
       Exon1    Exon2            Exon3
DTA 









Lynx3 Modulates A Novel Xenopus Oocyte Channel 
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 Summary 
 Lynx3 binds to and modulates nAChRs, and it has a specific expression pattern in 
epithelia and neurons. When lynx3 is overexpressed in Xenopus oocytes, the cells die in 
two days compared to fourteen days when other lynx proteins are expressed. Also, in 
voltage clamp recordings, we observed that lynx3 expressing oocytes have leak currents 
associated with opening of an endogenous oocyte channel, suggesting that the death is 
caused by continous activation of an ion channel. We hypothesized that this channel 
might be conserved in mammals, and it might be regulated by lynx3. Next, we analyzed 
electrophysiological properties of the lynx3-affected Xenopus channel. We identified a 
novel Xenopus channel with unique pharmacological properties. We are now cloning this 
Xenopus channel and its mammalian homologue by using different methods. 
Characterization of Lynx3 Affected Channel  
When expressed in Xenopus oocytes, lynx3 elicits leak currents in oocytes and the 
oocytes die after two days of lynx3 expression. I overcame this problem by using less 
Lynx3 mRNA for injection for analyzing the effect of Lynx3 on α4β2 nAChRs, however 
I thought that this was a curious event and might reveal another target channel for lynx3. 
The identity of this target channel would be very helpful in identifying another target 
channel in mammals; therefore, I continued analyzing. I speculated that Lynx3 was 
interacting with an oocyte channel causing it to stay open and thus the leak. In order to 
find out what type of a channel this was, I subjected the lynx3 expressing oocytes to 
different open channel blockers. One day after injecting the oocytes with 0.5ng lynx3 
 123
 mRNA, we applied different channel blockers for 20 seconds and analyzed the 
differences in the current that is passed through the oocyte membrane.  
To test for Na+ Permeability, NMG+ was replaced with Na+ in the Ringer solution. 
After oocytes were perfused with this solution for 20 secs, the currents elicited by 
channels effected by lynx3 were reduced due to lack of Na+, meaning that these channels 
pass through Na+ ions. This experiment was repeated with different lynx3 transcripts and 
multiple oocytes and the results are consistent (Figure 59).  
Ba2+ is a blocker for K+ channels. When perfused with a Ringer solution that 
contained 4mM Ba2+ for 20 seconds, the channels that are activated by lynx3 are partially 
blocked by Ba2+. This experiment was also repeated with multiple oocytes (Figure 60). 
Since lynx3 target channel passes through both K+ and Na+, I wanted to see if it 
was more permeable to K+ or Na+. To test this, we used a ringer solution in which Na+ 
ions were replaced by K+ ions. When lynx3 expressing oocytes were perfused with this 
solution, the leak current increased; this means that the channel that is causing this leak 
current has a preference for K+ ions over Na+ ions. This experiment was repeated with 
multiple oocytes with similar results (Figure 61). 
In order to investigate whether lynx3 target channel was permeable to divalent 
cations, a ringer solution in which Ca2+ ions were replaced with Mg2+ ions was used to 
perfuse lynx3-expressing oocytes. During the 20 second perfusion, the leak current 
caused by lynx3 affected channels increased by 76%, whereas the current increased by 
only 44% in non-injected oocytes. This experiment was done on multiple lynx3 
expressing oocytes and the results were consistent. To see if this result was due to  
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Figure 59: A representative 
recording demonstrating the 
effect of NMG containing 
Ringer solution exposure to 
the leak current in lynx3 in 
expressing oocytes.   
 
Figure 60: Ba2+ partially 
blocks lynx3-effected 
channel. A representative 
recording showing the effect 
of perfusing the lynx3 
expressing oocyte with Ba2+ 
containing Ringer solution.  
Figure 61: Na+ vs K+. 
Replacing Na+ ions with K+ 
ions increase the current 
passed through the lynx3-
effected channels. 
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 removal of Ca2+ or addition of Mg2+, I have prepared another Ca-free solution with 
EDTA and flufenamic acid (FFA) to block the hemi-gap channels [215] and perfused the 
lynx3-expressing oocytes for 20 seconds. I have observed a 10% increase in the leak 
current. I then used another solution where Ca2+ was replaced with Mg2+ and added 
flufenamic acid, and the leak current increased by 39%. This further supports that the 
channels affected by lynx3 pass through Mg2+ and are inhibited by Ca2+ (Figure 62) 
(Table 6).  
Non-selective cation channels are blocked by La3+ ions, so I decided to check 
whether lynx3 target channel would also be blocked by La3+. To test this, I added La3+ to 
the Ringer solution and perfused un-injected and lynx3-injected oocytes to this solution 
for 20 seconds. I observed that the channel was ~90% blocked (Figure 63). 
These results demonstrate that the channels that are effected by lynx3 in oocytes 
and cause leak currents are non-selective cation channels that are blocked by the 







Figure 62: Replacing Ca2+ ions with Mg2+ ions increase the current passed through 
the lynx3-effected channels. There’s no FFA to block Ca2+ inhibited hemi-gap 
channels in this solution. 
Figure 63: La3+ ions inhibit the currents elicited by lynx3 expression in Xenopus 
oocytes. Whole cell currents measured while perfusing the lynx3-expressing oocytes 
with Ringer solution containing 0.1 mM La3+ blocked most of the leak current.  
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 Table 6: Currents elicited by lynx3 expression were further augmented by presence of 
Mg2+ and absence of Ca2+. In the EDTA, which chelates Ca2+ ions, and when hemi-gap 
channels are blocked by FFA, the leak currents elicited by lynx3 expression increases 
10%, and in the presence of high calcium the current is increased by 29%. When Ca2+ 
ions are replaced with Mg2+ ions, and hemi-gap-channels are blocked with FFA, the 




(Ringer solution with) 
Percentage of 
Augmentation in lynx3 
expressing oocytes 
Percentage of 










, with FFA 39% 0% 
high Ca
2+
 (40mM) with FFA 29% -39% 
Ca-free with EDTA and FFA 10% 0% 
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 Table 7: Currents in lynx3 expressing oocytes were blocked by the chemicals below. 
La
3+
 blocks leak currents by 83%, while benzamil blocks 59%, Ringer solution 
containing NMG instead of Na, blocks it by 53%, Ba
2+
 containing ringer blocks by 27%, 
1mM amiloride blocks 22%, 2mM SITS blocks by 11%, SKF-963654 blocks by 9.7% 




(Ringer solution with) 
Percentage of Current 
Reduction in lynx3 
expressing oocytes 
Percentage of Current 
Reduction in control 
oocytes 
0.1mM La3+ 83% 0% 
1mM benzamil 59% 5.5% 
NMG 53% 0% 
Ba2+ 27% 0% 
1mM amiloride 22% 0% 
low pH Ringer 21% 0% 
2mM SITS 11% 0% 
100mM SKF-963654mM 9.7% 0% 
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 Finding the reversal potential of the channel 
I-V curves of the lynx3-injected oocytes were linear; therefore, lynx3-induced 
currents were mostly voltage independent. The reversal potential was ~15mV in average, 
which shows that this is a non-selective cation channel (Figure 64).  
Pharmacological Characterization of Lynx3 Target Channel 
 I searched the literature to find if the channel that is modulated by lynx3 has been 
identified before. I made a list of the endogenous Xenopus channels that were studied, 
and compared the lynx3-effected channel to these channels to see if this is a novel 
channel, by utilizing various chemicals that were used in previous studies. The effects of 
20-second perfusion of the oocytes with these chemicals are shown in table 7.  
A similar non-selective cation current was published by Arellano et. al  [216] in 
1995, and this current was suggested to be due to hemi-gap channels by Ebihara later 
[217]. One type of channel that fits the above description is the hemi-gap channel. 
Connexin38, which is expressed in the Xenopus oocytes, is a candidate for those hemi-
gap channels, so we decided to investigate this further. Hemi-gap channels are blocked 
by carbenoxolone and flufenamic acid. We perfused lynx3-injected oocytes with Ringer 
solution containing 100μM Carbenoxolone for 20 seconds and I didn’t observe any 
significant blockage. When I perfused the lynx3-injected oocytes with Ringer solution 
that contains 50μM flufenamic acid (FFA), there was no significant difference in the 
























Figure 64:Current-Voltage Relationships (I-V curves) of control oocytes and 
lynx3 mRNA injected oocytes and a representative recording of lynx3 injected 
oocytes for evaluating the I-V curves. Oocytes were bathed in Ringer solution 
and whole cell currents ere measured from a holding potential of 0 mV by 
sequentially stepping from -50 mV to +60 mV in 10 mV increments. Reversal 
potentials of both control oocytes and lynx3-injected oocytes were similar.  
   SITS (4-acetamido-4-isothiocyanatostilbene-2, 2-disulfonic acid), niflumic acid 
and bumetanide, which are potent blockers of chloride channels and also block some non-
selective cation channels, do not block the lynx3-affected channel significantly. The 
highest blockage due to these three chemicals was caused by SITS perfusion, which was 
only 11%.    
 Another non-selective cation channel that was published was activated by 
bisphosphonates (BP), which are drugs commonly used to treat osteoporosis. While 
looking for the effect of BP to epithelial sodium channel (ENaC) in Xenopus oocytes, 
Shao et. al. identified another nonselective cation current that was induced by BP. 
Although this current is similar to the current elicited by lynx3, in terms of the ions 
passed, currents elicited by BP are completely blocked by lower pH (6.4), but lynx3 
elicited current is only blocked 21% by ringer solution with a pH of 6.4. In addition, BP 
activated current is also blocked by 20μM amiloride; however, lynx3 activated current is 
not effected by 20μM amiloride, and gets blocked by 1mM amiloride by only 22%. 
 High levels of expression of heterologous membrane proteins have been shown to 
induce a hyperpolarization activated cation current in Xenopus oocytes previously, so I 
wanted to check if lynx3 elicited currents were also due to the same channels [219]. This 
hyperpolarization-activated cation current is blocked by DIDS (4,4'-
diisothiocyanostilbene-2, 2’-disulphonic acid) and TEA (tetraethylammonium). When 
lynx3-injected oocytes were perfused with ringer solution with 1mM DIDS or 100mM 
TEA for 20 seconds, I didn’t detect any significant changes in the current, which suggests 
that lynx3 elicited current is different from the non-selective cation current caused by 
overexpression of heterologous proteins.  
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 The last non-selective cation channel described in Xenopus oocytes is a current 
elicited by maitotoxin (MTX) [215, 220]. This current is blocked by 1mM benzamil, 
1mM amiloride and 100μM 1-(β-(3-(4-Methoxyphenyl)-propoxy)-4-methoxyphenethyl)-
1H-imidazole hydrochloride (SK&F 96365) by 81%, 62% and 65% respectively. When 
lynx3-injected oocytes were perfused with these solutions, lynx3-elicited current was 
blocked by 59% and 22.5% by benzamil and amiloride respectively, but was not affected 
by SK&F 96365 significantly. MTX-induced currents are also blocked by high 
extracellular Ca2+ (40mM); however, lynx3-elicited currents are not blocked by high 
Ca2+, instead they are augmented by it by 29%. These results suggest that MTX-induced 
currents and lynx3-induced currents are distinct. 
These results show that lynx3 expression in Xenopus oocytes activate a novel 
non-selective cation current that can be blocked by 0.1mM La3+ by 83% and partially 
blocked by 4mM Ba2+, 1mM benzamil, 115mM NMG+, 1mM amiloride and ringer 
solution with lower pH. Since both low extracellular Ca2+ and high extracellular Ca2+ 














The first Ly6 genes were first identified in lymphocytes [1], however, the extent 
of this gene family and its functions have remained largely unknown. I have analyzed 85 
members of Ly6SF through phylogenetic inference and have identified new sequence 
similarities. I have analyzed expression patterns of four mammalian Ly6SF members, 
lynx2, lynx3, lynx4 and Ly6H in CNS with a particular attention to lynx2 and lynx3. I 
have also examined expression patterns of lynx3 outside CNS. Interactions between 
nAChRs and lynx1, lynx2, lynx3 and Ly6H have also been analyzed and their effects on 
nicotinic receptors were observed through voltage clamp recordings on oocytes. Lynx2 
and lynx3 null mutant mice were made and lynx2-/- mice have been thoroughly analyzed 
through behavioral phenotyping. Lynx3 was found to effect a novel non-selective cation 
channel in Xenopus oocytes and pharmacological properties of this channel has been 
studied. 
We can draw four main conclusions from this study. First, the Ly6SF of genes is 
very extensive, including many members in both vertebrates and invertebrates. Although 
highly divergent, phylogenetic inference indicates that the Ly6SF evolved from a 
common ancestral gene, with recent evolutionary events that have expanded subfamilies 
of the Ly6SF. Second, properties of lynx1, including the ability to bind to and modulate 
nAChRs, are shared by other GPI-anchored Ly6SF genes expressed in neurons, allowing 
us to define a lynx subfamily of functional homologues within the Ly6SF. Third, despite 
their common functional properties in vitro, we can conclude the lynx family of proteins 
has non-redundant functions in vivo since the lynx1-/- and lynx2-/- mice exhibit different 
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 behaviors in anxiety, motor coordination and motor learning. Fourth, Ly6H is a CNS 
expressed Ly6SF gene that is functionally distinct from the lynx family of nAChR 
modulatory proteins. Although there is not yet sufficient biochemical and genetic data to 
prove a general role for Ly6SF proteins as modulators of signal transduction through 
interactions with specific classes of cell surface proteins, the receptor modulatory 
activities of the lynx proteins [67, 203], the snake venom α-neurotoxins [17], the SLURP 
proteins [64], and the recent data on the effect of Ly6 molecules on signaling in 
lymphocytes [51, 221] and non-lymphoid cells [30, 222] provide strong support for this 
idea. 
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 Identification and Phylogenetic Inference of Ly6 Gene 
The divergence of the sequences of Ly6SF proteins suggests that they evolved 
from a single gene through gene duplication very early in the evolutionary process. The 
numbers of cysteines and the spacings between them were considered to be the only 
conserved traits among the superfamily. In my studies, I have not only confirmed these 
earlier findings in a large number of proteins, but I also have showed that some other 
residues are also conserved in most of the Ly6SF members. These amino acids are more 
likely to be involved in structural properties of the Ly6 domain since Ly6SF proteins 
perform a diverse array of functions.  
Some sequence structures are more conserved among the lynx subfamily than 
they are in the rest of the Ly6 genes. The serine residues on the second and third loop of 
Ly6 domains, are very conserved in mouse and human lynx1, lynx2 and lynx3, however 
neither mouse nor human Ly6H does not have them. Sequence structures that are 
conserved in lynxs but not in Ly6H are especially important since Ly6H does not bind to 
or modulate nicotinic receptors but lynxs do. Conserved amino acids such as these serines 
should be investigated through targeted mutation analysis to help us learn more about the 
physical interaction between the nicotinic receptors and lynxs. 
lynx1 and lynx2 bind to all four nAChRs that I have investigated; however, lynx3 
only binds to α4β2 and α4β4 receptors. This is an important finding which might help us 
understand more about receptor binding specificity. Targeted mutations, through which 
different loops in the Ly6 domains of lynxs are exchanged, can be helpful to us in order 
to identify if any specific loop is important for target specificity. Smaller mutations inside 
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 the loops will also be helpful to determine which amino acids are crucial for receptor 
modulatory function of lynxs. nAChRs are implicated in the pathobiology of many 
diseases, and have been drug targets [223, 224]. Specificity among different nicotinic 
receptors has been a significant problem for drug development and the specificity among 
lynxs might be important for solving this problem. 
The Ly6 proteins that are expressed in lymphocytes are more closely related and 
they make up a single branch in the tree suggesting that they were formed by gene 
duplication from a single gene later in the evolutionary process. These hematopoietic cell 
expressed Ly6 genes are located on Ly6 locus on murine chromosome 15 and human 
chromosome 8, which further supports this idea. 
The results presented here characterize the Ly6SF of genes from several species, 
and identify a large number of novel family members in both vertebrates and 
invertebrates. Although the 85 genes we present here encode very divergent proteins, all 
share the same basic genomic structure and the core cysteine residues characteristic of 
Ly6 domain. These properties suggest that the Ly6SF evolved from a single ancestral 
gene early in evolution, although more recent evolutionary events are revealed by 
phylogenetic inference. For example, the single branch formed by mouse and human Ly6 
genes in the phylogenetic tree, and their clustering within 600CM region on murine 
chromosome 15 and its syntenic region on human chromosome 8, suggest that this 
subfamily of Ly6 genes arose recently in the mammalian lineage. Similar events may 
explain the phylogenetic clustering of some of the D. melanogaster Ly6SF genes. 
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 Expressional and Functional Characterization of Lynx1 
Homologues 
Given our previous studies identifying lynx1 as a novel nAChR modulatory 
protein expressed in the CNS [67, 203], and recent data demonstrating that the secreted 
Ly6SF member SLURP1 can modulate α7 nAChR activity [15, 64], I sought to identify 
other Ly6SF members that might play a role in receptor modulation in the central or 
peripheral nervous systems. Here I identify lynx2 and lynx3 as functional homologues of 
lynx1 that are expressed in distinct populations of CNS or peripheral nervous system 
(PNS) neurons. Both of these molecules are GPI-anchored, bind to nAChRs and 
modulate their desensitization kinetics. Based on their common structure, their expression 
in neurons, and the abilities of lynx1, lynx2, and lynx3 to functionally modulate nAChRs, 
I define these genes as the lynx subfamily of receptor modulatory proteins. Although the 
Ly6H gene is expressed broadly and at high levels in the CNS, our assays thus far have 
not demonstrated functional homology with lynx family of proteins. It remains possible 
that further studies of Ly6H or other Ly6SF members will reveal common functional 
properties with lynx1, lynx2 and lynx3, and justify their inclusion into the lynx family of 
nAChR modulatory proteins. 
While lynx1 and lynx2 are both expressed in neurons, and are able to modulate 
nAChR desensitization kinetics, their expression patterns and functional properties 
suggest non-redundant functions. Although the functional properties of lynx1 and lynx2 
are quite similar based upon the co-immunoprecipitation and oocyte electrophysiology 
experiments, their expression in cell populations in the hippocampus and cerebral cortex 
differ. α4β2, α3β4 and α7 nAChRs have been reported to be expressed in hippocampus 
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 and cortex and many neurons are affected by the actions of all three of these receptors 
[95, 98, 100, 105, 225, 226].  In contrast to lynx1 and lynx2, lynx3 is expressed 
predominantly in the periphery, including in olfactory sensory neurons, bronchial 
epithelial cells and in the trachea. α4β2, α3β4 and α7 nAChRs are also expressed in the 
bronchial epithelial cells. However, the expression of nAChRs have not been well studied 
in the other peripheral tissues where lynx3 is also expressed [204]. Furthermore, although 
lynx3 shares the ability to bind to and modulate α4β2 and α4β4 nAChRs with lynx1 and 
lynx2, it does not bind to α7 nAChRs. Taken together, these data demonstrate that lynx1, 
lynx2 and lynx3 must play distinct roles in vivo. 
The expression pattern and the functional properties of Ly6H suggest that its 
functions in the CNS must be distinct from the lynx subfamily of proteins. I have 
demonstrated that it neither binds to nor modulates the activities of the major CNS 
expressed nAChR subtypes and the muscle nAChR. It is possible that Ly6H could 
modulate other nAChR subtypes not assayed in this study, however, I regard this as 
unlikely because none of the remaining nAChR subtypes are co-expressed in the CNS 
with Ly6H [100, 105, 111, 112, 227]. Ly6H expression is widespread within the CNS, 
but it is noticeably absent from several CNS structures, including several brainstem 
nuclei and the cerebellum (our unpublished data, 
http://www.ncbi.nlm.nih.gov/projects/gensat/). Given the shared structural properties of 
Ly6SF proteins, and common evolutionary origins of nACh, GABA, Glycine, 5-HT3 and 
some glutamate receptors [69], it seems likely that Ly6H could modulate a distinct 
neurotransmitter receptor class.  
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 Despite the fact that Ly6H is closely related to lynx1 subfamily members, its 
functional difference suggests Ly6H might be a paralog that has formed through gene 
duplication with loss of original function. Since lynx1, lynx2 and lynx3 all modulate 
nAChRs, this might be the primitive function of this subfamily of proteins, from which 
Ly6H diverged. This model shows how nervous system evolves new functions through 
gene duplication.  
Lynx1 has been shown to increase agonist sensitivity for nAChRs [67]. It would 
be interesting to check whether lynx2 and lynx3 has a similar effect on nicotinic 
receptors. For this purpose, dose response curves of nicotinic receptor and lynx2/3 
expressing oocytes to various concentrations of ACh could be compared with dose 
response curves of oocytes expressing only nicotinic receptors. Lynx1 also delays 
recovery of nAChRs after receptor activation [67]. In order to assess whether lynx2 and 
lynx3 function through the same mechanism to modulate nicotinic receptors, the abilities 
of lynx2 and lynx3 to delay receptor recovery can be analyzed through voltage clamp 
recordings in Xenopus oocytes.  
Effects of lynx2 and lynx3 on nAChRs in mammalian cells have not been 
investigated. lynx1 increases the large conductance currents of nicotinic receptors in 
mammalian cells [67]. Analyzing modulation mechanisms of lynx2 and lynx3 in 
mammalian cells would help us understand the relationship between nAChRs and lynx 
subfamily of proteins. 
Although I have established that lynx1, lynx2 and lynx3 form stable complexes 
with nicotinic receptors in mammalian HEK cells, I have not shown that lynx subfamily 
members interact with nAChRs in brain. I have unsuccessfully tried immunoprecipitating 
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 nicotinic receptors from brain multiple times. Also, I wasn’t successful in co-
immunoprecipitation experiments with α3, α2, α6 and α9 subunit containing nicotinic 
receptors, because the available antibodies are not suitable for immunoprecipitation. Most 
nicotinic receptor antibodies that are commercially available have poor affinities to native 
receptors, which also causes problems in the immunohistochemistry studies. In order to 
better analyze nicotinic receptor function and effects of lynxs on them, I would need to 
make antibodies with higher affinities. 
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 Gene-targeted Deletion Analysis of lynx2 and lynx3 
 Tobacco smoking is the leading cause of preventable death in United States and 
the main target of nicotine in the brain is the nAChRs. Nicotinic receptors are also 
involved in the pathophysiology of various neuronal and non-neuronal diseases including 
Alzheimer’s disease, Parkinson’s disease, anxiety disorders, autism and skin disorders 
like autoimmune pemphigus, epidermolysis bullosa as well as gastritic cancer, and 
pancreas cancer [198, 228]. Nicotinic receptors are allosteric receptors, which go through 
mainly four states upon their activation: resting position, open channel, desensitized 
channel and closed channel. Desensitization of nicotinic receptors is an important means 
of modulation of their activity and lynx1 is one of the first endogenous proteins that 
modulates desensitization patterns of nAChRs. In my studies, I have shown that lynx2 
and lynx3 can also bind to and increase desensitization speed of nAChRs. In order to 
analyze the in vivo effects of lynx2 and lynx3, I have made null mutant mice for lynx2 
and lynx3. The lynx2-/- mice show various behavioral phenotypes that were previously 
shown to be regulated by nicotine. These phenotypes will be described below. I am in the 
process of analyzing the lynx3 null mutant mice.  
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 Effects of lynx2 null mutation on fear and anxiety 
Fear and anxiety are related, but different, psychological terms. They are both 
arised in situations where our senses impels our brain to act, but it cannot. Fear is an 
intense emotion that is produced against an immediate threat. Fear produces defensive 
behaviors and helps survival mechanisms. Anxiety, on the other hand, is a vague 
discomfort reflecting distress and diffuse fears without any particular threat. In humans, 
anxiety can be felt in various situations including crowded places, feeling helpless due to 
inability to react, experiencing unpredictable events in your life, or not being able to 
accept certain events like losing your job or a loved one. 
Nicotine alters anxiety related behaviors through its effect on nicotinic receptors. 
Nicotine has also been associated with panic attacks and depression. In rodents, nicotine 
can be anxiolytic or anxiogenic depending on the method of administration, the duration 
after administration and the dose of nicotine. When activation of nicotinic receptors 
affects serotonergic pathways, it is anxiogenic. On the other hand, anxiolytic effects of 
nAChRs might be due to their effects on GABAergic pathways and stress hormone 
levels. Anxiety related behaviors have been associated with multiple areas of the brain 
including amygdala, hippocampus, stria terminalis, periaqueductal gray and cortex; and 
nAChRs are expressed in all of these regions.  
Since nicotine can stimulate release of a variety of neurotransmitters, including 
GABA, serotonin and dopamine in various brain areas and the desensitization kinetics of 
nicotinic receptors vary depending on the subunit composition, understanding specificity 
of the nicotinic receptor activation becomes an important issue in apprehending the 
relationship between nicotine and anxiety. Lynx2 is expressed in specific cell populations 
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 in the areas associated with anxiety and it modulates nicotinic receptor desensitization, 
therefore, analyzing mechanisms and identifying receptor subtypes underlying the effect 
of lynx2 on anxiety will be very useful for understanding the effects of nicotine on 
anxiety.  
Among the anxiety related tests we have performed, light-dark box and social 
interaction tests are the potential models for generalized anxiety disorder, and elevated-
plus maze is a potential model for panic disorder and generalized anxiety disorder. The 
lynx2-/- mice have shown elevated anxiety related behavior in the social interaction test 
and light-dark box test compared to  WT mice. Although acute injection of nicotine 
increases anxiety levels in the WT mice in light-dark box test, it had no effect on the 
lynx2-/- mice. This suggests that the anxiolytic effect of nicotine might be considerably 
less apparent in the lynx2-/- mice since nicotinic receptors that are normally modulated by 
lynx2 are desensitizing more slowly. Also similar to lynx1, lynx2 might be affecting the 
sensitivity of the nAChRs to nicotine, which might reduce the effect of nicotine on 
anxiety. Although, the lynx2-/- mice performed comparable to the WT mice on elevated-
plus maze test, this doesn’t contradict with our results from the other anxiety tests since 
these tests measure different aspects of anxiety, and lynx2 might be effecting one aspect 
while not effecting the other.  
Another significant finding about anxiety in our tests was the jumping phenotype 
during open-field exploration test. This might indicate that the lynx2-/- mice are more 
excitable than the WT mice in novel environments, however, I have not found any 
literature on jumping phenotype during open field exploration and I will need to perform 
further analysis to test the excitability phenotype.   
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 On fear conditioning test, the lynx2-/- mice exhibited normal contextual-
associative learning behavior, however, better audio-cued-associative learning than the 
WT mice. Although the lynx2-/- mice show more anxiety related behavior than the WT 
mice, I don’t think that the audio-cued-associative learning phenotype is due to increased 
anxiety since the number of freezes in the 3-minute period in the novel environment, 
during which no tone was presented, were similar between both the lynx2-/- and WT mice. 
Nicotine alters learning and memory in mice and humans, thus the increased audio-cue-
associated learning in the lynx2-/- mice might also be through disturbances in the nicotinic 
receptor modulation in the lynx2-/- mice. This hypothesis can be further tested with more 
fear conditioning tests on nicotine or nAChR antagonist injected mice, or with patch 
clamp recordings on cells in basolateral amygdala, which is considered one of the 
primary sites associated with fear conditioning test [210]. Although both contextual 
associative learning and audio-cued associative learning in fear conditioning test are 
measures of associative learning, they are not controlled by the same brain regions. 
Contextual-associative learning has been shown to be controlled at least partially by 
hippocampus and audio-cued associative learning has been shown to be controlled 
mainly by basolateral amygdala. So the fact that lynx2-/- mice have a phenotype in one of 
these tests but not the other doesn’t contradict with each other.  
However, increased learning of lynx2-/- mice than WT animals also doesn’t 
necessarily mean that they are smarter than WT animals, since this increased learning can 
be due to increased fear in these mice. Since we have already observed an increased 
anxiety phenotype, this hypothesis becomes stronger. In order to check whether the result 
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 that I have gotten from the audio-cued conditioning is due to better learning capability in 
general, I’ll have to perform more learning tests.  
Cerebellum has also been shown to be involved in several anxiety related 
behaviors. Mice that are deficient in motor capabilities, like Lurcher mice, have shown 
different anxiety related behaviors; in addition, anxiolytic drugs that are widely used 
result in motor coordination problems and increased locomotion. Since lynx2-/- mice have 
also shown motor coordination and learning abnormalities and lynx2 is expressed in 
interneurons in cerebellum and very heavily expressed in inferior olive which sends 
cerebellum major excitatory input through climbing fibers, the motor coordination 
phenotype and anxiety phenotype might be interrelated and may be controlled by not 
only amygdala and related structures but also cerebellum. However, this hypothesis 
should further be tested with experiments that will be described in “Future Directions”.  
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 Effects of lynx2 null mutation on motor coordination and learning 
Nicotine also effects motor coordination and motor learning. Although the lynx2-/- 
mice exhibited less motor strength than the WT mice in the hanging wire test (This 
experiment will be repeated without a cut-off point to be analyzed with Student’s-T-test), 
they performed significantly better than the WT mice on rotarod test which measures 
motor coordination. This might suggest that when desensitization of nAChRs is slower 
due to lack of lynx2, motor coordination improves. To test this hypothesis I analyzed the 
effect of nicotine and nAChR antagonist, mecamylamine on motor coordination of the 
lynx2-/- mice. 
When injected with nicotine, rotarod performance of the WT mice were effected, 
however, the lynx2-/- mice were not effected, suggesting that the mechanism through 
which lynx2 effects motor coordination might be through nicotinic receptors. 
Intraperitoneal injections of nicotine and mecamylamine were shown to impair motor 
coordination in the WT mice, thus, activation and blocking of all nicotinic receptors 
worsens motor performance, probably due to release of various neurotransmitters from 
both excitatory and inhibitory synapses. Lynx2 is expressed in specific regions of the 
brain and the spinal cord. Since lynx2 slows desensitization, I’m hypothesizing that the 
cells where nicotinic receptors are affected by lynx2 modulation, are involved in one type 
of neurotransmitter release. So when the mice were injected with nicotine, nicotine does 
not affect motor performance of the lynx2-/- mice because the normally-lynx2-expressing-
cells either already have open channels, or when they are activated with nicotine, they are 
kept open longer. However, when nAChRs are blocked with mecamylamine, since the 
slowly desensitizing nicotinic receptors are also blocked, mecamylamine exerts the same 
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 effect it does in the WT mice. Hexamethonium, which is a blocker or nicotinic receptors 
outside CNS, has little effect on the motor performance or learning of either the WT or 
the lynx2-/- mice, which suggests that the receptors involved in rotarod performance and 
learning are inside the CNS.  
When the mice were injected with mecamylamine, and with nicotine 10 minutes 
later, they acted similar to nicotine-injected mice. The reason for this might be the 
mechanism of action of mecamylamine. Mecamylamine has been shown to act both as a 
competitive antagonist and a non-competitive antagonist depending on the type of the 
nicotinic receptor that it blocks [130]. Therefore, the reason between the mecamylamine-
nicotine injections and mecamylamine injections might be due to the type of receptors 
that lynx2 is normally modulating.  
Since primarily deep nuclei and cerebellum are responsible for motor 
coordination and learning, and lynx2 is expressed in interneurons in cerebellum, inferior 
olive and scattered cells in cerebellar nuclei, I propose that the lack of modulation of 
nicotinic receptors by lynx2 in these cells might be causing increased motor learning in 
the lynx2-/- mice. It also might be caused by enhanced motor performance due to 
increased fear in lynx2-/- mice. To test my hypothesis and to learn more about the 
mechanism of lynx2 effect on motor learning and coordination, conditional lynx2-/- mice, 
where only the inferior olive or interneurons in cerebellum are affected by the lynx2-/- 
allele, might be generated and tested on accelarated rotarod. Double labeling with lynx2 
and different nicotinic receptor subtypes as well as patch clamp electrophysiology with 
different channel blockers will also improve our knowledge of which nicotinic receptor 
lynx2 normally modulates in these cells. Injection of mice with nicotinic receptor subtype 
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 specific antagonists like α7 receptor blocker MLA or α4β2 receptor blocker DHβ, and 
then testing them on rotarod also might help us understand which receptor subtype lynx2 
is modulating for motor performance. In order to test whether the reason for increased 
motor performance of lynx2-/- mice is due to increased fear, I can inject mice with 
anxiolytic drugs and test them on rotarod apparatus.  
The lynx2-/- mice have not shown any significant difference in the olfaction and 
pain perception tests when compared with the WT mice. However, I have not tested the 
effects of nicotine on the WT and lynx2-/- mice during these tests. Since nicotine has been 
shown to effect both nociception and olfaction [130, 229-232], further tests, including 
more detailed olfaction tests and hot plate test with nicotine and mecamylamine 
injections are necessary to figure out if lynx2 is effecting these two pathways.
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Review of Behavioral  Phenotype of Lynx2 KO mice  
Lynx2 KO mice have increased fear and anxiety in various tests including light-
dark box, social interaction test and audio-cued fear-conditioning test. They also jump 
more in a novel environment, in open-field locomotion test, which might reflect increased 
escape tendency due to increased fear and anxiety. In rotarod test, lynx2 KO mice exhibit 
increased motor coordination which might reflect the effect of increased fear and anxiety 
on motor performance.  
However, the effect of lynx2 on motor coordination and audio-cued asssociative 
learning may also be independent of its effect on anxiety and fear. lynx2 is expressed in 
various regions in brain and nicotinic receptors are involved in various mechanisms 
controlling learning and motor coordination; therefore, further tests should be performed 
to analyze whether the effect of lynx2 null mutation on motor coordination and fear 
conditioning is due to its effect on fear and anxiety. 
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 Lynx3 is Modulating A Novel Xenopus Oocyte Channel 
 Although I have shown that lynx3 binds to and modulates nAChRs in vitro, I 
cannot conclude that nAChRs are the only channels affected by lynx3 in mammals. When 
I observed the leak currents during voltage clamp recordings in oocytes that were caused 
by lynx3 expression, I decided that the identity of the endogenous Xenopus channels 
opened by lynx3 will be beneficial in identifying any potential mammalian orthologs of 
that channel that might be modulated by lynx3. Through pharmacological analysis, I have 
concluded that the channel affected by lynx3 is a non-selective cation channel. In 1995, 
Arellano et al. [216] have identified properties of a non-selective cation current in 
Xenopus oocytes and this current was suggested to be due to hemi-gap channels by 
Ebihara et. al. [217]. The channel properties that were described by Arellano et. al. also 
match the properties of the channel that is effected by lynx3, however, lynx3 effected 
channel is not a hemi-gap channel since it doesn’t get blocked by neither carbenoxolone 
nor flufenamic acid, both of which are potent blockers of hemi-gap channels. 
 After database searches, I have found 3 other non-selective cation channel types, 
however, neither one of them has a similar pharmacology to lynx3 affected channels. 
When I matured the lynx3 expressing oocytes with progesterone treatment, lynx3 
continued to cause leak currents, suggesting that the lynx3-affected-channel continues to 
be expressed in mature oocytes. Thus, I conclude that lynx3 is modulating a novel non-
selective cation channel in Xenopus oocytes. 
 I was not able to clone this channel yet. I am currently trying other methods, one 
for identifying the Xenopus channel, the other for finding a possible target channel in 
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 mammals. For oocyte channel, I have collaborated with a lab in Argentina to express 
lynx3 in Bufo arenarum oocytes, and we observed that at low doses of expression lynx3 
is not showing toxicity in these oocytes. We will try stronger expression of lynx3, and if 
that is not toxic, I will prepare mRNA from a Xenopus oocyte library, and screen the 
library for toxic effects of lynx3 and clone the channel. In order to find the mammalian 
channel that lynx3 might effect, I have done literature searches and have not found a 
channel that shares a similar pharmacology to the oocyte channel and that is expressed in 
lynx3 expressing tissues.  
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 Future Directions 
Mechanisms and pathways of anxiety have been studied mostly through imaging 
studies in humans and lesion studies in rodents. However, the lesion studies were only 
helpful in analyzing the effects of lesions in certain regions of the brain on various 
anxiety tests like light-dark box test, social interaction test and elevated-plus maze test. 
The lesion studies have shown that the pathways that control these tests are scattered 
throughout the brain and they are not controlled by the same brain regions. Therefore, 
more extensive imaging studies and more detailed behavior tests are required to analyze 
anxiety mechanisms in rodents. Anxiety trait can be influenced by strain differences, age 
and even the number and type of tests done on mice prior to the anxiety tests, which 
makes studying anxiety pathways more difficult.    
Mechanisms of fear have been more extensively studied in rodents. Fear 
conditioning test has been used to analyze the anatomical regions, the controlling neurons 
and their signals for analyzing the fear pathways. These works have formed foundations 
of the neurobiological studies of emotion in mammals. Imaging studies in healthy human 
subjects and patients who suffer from psychological diseases have also helped these 
analysis. However, there is still much to be done to analyze neurobiology of emotions in 
both rodents and humans. I believe that mouse models which show an abnormality in 
emotional behaviors, like lynx2-/- mice, are essential for studying these mechanisms 
further.  
In order to analyze the function of lynx2 in maintaining a normal level of anxiety 
and fear, I would like to increase the number of animals that were used in anxiety tests, 
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 which will also make the results of the tests more statistically significant. I also would 
like to inject mice with different drugs including mecamylamine, to see the effect of 
nicotinic receptor function on the lynx2-controlled anxiety, and different anxiolytic drugs 
including benzodiazepines, to see whether the effect of lynx2 is through GABAergic 
signaling, and selective serotonin re-uptake inhibitor, SSRI, drugs, to observe whether 
lynx2 is working though serotonergic pathways.  
More detailed anatomical analysis of the expression pattern of lynx2 will also be 
helpful in analyzing the pathways in which lynx2 is involved. Double labeled in situ 
hybridizations with lynx2 and markers for GABAergic neurons, and serotonergic neurons 
might tell us which neurons lynx2 is directly effecting. Also patch-clamp 
electrophysiology on the lynx2 expressing cells in WT and lynx2-null mutant mice will 
be helpful in understanding the electrical changes caused by lynx2 null-mutation. 
Immunohistochemistry with antibodies for markers for different cell types on lynx2-/- 
animal brain slices will also help us analyze in more detail what effects lynx2 null 
mutation has in anatomical structures in these animals, if there are any anatomical effects.  
Another hypothesis was the difference in the motor coordination performance of 
lynx2-/- mice and WT mice might be due to increased fear in mutant animals. To test this, 
mice can be injected with anxiolytic drugs like benzodiazepines and SSRIs and can be 
tested on accelerated rotarod to see whether the increased motor performance persists.  
 The increase in number of freezes in fear conditioning test-part 2 should also be 
investigated further. To test whether the increase in lynx2-/- mice is due to increased fear 
or increased learning capability, anxiety drugs might be administered prior to the test and 
their effects might be measured. Another curious matter about fear conditioning results 
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 was whether the effect of lynx2 null mutation is due to differences in nicotinic receptor 
modulation. To test this, nicotine or nicotinic receptor antagonists, like mecamylamine, 
might be injected to the mice prior to the tests and their effects might be measured and 
compared between mutant and WT mice.  
Conditional KO mice for lynx2 might be generated through breeding the mice to 
different cre-transgenic mice. Since lynx2 is heavily expressed in amygdala, an amygdala 
specific KO might tell us whether the effect of lynx2 null mutation on fear and anxiety is 
due to amygdala or another region. Also, cerebellum and inferior olive specific 
conditional lynx2 KO mice will also be useful in sorting out whether the effect of lynx2 
null mutation on motor coordination is due to lack of lynx2 function in cerebellum or due 
to lynx2 malfunction in other brain regions.  
Since lynx2 is also heavily expressed in regions associated with nociception, like 
anterior pretectal nucleus, I have tested lynx2 mutant mice on hot plate test but didn’t see 
a significant difference between mutant and WT mice. Nicotinic receptors are involved in 
nociception mechanisms and sometimes the effect of nicotinic receptor function can only 
be observed when pain tests are performed after nicotine injections. That’s why, I think 
that more pains tests including hot plate and tail-flick should be performed on lynx2 null 
mutant mice after nicotine, mecamylamine or saline injections and the effects of these 
drugs on WT and mutant mice should be compared for assessing the effect of lynx2 on 
nociception.  
For analyzing the function of lynx3, lynx3 KO mice bred with lynx3-EGFP BAC 
transgenic mice can be used for anatomical analysis. EGFP expressing lynx3 KO mice 
and WT mice can be compared at lynx3 expression sites and if there are any anatomical 
 156
 differences, the EGFP expression might make the analysis easier. Also since several ly6 
family members have been implicated in nicotinic receptor mediated cell-to cell 
interactions, cell adhesion and cell-death, lynx3 KO mice can be subjected to different 
tests, like smoke inhalation, and the effects of this procedure on the epithelial cells, which 
express lynx3, in the nasal cavity, trachea and lungs, can be investigated.    
In order to identify if there is another mammalian channel that lynx3 is 
modulating, a homologue of the channel that is modulated by lynx3 in Xenopus oocytes, 
I’ve made lynx3-BAC array mice. These mice express an EGFP-tagged-ribosomal-
protein under lynx3 promoter, and when the EGFP-tagged ribosomal protein is 
immunoprecipitated with an anti-EGFP antibody, the total RNA in the cells that express 
this protein is also immunoprecipitated. When this immunoprecipitated total RNA and 
the not-immunoprecipitated total RNA, which is expressed in cells that do not express 
this protein, are compared on a microarray analysis study,  the difference will give us 
RNA that is expressed lynx3-expressing cells. When this experiment is done in multiple 
tissues that have lynx3-expresing cells, like lungs and stomach, the common channels 
that are expressed in both these cell types might be analyzed to see which ones are the 
non-selective cation channel ones and the target mammalian channel might be identified. 
This experiment also will be helpful in identifying transcripts that are specific for these 
cell types. It might be the foundation of another project that analyzes epithelia specific 
proteins.  
In order to investigate the effects of the lack of nicotinic receptors in lynx2 null 
mutant mice, I’ll breed lynx2 mutant mice to nicotinic receptor KO animals. The double-
KO mice will be then tested on the different behavior tests that I’ve performed on lynx2 
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 mutant mice and the results will be compared to see whether the lack of nicotinic receptor 
subunits can compensate for lynx2 mutation.  
There are many experiments that can be done on lynx2 and lynx3 mutant mice 
and the lynx3-ribosome-BAC transgenic mice, some of which are mentioned above. I 
believe that these tests will be extremely valuable in understanding nicotinic receptor 













Materials and Methods 
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 Identification and Phylogenetic Inference of Ly6 Genes 
I searched NCBI and Celera genomic and est sequences to find genes that fit the 
following criteria: 
 -Their exon-intron structures were analyzed to exclude the pseudogenes 
 -The proteins having any other structurally important domains than Ly6 and GPI 
anchorage were excluded  
 -All the selected proteins had only one Ly6 domain 
The Ly6 domains of these sequences were aligned to UPAR_LY6 protein domain HMM 
profile of PFAM [233]. After initial alignment using DIALIGN2 [234], we manually 
corrected the alignments in order to best preserve the alignments of the cysteines. The 
alignment sequence for all Ly6SF members analyzed were later viewed with Chroma 
[235]. I have collaborated with Dr. Marcelo Briones for modeling the phylogenetic tree 
of these proteins. Phylogenetic inference was performed using the Vanilla 1.2 frontend to 
PAL 1.2 (Phylogenetic Analysis Library) [207]. An unrooted tree was inferred from 
maximum likelihood distance matrices computed using the JTT substitution model, 
Gamma model for rate heterogeneity with 8 rate variations over sites and Alpha 
parameter equal to 1.0. The sequences of mouse and human lynx1, lynx2, lynx3 and 
Ly6H have been aligned using DIALIGN2 and Boxshade programs. 
Cloning 
For in situ hybridization analysis of Lynx2, the cDNA sequence encoding mouse 
Lynx2 flanked by its 3′ and 5′ untranslated sequences was subcloned into the pBluscript-
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 SK. For immunoprecipitation experiments, Ly6 domains and GPI anchorage sites and 
signals of Lynx1, Lynx2, Lynx3 and Ly6H were subcloned into mammalian expression 
vector pFlag-CMV-1. cDNAs encoding nAChR α4, β2, α7, β4, α1, β1, γ and δ subunits 
were kind gifts from Dr. Jerry A. Stitzel, Dr. Marc Ballivet and Dr. José Ramirez-
LaTorre. They were flag tagged and subcloned into oocyte expression vector pCS2+ and 
used for immunoprecipitation and in vitro transcription experiments. cDNAs encoding 
Lynx1, Lynx2, Lynx3 and Ly6H were also subcloned into oocyte expression vector 
pCS2+ and used for in vitro transcription experiments. 
For cloning the KO constructs, C57Bl6 genomic DNA containing bacterial 
artificial chromosomes from Research Genetics, and 10kb genomic DNA containing 
clones from Open BioSystems were used as template. The PCR reactions were performed 
with long-template PCR kit from Invitrogen. The backbones of the constructs were 
pBluescript vector (pSK).  
RT-PCR: 
The est-clones were purchased from Invitrogen, the exon-intron structures were 
analyzed and PCR primers were designed to span two different exons so that 
amplification of gDNA and cDNA would result in products with two different lengths. 
Single-step RT-PCR kit from Invitrogen was used for all amplifications. The sequences 
of the PCR primers and the lengths of the products are below.  
AK008654 is located on Chr 7. PCR product length when cDNA is amplified:~490 bp 
PCR product length when gDNA is amplified: cDNA>1500 bp 
5’ Primer: CAGGCTCCCAGGCCCTAC 
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 3’ Primer: GCAGGTCGATGGATGTCCA 
AI747831 is located on Chr 15. PCR product length when cDNA is amplified:~350 bp 
PCR product length when gDNA is amplified:>1500 bp  
5’ Primer: CCCAGGATGGACAATTCT 
3’ Primer: TGAGGGTTGTTGTTGGAAGGA 
BB646386 is located on Chr 15. PCR product length when cDNA is amplified: ~840 bp 
PCR product length when gDNA is amplified:~1500 bp  
5’ Primer: AGGCGTTGAAGTGTCATG 
3’ Primer: GAGGCCGAGGGCCAGCAAT 
AK009303 is located on Chr 17. PCR product length when cDNA is amplified:~420 bp 
PCR product length when gDNA is amplified:~1500 bp 
5’ Primer: GTCTTGGGCAGGTGTGTC 
3’ Primer: GCAAGGGGTAGCAGAGTC 
AV082481 is located on Chr 15. PCR product length when cDNA is amplified:~210 bp 
PCR product length when gDNA is amplified: >2500 bp  
5’ Primer: TGGTCTTGAGCATGGAGC 
3’ Primer: CAGCAGGCGATGGATACAT 
AK009282 is located in Chr 2. PCR product length when cDNA is amplified: ~450 bp 
PCR product length when gDNA is amplified: >3000 bp 
5’ Primer: CAGCCCGGAGCGGGGTGTC 
3’ Primer: AGAATGTGGCAGAGGAGC 
For the amplification of B-actin control the following primer pair was used: 
5’ Primer: TGAGACCTTCAACACCCCAG 
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 3’ Primer: GAGCCAGAGCAGTAATCTCC  
Northern Blot 
Northern Blots were purchased from Invitrogen. Coding regions were amplified 
with PCR that gave 300-500bp products, which were later labeled with P32. The 
radioactive probed were purified with G50 columns and all hybridizations were 
performed in ExpressHyb hybridization buffer from Stratagene overnight at 55ºC. The 
blots were then washed thoroughly and were exposed to films at –80ºC for 24-72 hours 
depending on the strength of the signal.  
Western Blot 
 For all western blots, C57Bl6 mice were sacrificed with CO2 and organs were 
harvested and frozen in liquid nitrogen immediately.  The tissues were than sonicated in a 
sonication buffer in ice with 8M urea. The protein concentrations were measured with 
BSA measuring kit from PIERCE. Samples were mixed with sample buffer and sample 
reducing agent, kept in a 98C heat-block for 2 minutes, centrifuged briefly and loaded to 
4-12% bis-tris gels from Novagen at equal concentrations. Gels were run at 80-90V for 
2.5 hours at room temperature and were blotted to membranes with semi-dry blotting 
apparatus. The membranes were blocked with blocking solution of PBS with 5% milk 
powder and 0.5% Tween-20 for one hour at room temperature, then incubated in 
blocking solution with primary antibody overnight at 4ºC, washed with PBS with 0.5% 
Tween-20 for 10 minutes at room temperature 3 times and incubated with secondary 
antibody in blocking solution for 45 minutes. Then they were rinsed with water once, 
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 washed with PBS-Tween for 10 minutes, with water for 10 minutes and with PBS-Tween 
for another 5 minutes, treated with Immunochemiluminascence kit from Amersham for 
one minute and exposed to film.  
In situ hybridization 
Adult brain sections were prepared as described [208]. 3’UTR region of Lynx2 
was used as probe for these experiments. Digoxigenin- (Dig-) labeled riboprobe was 
transcribed using 2 μm Dig–NTP (Boehringer-Mannheim) in the transcription reaction. 
Sections were incubated at 60°C overnight in hybridization buffer (50% formamide, 5X 
SSC, 5X Denhardt’s reagent, 500 μg/ml herring sperm DNA, and 250 μg/ml yeast tRNA 
(Sigma R6750)) and washed extensively with 50% formamide and 2× SSC at 60°C. 
Riboprobe was detected with anti-Dig Fab fragments conjugated to Alkaline Phosphatase 
and NBT/BCIP substrate mixture. 
Polyclonal Antibody Production: 
 Two different antibodies were made for both Lynx2 and Lynx3. All of the 
antibodies were made against synthesized peptides, which had the following sequences.  
Lynx2 polyclonal antibody against second finger: was made against 
EFQLNNDCSSPEFIV, which corresponds to the peptide sequence of the first finger in 
lynx2 protein. Two rabbits were injected with KLH-conjugated peptides. The 4 week, 8 
week, 10 week, and 20 week bleeds were IgG purified in purification columns from 
Pierce. The purified serums were tested on western blots at various concentrations 
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 starting from 1:50 to 1:2000. They were also tested on lynx2 transfected HEK293 cells at 
different concentration to see if the antibodies bind to non-linearized lynx2.  
Lynx2 polyclonal antibody against first finger: This was the first antibody 
made and it was made against KLH-conjugated peptide KEVTEQSAGIMYRKS, which 
corresponds to the sequence on the second loop of lynx2 protein. It was made the same 
way the first finger antibody was made. The IgG purified antibodies bound to lynx2 on 
western blots and lynx2-expressing HEK293 cells, however, it didn’t work on brain 
sections so the serum was affinity purified with the peptide that it was made against.  
Lynx3 polyclonal antibody against second finger: This was the first antibody 
made against Lynx3. The sequence of peptide that was KLH-conjugated was 
TTLYSLEIVFPFLGD. The 4-week, 8 week, 10 week and 14 week bleeds from the two 
rabbits that were injected with this peptide were tested on western blots and lynx3 
transfected HEK293 cells.  
Lynx3 polyclonal antibody against third finger: When the first antibody 
generated against lynx3 didn’t work, we have generated another antibody by using the 
sequence from the third finger of lynx3 protein, which was: EPSDVDGIGQTRPVS.  
Immunocytochemistry 
 For immunocytochemistry, the transfected or untransfected cells that were grown 
on poly-D-lysine coated cover slips were washed with PBS, fixed with 4% 
paraformaldehyde for 10-15 minutes, treated with blocking solution with either detergent 
or no detergent for one hour and were incubated overnight with primary antibodies at 
4ºC. The next day, the cells were washed with PBS and incubated with the secondary 
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 antibody for 1 hour at room temperature. The cells are then washed and mounted on 
slides.  
Histology and Immunohistochemistry 
 Immunohistochemistry on BAC-transgenic animals were done as described in 
Gong et. al [208]. For other experiments, mice were perfused with PBS, then 4% 
paraformaldehyde. Brains were harvested and frozen in embedding medium on dry ice, 
and transferred to –80ºC.  
 For KO and WT brain sections that are prepared with Hematoxylene-Eosin 
staining, were cut and stained by Neuro Science Associates (NSA). The mice were 
perfused with PBS, followed by Na-cacodylate containing perfusion solution and Na-
cacodylate wash solution. Perfusion solution contains: 1.4% Na-cacodylate, 4% 
paraformaldehyde, and 4% sucrose. Perfusion wash solution contains: 0.034% Na-
cacodylate, 0.023% CaCl2, 0.8% sucrose, 0.8% NaCl, and 0.4% dextrose.    
Expression and Immunoprecipitation from HEK293T Cells 
HEK 293T cells were transfected by calcium phosphate precipitation with the 
expression vectors containing the cDNAs of Lynx1, Lynx2, Lynx3, Lynx4, Ly6H, α7 
nAChR, Flag-tagged α4, β2, β4, γ and δ nAChR subunits. Two days after transfection, 
cells were washed with PBS, harvested in lysis buffer (150 mM NaCl, 50 mM HEPES, 
100 mM PMSF, 1.5 μg/ml aprotinin, 10 μg/ml leupeptin, and protease inhibitor cocktail) 
containing 1% Triton X-100 and centrifuged at 14,000 rpm for 2 min. All the other steps 
were same as described [67]. 
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 Injection of Xenopus Oocytes with mRNA: 
The cRNAs for Lynx1, Lynx2, Lynx3, Ly6H and nAChR subunits (α4, β2, β4, α1, 
β2, γ and δ) were synthesized with T7 or SP6 RNA polymerases (mMESSAGE 
mMACHINE, Ambion, Austin, TX) through in vitro transcription. To quantify the yield 
of the synthesized transcripts, they were run on an agarose gel. Xenopus oocytes were 
prepared for injection as described [67]. Oocytes were injected with 0.5 ng of the cRNA 
encoding each nAChR subunit 3 ng of lynx1, lynx2, lynx3 and Ly6H. The volume 
injected was 20 nl per oocyte. 
Electrophysiology 
Functional Analysis of Lynx1 homologues in Oocytes 
The voltage-clamp recordings were done on injected oocytes one to two days after 
injection as described [67].  
Analysis of the Xenopus Ion Channel opened by Lynx3 
In order to find the channel that was opened by lynx3 and caused the leak currents 
in the lynx3 injected oocytes, I’ve exposed the control oocytes and lynx3 injected oocytes 
to various solutions for 20 seconds and analyzed the recordings. The solution recipes are 
below: 
• Composition of Ringer Solution: 115 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 5 
mM HEPES pH ~7.4Q 
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 • To test for Na+ Permeability: 115 mM NMG, 2 mM KCl, 1.8 mM CaCl2, 5mM 
HEPES pH ~7.4  (pH adjusted to ~7.4 with HCl (~115mM)) 
• To test for Ba2+ blockage: 115 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 5 mM 
HEPES pH ~7.4, 4 mM BaCl2 
• To test permeability for Na+ vs K+: 117 mM KCl, 1.8 mM CaCl2, 5 mM HEPES 
pH ~7.4          
• To test for Ca2+-Mg2+: 115 mM NaCl, 2 mM KCl, 2.6 mM MgCl2, 5 mM HEPES 
pH ~7.4 
• To test for La3+ blockage: 115 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 5 mM 
HEPES pH  ~7.4, 0.1 mM LaCl3 
• To test permeability for Ca2+ vs Ba2+ blockage: 115 mM NaCl, 2 mM KCl, 2.6 
mM MgCl2, 5 mM HEPES pH ~7.4, 4 mM BaCl2 
• Ca-free solution with flufenamic acid-1: 115 mM NaCl, 2 mM KCl, 1.8 mM 
CaCl2, 5 mM HEPES pH ~7.4, 0.5 mM EDTA, 80 μM FFA 
• Ca-free solution with flufenamic acid-2: 115 mM NaCl, 2 mM KCl, 2.6 mM 
MgCl2, 5 mM HEPES pH ~7.4, 80μM FFA 
• High Ca Solution: 75 mM NaCl, 2 mM KCl, 40 mM CaCl2, 5 mM HEPES pH 
~7.4, 80 μM FFA 
• To test permeability for NH4+ vs K+: 117 mM NH4Cl, 1.8 mM CaCl2, 5 mM 
HEPES pH ~7.4. All K-no Na solution was used as ringer and replaced with 
NH4Cl solution for 20 sec/s 
To see if the following blockers of hemi-gap channels block the current caused by 
lynx3 expression, oocytes injected with lynx3 mRNA were perfused with the following 
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 solutions for 20 seconds: 100μM Carbenoxolone + Ringer Solution, or 50μM FFA 
(flufenamic acid) + Ringer Solution 
For pharmacological analysis of the target channel, I’ve exposed the lynx3 
injected oocytes were perfused with Ringer Solution with the following chemicals for 20 
seconds. At least 3 oocytes were recorded for each chemical and concentration mentioned 
below: 2mM SITS; 1mM DIDS; 1mM Niflumic acid; 1mM Bumetanide; ringer solution 
with a pH of ~6.4; 100μM Genistein; 20uM PTPI-IV; 20μM Amiloride; 1mM Benzamil; 
20mM NH4Cl; 100mM SKF-96365; 1mM Amiloride; 115mM NMG; 100mM TEA and 
100μM TEA. All the chemicals were purchased from SIGMA.   
Antibodies 
 The monoclonal antibodies anti-FlagM2, anti-α7 mAb 306, anti-α7 mAb 319, anti-
α4 mAb 299, anti-β1 mAb 111 and HRP-coupled anti-Flag M2 antibodies were purchased 
from SIGMA. 
Behavioral Phenotyping Experiments 
Open-Field Exploration Test 
 Ethovision computer program and equipment, from NOLDUS, were used for 
open field exploration test. Four rectangular containers in the size of a rat cage, which 
were labeled as Arena 1-4, were placed under a security camera that is connected to the 
computer. The camera visualized the test mice as objects darker and different from 
background since the arenas were white and all the test mice tested were black. A 
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 rectangular area in the middle of each arena was labeled as center of the arena. The 
computer recorded the movement patterns of the test mice for 20 minutes. We have 
recorded how many times the mice jumped manually. Four mice were tested every 
session. The Ethovision program did all the calculations for the behaviors that were 
measured. The containers were cleaned with isopropanol between each session to remove 
the excretions and odors of the mice from the previous session. The room that the tests 
were performed was darkened with black curtains and the only source of light was a light 
bulb in the middle of the room. 
Hanging Wire Assay and Reflex Checks 
 For hanging wire assay, a rat cage wire lid was used. The ends of the lid were 
taped so that the mice could not crawl back.  The mice were hang on the lid by gently 
shaking the lid twice when the mice are on top of the lid, then the lid was turned upside 
down, about one meter over a container with a lot of bedding material in it to minimize 
the shock of the fall on the mice. The latency of fall was measured with a stop watch. The 
measurement was stopped at 60 seconds whether the mice fell or not.  
 A clean Q-tip was used for checking eye-blink and ear-twitch reflexes. The cotton 
ball tip was brought close to the eye and the ability of the mice to close its eyelids was 
measured. For ear-twitch reflex, a clean Q-tip was used to touch mouse’s ear, and the 
ability of the mice to twitch their ears was checked. 
Rotarod Assay 
 Economex Rotarod equipment from Columbus Instruments was used for rotarod 
tests. Each mouse was tested four times a day with 5-minute intervals for four days. The 
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 rod started to turn at a speed of 1 RPM and accelerated with a rate of 0.1RPM /sec. The 
latency to grab the rod and turn once or to fall was measured with a stopwatch. During 
experiments for testing the effect of nicotine and nicotinic antagonists, the mice were 
injected intraperitoneally with nicotine, saline, mecamylamine, and hexamethonium so 
that the injection solution would be 100-200 μl, depending on the weight of the mice. The 
resulting concentrations of the drugs in mice were 1mg/kg of nicotine (nicotine tartrate 
from SIGMA), 4mg/kg of mecamylamine (SIGMA) and 4mg/kg of hexamethonium 
(SIGMA). All the stock solutions and injection solutions were prepared in physiological 
saline. For tests with nicotine and saline, mice were injected with nicotine/saline and 
tested 5 minutes later. For tests with mecamylamine and hexamethonium, the mice were 
tested 15 minutes after injection. For mecamylamine and nicotine tests, mice were 
injected with mecamylamine, kept in their cages for 10 minutes, injected with nicotine 
and tested 5 minutes later.  
Light-Dark Box Test 
 The test apparatus was novel to each test mouse. Test started 10 seconds after the 
mice were put inside the light compartment of the light-dark box for 10 minutes. A 
security camera that is connected to a computer with Ethovision was used for recording 
the movement patterns of the mice and the calculations of the entries into the light and 
dark compartments and the time spent in each compartment were done automatically by 
Ethovision program in the computer.  
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  For testing the effect of nicotine on anxiety related behavior of lynx2-/- mice, mice 
were injected with nicotine 1mg/kg and were kept in a cage for 40 minutes before the 
test. The same procedure was used for saline injected mice as well.  
Social Interaction Test 
 A diagram showing the parts of social interaction test are shown in figure 49.  The 
model for social interaction test was based on the apparatus described previously [236]. 
The apparatus consists of three compartments; two on each end with small wire cages in 
them and one middle compartment, all of which were separated with removable doors. 
The wires on the cages were 1 cm apart, enough to give a chance for mice to sniff each 
other through them. In the first part of the test, a novel mouse was placed in a cage in the 
first compartment, and the test mouse was placed in the middle compartment for 10 
minutes for habituation. After habituation, the doors were removed and the test mouse 
explored freely among the compartments. The amount of time spent in each compartment 
and the time spent sniffing the empty cage and the cage with the novel mice were all 
recorded with a security camera and Ethovision program. All the calculations and 
measurements were made with Ethovision program on the computer. 
 During the second part of the test, a novel mouse was placed inside the empty 
cage in the third compartment and the previously associated novel mouse-1 was kept in 
its original cage. The test mouse roamed freely among the compartments and the analysis 
were done the same way. The equipment was cleaned with isopropanol between each 
trial. 
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 Elevated Plus Maze Test 
 Each mouse was placed on the center of the apparatus facing an open-arm and its 
movements were recorded with Ethovision for five minutes. We also manually recorded 
each entry to the center, open or closed-arm. The calculations for manually recorded and 
computer recorded movements were all done by analysis program of Ethovision and were 
found to be similar. The number of entries into open arms, time spent in the center, time 
spent in closed arms and time spent in center area were analyzed. The equipment was 
cleaned with isopropanol to remove excretions and odors from the previous test mouse 
between each trial. 
Fear Conditioning Test 
 A conditioning apparatus from Med Associates was used for fear conditioning 
tests with a program that was described earlier [237]. The mice were given 2-second 
0.5mA shocks at the two last seconds of a 30-second long 80 db tone, twice on training 
day. The number of freezes were counted every 10 seconds before and after the shocks 
were given and recorded as pre-shock Day1 and post-shock Day1. 24 hours later, the 
mice were placed in the same environment without any tone or shock and the number of 
freezes every ten seconds were recorded as contextual day2. On the second part of the 
test, the mice were placed in a novel environment with a different ceiling, walls and a 
smell of orange extract and were kept in that environment for 3 minutes before subjected 
to an 80 db tone for another 3 minutes. The total numbers of freezes before and after tone 
were recorded as pre-tone day2 and during-tone day2.  
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 Hot Plate Test 
 A hot plate test apparatus from Columbus Instruments was used for this pain 
perception test. The hot plate is kept at a constant temperature of 55ºC and is covered 
with a clear plexiglass. The mice were placed on the plate and were kept there until they 
either tapped their hind feet or licked their paws. The test was performed once per animal 
to minimize the tissue damage. The latency to respond to pain through above means was 
measured with a stopwatch. 
Finding Buried Food Test 
  The test mice were starved without food or water for 18 hours before the test. A 
food pellet was hidden under 1cm of bedding in a clean mouse cage and the mouse was 
placed in the center of the cage. The latency to the mouse to find the pellet and hold it in 
its front paws or eat it was measured with a stopwatch. The mice were then given food 
for 4 hours, and starved for another 18 hours for the next day of testing. After first day of 
testing, the mice were not tested for a 24-hour period and were tested the next day after 
18 hour starvation. The food pellet was placed on a different location every day, for three 
consecutive days. Every mouse was tested only once with this test and were placed in a 
clean cage after each test. 
Statistical Analysis 
 Student-T-tests were performed by using Microsoft Excel. To analyze data with 
repeated measurements over time, we used Mixed Effects Models, also known as Mixed 
ANOVA models. This approach is based on likelihood estimation rather than moment 
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 estimation as in typical repeated-measures ANOVA analysis, and it is more robust to 
missing values. The mixed linear model is a generalization of the standard linear model 
in which errors are permitted to exhibit correlations and non-constant variability, two 
properties that would violate key assumptions of standard ANOVA models. The mixed 
model is written as:  
y=Xβ+Zγ+ε 
where to the terms Xβ+ε defining the general linear model, are added the known design 
matrix Z, times the vector of unknown random-effects parameters γ. Both γ and ε are 
assumed to follow a normal distribution with zero mean and covariance matrices G and 
R, respectively. The name mixed model comes from the fact that the model contains both 
fixed-effects parameters β and random-effects parameters γ. A variety of correlation 
structures can be used by specifying the G and R matrices. 
All models were fitted using the PROC MIXED procedure in SAS 9.1.3. (SAS 
Institute, Cary, NC). Genotype, day and its interaction were considered in all models. In 
the case of RR with treatment, this factor was also included and the interactions with 
Genotype and Day were explored. To model the within-subject covariance’s structure we 
considered several structures available through SAS’s MIXED procedure, specifically: 
autoregressive (ar(1)), unconstrained and compound symmetric (cs) structures. Slight 
variations of those models were tested and the best model, as determined through the 
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